CA2629555A1 - Related/overlapping innovations in health/energy/transport/farming and infrastructure - Google Patents
Related/overlapping innovations in health/energy/transport/farming and infrastructure Download PDFInfo
- Publication number
- CA2629555A1 CA2629555A1 CA002629555A CA2629555A CA2629555A1 CA 2629555 A1 CA2629555 A1 CA 2629555A1 CA 002629555 A CA002629555 A CA 002629555A CA 2629555 A CA2629555 A CA 2629555A CA 2629555 A1 CA2629555 A1 CA 2629555A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- stem cells
- bacteria
- cell
- microbes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000009313 farming Methods 0.000 title claims description 8
- 230000036541 health Effects 0.000 title claims description 7
- 210000000130 stem cell Anatomy 0.000 claims description 170
- 210000004027 cell Anatomy 0.000 claims description 149
- 210000000988 bone and bone Anatomy 0.000 claims description 101
- 108090000623 proteins and genes Proteins 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 79
- 241000894006 Bacteria Species 0.000 claims description 57
- 210000001519 tissue Anatomy 0.000 claims description 49
- 239000000463 material Substances 0.000 claims description 47
- 229920001661 Chitosan Polymers 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 239000000047 product Substances 0.000 claims description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 108020004414 DNA Proteins 0.000 claims description 37
- 229910052751 metal Inorganic materials 0.000 claims description 37
- 239000002184 metal Substances 0.000 claims description 37
- 102000004190 Enzymes Human genes 0.000 claims description 35
- 108090000790 Enzymes Proteins 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 238000011160 research Methods 0.000 claims description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 31
- 239000000126 substance Substances 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 241000282414 Homo sapiens Species 0.000 claims description 27
- 230000035755 proliferation Effects 0.000 claims description 26
- 210000003608 fece Anatomy 0.000 claims description 25
- 230000012010 growth Effects 0.000 claims description 25
- 230000008569 process Effects 0.000 claims description 25
- 238000012360 testing method Methods 0.000 claims description 25
- 229910001385 heavy metal Inorganic materials 0.000 claims description 24
- 231100000765 toxin Toxicity 0.000 claims description 24
- 239000003053 toxin Substances 0.000 claims description 24
- 108700012359 toxins Proteins 0.000 claims description 24
- 150000002739 metals Chemical class 0.000 claims description 22
- 241000894007 species Species 0.000 claims description 22
- 238000010367 cloning Methods 0.000 claims description 20
- 230000008901 benefit Effects 0.000 claims description 19
- 230000001965 increasing effect Effects 0.000 claims description 19
- 239000010871 livestock manure Substances 0.000 claims description 19
- 210000002784 stomach Anatomy 0.000 claims description 19
- 210000001185 bone marrow Anatomy 0.000 claims description 18
- 239000011575 calcium Substances 0.000 claims description 18
- 235000015097 nutrients Nutrition 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 18
- 239000013589 supplement Substances 0.000 claims description 18
- 229910052791 calcium Inorganic materials 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 17
- 210000000515 tooth Anatomy 0.000 claims description 17
- 241000283690 Bos taurus Species 0.000 claims description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 16
- 240000008042 Zea mays Species 0.000 claims description 16
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 16
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 16
- 230000008468 bone growth Effects 0.000 claims description 16
- 235000005822 corn Nutrition 0.000 claims description 16
- 210000000805 cytoplasm Anatomy 0.000 claims description 16
- 210000003414 extremity Anatomy 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- -1 Pro aromatic Trp Chemical compound 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 108020003175 receptors Proteins 0.000 claims description 15
- 102000005962 receptors Human genes 0.000 claims description 15
- 210000002421 cell wall Anatomy 0.000 claims description 14
- 210000002865 immune cell Anatomy 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 241000196324 Embryophyta Species 0.000 claims description 13
- 241000287828 Gallus gallus Species 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 210000004556 brain Anatomy 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 239000003102 growth factor Substances 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 241000282412 Homo Species 0.000 claims description 12
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 12
- 244000061456 Solanum tuberosum Species 0.000 claims description 12
- 238000005516 engineering process Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 230000004060 metabolic process Effects 0.000 claims description 12
- 239000010865 sewage Substances 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 238000011161 development Methods 0.000 claims description 11
- 230000018109 developmental process Effects 0.000 claims description 11
- 244000005700 microbiome Species 0.000 claims description 11
- 230000037361 pathway Effects 0.000 claims description 11
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 10
- 210000004379 membrane Anatomy 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- 239000010815 organic waste Substances 0.000 claims description 10
- 239000000123 paper Substances 0.000 claims description 10
- 230000035939 shock Effects 0.000 claims description 10
- 244000269722 Thea sinensis Species 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 9
- 230000006870 function Effects 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- 239000001506 calcium phosphate Substances 0.000 claims description 8
- 230000005754 cellular signaling Effects 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 8
- 235000005911 diet Nutrition 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 210000002381 plasma Anatomy 0.000 claims description 8
- 235000012015 potatoes Nutrition 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000002699 waste material Substances 0.000 claims description 8
- 208000030507 AIDS Diseases 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 7
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 7
- 108700020796 Oncogene Proteins 0.000 claims description 7
- 240000007594 Oryza sativa Species 0.000 claims description 7
- 235000007164 Oryza sativa Nutrition 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000002609 medium Substances 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- 244000052769 pathogen Species 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 235000009566 rice Nutrition 0.000 claims description 7
- 239000011435 rock Substances 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 230000035882 stress Effects 0.000 claims description 7
- 241000251468 Actinopterygii Species 0.000 claims description 6
- 241000238017 Astacoidea Species 0.000 claims description 6
- 241000270722 Crocodylidae Species 0.000 claims description 6
- 241000086550 Dinosauria Species 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 6
- 230000037213 diet Effects 0.000 claims description 6
- 230000005611 electricity Effects 0.000 claims description 6
- 239000006260 foam Substances 0.000 claims description 6
- 239000013505 freshwater Substances 0.000 claims description 6
- 230000035876 healing Effects 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 229920002101 Chitin Polymers 0.000 claims description 5
- 241000195493 Cryptophyta Species 0.000 claims description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 108091000080 Phosphotransferase Proteins 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 5
- 230000015556 catabolic process Effects 0.000 claims description 5
- 239000002361 compost Substances 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 210000003743 erythrocyte Anatomy 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 5
- 230000035800 maturation Effects 0.000 claims description 5
- 230000003278 mimic effect Effects 0.000 claims description 5
- 239000010813 municipal solid waste Substances 0.000 claims description 5
- 210000003463 organelle Anatomy 0.000 claims description 5
- 102000020233 phosphotransferase Human genes 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 239000002689 soil Substances 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 239000000919 ceramic Substances 0.000 claims description 4
- 239000013522 chelant Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 239000003599 detergent Substances 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 239000007789 gas Substances 0.000 claims description 4
- 230000005484 gravity Effects 0.000 claims description 4
- 238000003306 harvesting Methods 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 241000238557 Decapoda Species 0.000 claims description 3
- 241000221089 Jatropha Species 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 210000002805 bone matrix Anatomy 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 230000006020 chronic inflammation Effects 0.000 claims description 3
- 230000001086 cytosolic effect Effects 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 239000010432 diamond Substances 0.000 claims description 3
- 229920001971 elastomer Polymers 0.000 claims description 3
- 210000004602 germ cell Anatomy 0.000 claims description 3
- 239000000122 growth hormone Substances 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 210000003716 mesoderm Anatomy 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229940053128 nerve growth factor Drugs 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 210000000287 oocyte Anatomy 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 239000000902 placebo Substances 0.000 claims description 3
- 229940068196 placebo Drugs 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 230000000306 recurrent effect Effects 0.000 claims description 3
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 239000005060 rubber Substances 0.000 claims description 3
- 235000015170 shellfish Nutrition 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 229940034610 toothpaste Drugs 0.000 claims description 3
- 239000000606 toothpaste Substances 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 208000020222 Acanthamoeba infectious disease Diseases 0.000 claims description 2
- 208000004881 Amebiasis Diseases 0.000 claims description 2
- 206010006448 Bronchiolitis Diseases 0.000 claims description 2
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 2
- 244000060011 Cocos nucifera Species 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 235000002678 Ipomoea batatas Nutrition 0.000 claims description 2
- 244000017020 Ipomoea batatas Species 0.000 claims description 2
- 206010024639 Listeria infections Diseases 0.000 claims description 2
- 206010024641 Listeriosis Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 102000029749 Microtubule Human genes 0.000 claims description 2
- 108091022875 Microtubule Proteins 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 208000012868 Overgrowth Diseases 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- 240000000111 Saccharum officinarum Species 0.000 claims description 2
- 235000007201 Saccharum officinarum Nutrition 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 241000223997 Toxoplasma gondii Species 0.000 claims description 2
- 102000004243 Tubulin Human genes 0.000 claims description 2
- 108090000704 Tubulin Proteins 0.000 claims description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 208000021240 acute bronchiolitis Diseases 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 201000002816 chronic venous insufficiency Diseases 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 238000002591 computed tomography Methods 0.000 claims description 2
- 230000001276 controlling effect Effects 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 235000004879 dioscorea Nutrition 0.000 claims description 2
- 235000021186 dishes Nutrition 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000003176 fibrotic effect Effects 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 210000000274 microglia Anatomy 0.000 claims description 2
- 210000004688 microtubule Anatomy 0.000 claims description 2
- 239000002324 mouth wash Substances 0.000 claims description 2
- 229940051866 mouthwash Drugs 0.000 claims description 2
- 230000003959 neuroinflammation Effects 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 230000001172 regenerating effect Effects 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 210000003625 skull Anatomy 0.000 claims description 2
- 239000003104 tissue culture media Substances 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 230000032258 transport Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 201000002282 venous insufficiency Diseases 0.000 claims description 2
- 210000000707 wrist Anatomy 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 claims 46
- 235000018291 probiotics Nutrition 0.000 claims 46
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims 41
- 229910052753 mercury Inorganic materials 0.000 claims 41
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 39
- 230000000529 probiotic effect Effects 0.000 claims 35
- 210000004185 liver Anatomy 0.000 claims 34
- 229940088598 enzyme Drugs 0.000 claims 33
- 235000018102 proteins Nutrition 0.000 claims 26
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 24
- 108700005087 Homeobox Genes Proteins 0.000 claims 23
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims 19
- 229960003180 glutathione Drugs 0.000 claims 19
- 210000000056 organ Anatomy 0.000 claims 19
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims 18
- 210000003205 muscle Anatomy 0.000 claims 18
- 230000002062 proliferating effect Effects 0.000 claims 18
- 108010024636 Glutathione Proteins 0.000 claims 17
- 229960004452 methionine Drugs 0.000 claims 17
- 229910052717 sulfur Inorganic materials 0.000 claims 17
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 16
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 16
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 16
- 235000013601 eggs Nutrition 0.000 claims 16
- 210000000987 immune system Anatomy 0.000 claims 16
- 235000013406 prebiotics Nutrition 0.000 claims 16
- 239000011593 sulfur Substances 0.000 claims 16
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- 210000003899 penis Anatomy 0.000 claims 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 14
- 230000009286 beneficial effect Effects 0.000 claims 14
- 229960002433 cysteine Drugs 0.000 claims 14
- 230000002068 genetic effect Effects 0.000 claims 14
- 210000001865 kupffer cell Anatomy 0.000 claims 14
- 241000186000 Bifidobacterium Species 0.000 claims 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 13
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 13
- 235000018417 cysteine Nutrition 0.000 claims 13
- 229930182817 methionine Natural products 0.000 claims 13
- 239000002243 precursor Substances 0.000 claims 13
- 231100000331 toxic Toxicity 0.000 claims 13
- 230000002588 toxic effect Effects 0.000 claims 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 12
- 230000000968 intestinal effect Effects 0.000 claims 12
- 229940024606 amino acid Drugs 0.000 claims 11
- 235000001014 amino acid Nutrition 0.000 claims 11
- 239000003963 antioxidant agent Substances 0.000 claims 11
- 230000003078 antioxidant effect Effects 0.000 claims 11
- 235000013330 chicken meat Nutrition 0.000 claims 11
- 150000003271 galactooligosaccharides Chemical class 0.000 claims 11
- 210000002700 urine Anatomy 0.000 claims 11
- 239000002551 biofuel Substances 0.000 claims 10
- 239000001913 cellulose Substances 0.000 claims 10
- 229920002678 cellulose Polymers 0.000 claims 10
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims 10
- 210000000936 intestine Anatomy 0.000 claims 10
- JLVSRWOIZZXQAD-UHFFFAOYSA-N 2,3-disulfanylpropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(S)CS JLVSRWOIZZXQAD-UHFFFAOYSA-N 0.000 claims 9
- 240000007154 Coffea arabica Species 0.000 claims 9
- 241000256602 Isoptera Species 0.000 claims 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 9
- 235000006708 antioxidants Nutrition 0.000 claims 9
- 210000002459 blastocyst Anatomy 0.000 claims 9
- 230000029142 excretion Effects 0.000 claims 9
- 210000003754 fetus Anatomy 0.000 claims 9
- 210000002569 neuron Anatomy 0.000 claims 9
- 230000035807 sensation Effects 0.000 claims 9
- 239000000829 suppository Substances 0.000 claims 9
- 229910052725 zinc Inorganic materials 0.000 claims 9
- 239000011701 zinc Substances 0.000 claims 9
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 claims 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 8
- 230000007246 mechanism Effects 0.000 claims 8
- 229910000497 Amalgam Inorganic materials 0.000 claims 7
- WMTIOGUVKBSEOW-UHFFFAOYSA-N ClC1(Cl)OP(=O)OP(=O)O1 Chemical compound ClC1(Cl)OP(=O)OP(=O)O1 WMTIOGUVKBSEOW-UHFFFAOYSA-N 0.000 claims 7
- 241000192700 Cyanobacteria Species 0.000 claims 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 7
- 241000186660 Lactobacillus Species 0.000 claims 7
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims 7
- 210000001072 colon Anatomy 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 7
- 238000001990 intravenous administration Methods 0.000 claims 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 7
- 210000002540 macrophage Anatomy 0.000 claims 7
- 239000011707 mineral Substances 0.000 claims 7
- 230000004044 response Effects 0.000 claims 7
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims 7
- 229960004245 silymarin Drugs 0.000 claims 7
- 235000017700 silymarin Nutrition 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 7
- 241001430294 unidentified retrovirus Species 0.000 claims 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 6
- 102000009331 Homeodomain Proteins Human genes 0.000 claims 6
- 108010048671 Homeodomain Proteins Proteins 0.000 claims 6
- 240000001046 Lactobacillus acidophilus Species 0.000 claims 6
- 235000010841 Silybum marianum Nutrition 0.000 claims 6
- 230000003416 augmentation Effects 0.000 claims 6
- 230000003115 biocidal effect Effects 0.000 claims 6
- 238000001784 detoxification Methods 0.000 claims 6
- 238000001415 gene therapy Methods 0.000 claims 6
- 239000011777 magnesium Substances 0.000 claims 6
- 229910052749 magnesium Inorganic materials 0.000 claims 6
- 210000005036 nerve Anatomy 0.000 claims 6
- 230000001537 neural effect Effects 0.000 claims 6
- 210000001938 protoplast Anatomy 0.000 claims 6
- 231100000241 scar Toxicity 0.000 claims 6
- 230000001988 toxicity Effects 0.000 claims 6
- 231100000419 toxicity Toxicity 0.000 claims 6
- 108010000912 Egg Proteins Proteins 0.000 claims 5
- 102000002322 Egg Proteins Human genes 0.000 claims 5
- 241000588724 Escherichia coli Species 0.000 claims 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 5
- 244000046052 Phaseolus vulgaris Species 0.000 claims 5
- 241000320380 Silybum Species 0.000 claims 5
- 240000006677 Vicia faba Species 0.000 claims 5
- 235000010749 Vicia faba Nutrition 0.000 claims 5
- 235000002098 Vicia faba var. major Nutrition 0.000 claims 5
- 239000003242 anti bacterial agent Substances 0.000 claims 5
- 150000001720 carbohydrates Chemical class 0.000 claims 5
- 235000014633 carbohydrates Nutrition 0.000 claims 5
- 239000002738 chelating agent Substances 0.000 claims 5
- 230000009920 chelation Effects 0.000 claims 5
- 235000012000 cholesterol Nutrition 0.000 claims 5
- 238000007667 floating Methods 0.000 claims 5
- 208000006454 hepatitis Diseases 0.000 claims 5
- 239000004615 ingredient Substances 0.000 claims 5
- 210000002751 lymph Anatomy 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 5
- 210000000664 rectum Anatomy 0.000 claims 5
- 230000000392 somatic effect Effects 0.000 claims 5
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 claims 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 4
- 240000002234 Allium sativum Species 0.000 claims 4
- 108091007065 BIRCs Proteins 0.000 claims 4
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims 4
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims 4
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 102000011727 Caspases Human genes 0.000 claims 4
- 108010076667 Caspases Proteins 0.000 claims 4
- 241000269333 Caudata Species 0.000 claims 4
- 241000271559 Dromaiidae Species 0.000 claims 4
- 102100034633 Homeobox expressed in ES cells 1 Human genes 0.000 claims 4
- 101001067288 Homo sapiens Homeobox expressed in ES cells 1 Proteins 0.000 claims 4
- 229920001202 Inulin Polymers 0.000 claims 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 4
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims 4
- 244000199866 Lactobacillus casei Species 0.000 claims 4
- 102000003792 Metallothionein Human genes 0.000 claims 4
- 108090000157 Metallothionein Proteins 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 206010033799 Paralysis Diseases 0.000 claims 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 4
- 108700025071 Short Stature Homeobox Proteins 0.000 claims 4
- 241000282887 Suidae Species 0.000 claims 4
- 241000282898 Sus scrofa Species 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 206010048259 Zinc deficiency Diseases 0.000 claims 4
- 230000009102 absorption Effects 0.000 claims 4
- 238000010521 absorption reaction Methods 0.000 claims 4
- 229940088710 antibiotic agent Drugs 0.000 claims 4
- 230000001580 bacterial effect Effects 0.000 claims 4
- 244000052616 bacterial pathogen Species 0.000 claims 4
- 210000000941 bile Anatomy 0.000 claims 4
- 230000008499 blood brain barrier function Effects 0.000 claims 4
- 210000001218 blood-brain barrier Anatomy 0.000 claims 4
- 229910052793 cadmium Inorganic materials 0.000 claims 4
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims 4
- 238000002655 chelation therapy Methods 0.000 claims 4
- 238000002512 chemotherapy Methods 0.000 claims 4
- 229930002875 chlorophyll Natural products 0.000 claims 4
- 235000019804 chlorophyll Nutrition 0.000 claims 4
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims 4
- 230000001010 compromised effect Effects 0.000 claims 4
- 210000002808 connective tissue Anatomy 0.000 claims 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 4
- 230000008030 elimination Effects 0.000 claims 4
- 238000003379 elimination reaction Methods 0.000 claims 4
- 230000013020 embryo development Effects 0.000 claims 4
- 230000002550 fecal effect Effects 0.000 claims 4
- 238000000855 fermentation Methods 0.000 claims 4
- 230000004151 fermentation Effects 0.000 claims 4
- 239000003337 fertilizer Substances 0.000 claims 4
- 235000004611 garlic Nutrition 0.000 claims 4
- 231100000283 hepatitis Toxicity 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 4
- 229940029339 inulin Drugs 0.000 claims 4
- 229910052742 iron Inorganic materials 0.000 claims 4
- 229940016409 methylsulfonylmethane Drugs 0.000 claims 4
- 230000000813 microbial effect Effects 0.000 claims 4
- 238000000520 microinjection Methods 0.000 claims 4
- 230000005012 migration Effects 0.000 claims 4
- 238000013508 migration Methods 0.000 claims 4
- 210000001616 monocyte Anatomy 0.000 claims 4
- 210000003061 neural cell Anatomy 0.000 claims 4
- 210000004681 ovum Anatomy 0.000 claims 4
- 230000007170 pathology Effects 0.000 claims 4
- 230000003389 potentiating effect Effects 0.000 claims 4
- 230000002829 reductive effect Effects 0.000 claims 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 4
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims 4
- 230000035900 sweating Effects 0.000 claims 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims 3
- 241000234282 Allium Species 0.000 claims 3
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims 3
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 3
- 241000186016 Bifidobacterium bifidum Species 0.000 claims 3
- 241001608472 Bifidobacterium longum Species 0.000 claims 3
- 244000045232 Canavalia ensiformis Species 0.000 claims 3
- 208000015879 Cerebellar disease Diseases 0.000 claims 3
- 244000018436 Coriandrum sativum Species 0.000 claims 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 3
- 206010012735 Diarrhoea Diseases 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 3
- 239000004471 Glycine Substances 0.000 claims 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 3
- 229930195722 L-methionine Natural products 0.000 claims 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims 3
- 240000006024 Lactobacillus plantarum Species 0.000 claims 3
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 claims 3
- 241000186869 Lactobacillus salivarius Species 0.000 claims 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 3
- 244000046095 Psophocarpus tetragonolobus Species 0.000 claims 3
- 241001092490 Purshia Species 0.000 claims 3
- 241000700159 Rattus Species 0.000 claims 3
- 241000194020 Streptococcus thermophilus Species 0.000 claims 3
- 241000271567 Struthioniformes Species 0.000 claims 3
- 108010002687 Survivin Proteins 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 108010017842 Telomerase Proteins 0.000 claims 3
- 235000021307 Triticum Nutrition 0.000 claims 3
- 241000209140 Triticum Species 0.000 claims 3
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 3
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims 3
- 229930003268 Vitamin C Natural products 0.000 claims 3
- 229910021536 Zeolite Inorganic materials 0.000 claims 3
- 230000002378 acidificating effect Effects 0.000 claims 3
- 230000002411 adverse Effects 0.000 claims 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 3
- 210000001367 artery Anatomy 0.000 claims 3
- 238000013473 artificial intelligence Methods 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 230000007177 brain activity Effects 0.000 claims 3
- 230000006931 brain damage Effects 0.000 claims 3
- 231100000874 brain damage Toxicity 0.000 claims 3
- 208000029028 brain injury Diseases 0.000 claims 3
- 239000006227 byproduct Substances 0.000 claims 3
- 238000004113 cell culture Methods 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 230000000052 comparative effect Effects 0.000 claims 3
- 239000004062 cytokinin Substances 0.000 claims 3
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 claims 3
- 230000007123 defense Effects 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 3
- 210000001787 dendrite Anatomy 0.000 claims 3
- 230000029087 digestion Effects 0.000 claims 3
- 230000001079 digestive effect Effects 0.000 claims 3
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims 3
- 235000014103 egg white Nutrition 0.000 claims 3
- 210000000969 egg white Anatomy 0.000 claims 3
- 230000007613 environmental effect Effects 0.000 claims 3
- 235000019197 fats Nutrition 0.000 claims 3
- 235000012055 fruits and vegetables Nutrition 0.000 claims 3
- 239000010903 husk Substances 0.000 claims 3
- 238000011534 incubation Methods 0.000 claims 3
- 230000028709 inflammatory response Effects 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 229940039696 lactobacillus Drugs 0.000 claims 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims 3
- 229910052750 molybdenum Inorganic materials 0.000 claims 3
- 239000011733 molybdenum Substances 0.000 claims 3
- 238000002703 mutagenesis Methods 0.000 claims 3
- 231100000350 mutagenesis Toxicity 0.000 claims 3
- 230000007935 neutral effect Effects 0.000 claims 3
- 210000000440 neutrophil Anatomy 0.000 claims 3
- 210000004940 nucleus Anatomy 0.000 claims 3
- 229920001542 oligosaccharide Polymers 0.000 claims 3
- 150000002482 oligosaccharides Chemical class 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 231100000614 poison Toxicity 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 235000021251 pulses Nutrition 0.000 claims 3
- 150000003254 radicals Chemical class 0.000 claims 3
- 230000037390 scarring Effects 0.000 claims 3
- 230000001568 sexual effect Effects 0.000 claims 3
- 210000001082 somatic cell Anatomy 0.000 claims 3
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 claims 3
- 230000009469 supplementation Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 235000013311 vegetables Nutrition 0.000 claims 3
- 210000003462 vein Anatomy 0.000 claims 3
- 235000019154 vitamin C Nutrition 0.000 claims 3
- 239000011718 vitamin C Substances 0.000 claims 3
- 239000010457 zeolite Substances 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims 2
- 229910001312 Amalgam (dentistry) Inorganic materials 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 2
- 241001532704 Azolla Species 0.000 claims 2
- 229920005721 BUTONAL® Polymers 0.000 claims 2
- 241000606125 Bacteroides Species 0.000 claims 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 claims 2
- 241000219495 Betulaceae Species 0.000 claims 2
- 240000007124 Brassica oleracea Species 0.000 claims 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- 101150012716 CDK1 gene Proteins 0.000 claims 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims 2
- 235000010520 Canavalia ensiformis Nutrition 0.000 claims 2
- 102100026548 Caspase-8 Human genes 0.000 claims 2
- 108090000538 Caspase-8 Proteins 0.000 claims 2
- 108010059892 Cellulase Proteins 0.000 claims 2
- 241001092054 Cercocarpus Species 0.000 claims 2
- 241001243662 Chamaebatia Species 0.000 claims 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 2
- 241000227999 Coffea canephora Species 0.000 claims 2
- 241001572170 Coffea liberica var. dewevrei Species 0.000 claims 2
- 235000002187 Coffea robusta Nutrition 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims 2
- 102000003849 Cytochrome P450 Human genes 0.000 claims 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims 2
- 102000004648 Distal-less homeobox proteins Human genes 0.000 claims 2
- 108010003661 Distal-less homeobox proteins Proteins 0.000 claims 2
- 241001508399 Elaeagnus Species 0.000 claims 2
- 244000223060 Erythrina herbacea Species 0.000 claims 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 claims 2
- 229920001503 Glucan Polymers 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 108010051696 Growth Hormone Proteins 0.000 claims 2
- 101150033506 HOX gene Proteins 0.000 claims 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 2
- 102100030087 Homeobox protein DLX-1 Human genes 0.000 claims 2
- 102100022377 Homeobox protein DLX-2 Human genes 0.000 claims 2
- 102100022376 Homeobox protein DLX-3 Human genes 0.000 claims 2
- 102100022374 Homeobox protein DLX-4 Human genes 0.000 claims 2
- 102100035349 Homeobox protein DLX-6 Human genes 0.000 claims 2
- 101000864690 Homo sapiens Homeobox protein DLX-1 Proteins 0.000 claims 2
- 101000901635 Homo sapiens Homeobox protein DLX-2 Proteins 0.000 claims 2
- 101000901646 Homo sapiens Homeobox protein DLX-3 Proteins 0.000 claims 2
- 101000901614 Homo sapiens Homeobox protein DLX-4 Proteins 0.000 claims 2
- 101000804582 Homo sapiens Homeobox protein DLX-6 Proteins 0.000 claims 2
- 101100477520 Homo sapiens SHOX gene Proteins 0.000 claims 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 102000040104 IAP family Human genes 0.000 claims 2
- 108091069885 IAP family Proteins 0.000 claims 2
- 101710205425 Immediate-early protein 2 Proteins 0.000 claims 2
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 claims 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims 2
- 102000004125 Interleukin-1alpha Human genes 0.000 claims 2
- 108010082786 Interleukin-1alpha Proteins 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- 235000010671 Lathyrus sativus Nutrition 0.000 claims 2
- 240000005783 Lathyrus sativus Species 0.000 claims 2
- 235000007252 Lathyrus tuberosus Nutrition 0.000 claims 2
- 244000237786 Lathyrus tuberosus Species 0.000 claims 2
- 241000219739 Lens Species 0.000 claims 2
- 241000186781 Listeria Species 0.000 claims 2
- 241000219745 Lupinus Species 0.000 claims 2
- 240000005265 Lupinus mutabilis Species 0.000 claims 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 102000043136 MAP kinase family Human genes 0.000 claims 2
- 108091054455 MAP kinase family Proteins 0.000 claims 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 244000131099 Macrotyloma uniflorum Species 0.000 claims 2
- 102000011961 Maturation-Promoting Factor Human genes 0.000 claims 2
- 108010075942 Maturation-Promoting Factor Proteins 0.000 claims 2
- 240000004658 Medicago sativa Species 0.000 claims 2
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 claims 2
- 208000008763 Mercury poisoning Diseases 0.000 claims 2
- 206010027439 Metal poisoning Diseases 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 claims 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims 2
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 claims 2
- 101710091942 N-formyl peptide receptor 2 Proteins 0.000 claims 2
- 229910002651 NO3 Inorganic materials 0.000 claims 2
- 235000019482 Palm oil Nutrition 0.000 claims 2
- 229930182555 Penicillin Natural products 0.000 claims 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 2
- 206010057249 Phagocytosis Diseases 0.000 claims 2
- 241000219843 Pisum Species 0.000 claims 2
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 claims 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims 2
- 241000219100 Rhamnaceae Species 0.000 claims 2
- 108020001027 Ribosomal DNA Proteins 0.000 claims 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 2
- 241001508793 Shepherdia Species 0.000 claims 2
- 102000048489 Short Stature Homeobox Human genes 0.000 claims 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 102100038803 Somatotropin Human genes 0.000 claims 2
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 claims 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 2
- 108010012715 Superoxide dismutase Proteins 0.000 claims 2
- 102000040945 Transcription factor Human genes 0.000 claims 2
- 108091023040 Transcription factor Proteins 0.000 claims 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 claims 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 2
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 claims 2
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 2
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 claims 2
- 241000219977 Vigna Species 0.000 claims 2
- 101710160067 Viral transcription factor IE2 Proteins 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- 208000034817 Waterborne disease Diseases 0.000 claims 2
- 108010076089 accutase Proteins 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000018254 acute transverse myelitis Diseases 0.000 claims 2
- 210000004504 adult stem cell Anatomy 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 239000002473 artificial blood Substances 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 230000003190 augmentative effect Effects 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 208000018300 basal ganglia disease Diseases 0.000 claims 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 claims 2
- 235000013361 beverage Nutrition 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000011111 cardboard Substances 0.000 claims 2
- 150000001746 carotenes Chemical class 0.000 claims 2
- 235000005473 carotenes Nutrition 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 claims 2
- 230000004087 circulation Effects 0.000 claims 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 claims 2
- 239000004927 clay Substances 0.000 claims 2
- 235000009508 confectionery Nutrition 0.000 claims 2
- 239000000470 constituent Substances 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 229910052802 copper Inorganic materials 0.000 claims 2
- 239000010949 copper Substances 0.000 claims 2
- 229960003067 cystine Drugs 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 235000013365 dairy product Nutrition 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 230000003210 demyelinating effect Effects 0.000 claims 2
- 239000000448 dental amalgam Substances 0.000 claims 2
- 230000000378 dietary effect Effects 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 235000019621 digestibility Nutrition 0.000 claims 2
- 210000002249 digestive system Anatomy 0.000 claims 2
- 235000013399 edible fruits Nutrition 0.000 claims 2
- 230000002500 effect on skin Effects 0.000 claims 2
- 239000003792 electrolyte Substances 0.000 claims 2
- 230000037149 energy metabolism Effects 0.000 claims 2
- 230000002255 enzymatic effect Effects 0.000 claims 2
- 239000004060 excitotoxin Substances 0.000 claims 2
- 230000007717 exclusion Effects 0.000 claims 2
- 206010016256 fatigue Diseases 0.000 claims 2
- 230000008175 fetal development Effects 0.000 claims 2
- 210000002950 fibroblast Anatomy 0.000 claims 2
- 238000011049 filling Methods 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- 230000000762 glandular Effects 0.000 claims 2
- 239000011521 glass Substances 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 2
- 239000000383 hazardous chemical Substances 0.000 claims 2
- 239000002920 hazardous waste Substances 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- 235000008216 herbs Nutrition 0.000 claims 2
- 230000003284 homeostatic effect Effects 0.000 claims 2
- 102000058223 human VEGFA Human genes 0.000 claims 2
- 230000006872 improvement Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 claims 2
- 229940066544 lactobacillus sporogenes Drugs 0.000 claims 2
- 235000021374 legumes Nutrition 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 230000003859 lipid peroxidation Effects 0.000 claims 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims 2
- 235000019136 lipoic acid Nutrition 0.000 claims 2
- 230000001926 lymphatic effect Effects 0.000 claims 2
- 210000004324 lymphatic system Anatomy 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 235000012054 meals Nutrition 0.000 claims 2
- 231100000783 metal toxicity Toxicity 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- 230000000394 mitotic effect Effects 0.000 claims 2
- 210000004877 mucosa Anatomy 0.000 claims 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 231100000252 nontoxic Toxicity 0.000 claims 2
- 230000003000 nontoxic effect Effects 0.000 claims 2
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 2
- 239000002540 palm oil Substances 0.000 claims 2
- 229940049954 penicillin Drugs 0.000 claims 2
- 239000000575 pesticide Substances 0.000 claims 2
- 230000008782 phagocytosis Effects 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 235000002949 phytic acid Nutrition 0.000 claims 2
- 239000002574 poison Substances 0.000 claims 2
- 235000017924 poor diet Nutrition 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 235000021489 probiotic drink Nutrition 0.000 claims 2
- 102000003998 progesterone receptors Human genes 0.000 claims 2
- 108090000468 progesterone receptors Proteins 0.000 claims 2
- 235000019260 propionic acid Nutrition 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 2
- 230000002797 proteolythic effect Effects 0.000 claims 2
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 2
- 230000009103 reabsorption Effects 0.000 claims 2
- 210000005084 renal tissue Anatomy 0.000 claims 2
- 230000002629 repopulating effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000033764 rhythmic process Effects 0.000 claims 2
- 230000000630 rising effect Effects 0.000 claims 2
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 239000011669 selenium Substances 0.000 claims 2
- 229910052711 selenium Inorganic materials 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 150000004666 short chain fatty acids Chemical class 0.000 claims 2
- 238000004904 shortening Methods 0.000 claims 2
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 238000009987 spinning Methods 0.000 claims 2
- 239000007858 starting material Substances 0.000 claims 2
- 239000010902 straw Substances 0.000 claims 2
- 229960005322 streptomycin Drugs 0.000 claims 2
- 235000000346 sugar Nutrition 0.000 claims 2
- 125000004354 sulfur functional group Chemical group 0.000 claims 2
- 230000002459 sustained effect Effects 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 229960003080 taurine Drugs 0.000 claims 2
- 229960002663 thioctic acid Drugs 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 238000012549 training Methods 0.000 claims 2
- 230000002103 transcriptional effect Effects 0.000 claims 2
- 230000001052 transient effect Effects 0.000 claims 2
- 208000009174 transverse myelitis Diseases 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 2
- 229940094720 viagra Drugs 0.000 claims 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims 2
- 235000019158 vitamin B6 Nutrition 0.000 claims 2
- 239000011726 vitamin B6 Substances 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 239000002023 wood Substances 0.000 claims 2
- 239000002916 wood waste Substances 0.000 claims 2
- 235000020138 yakult Nutrition 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 claims 1
- CDOSHBSSFJOMGT-SNVBAGLBSA-N (S)-linalool Chemical compound CC(C)=CCC[C@](C)(O)C=C CDOSHBSSFJOMGT-SNVBAGLBSA-N 0.000 claims 1
- VLTXBOGHSBHSAC-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6-undecafluoro-6-[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]cyclohexane Chemical compound FC(F)(F)C(C(F)(F)F)(C(F)(F)F)C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F VLTXBOGHSBHSAC-UHFFFAOYSA-N 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- 102000004899 14-3-3 Proteins Human genes 0.000 claims 1
- 101710112812 14-3-3 protein Proteins 0.000 claims 1
- UPLPHRJJTCUQAY-WIRWPRASSA-N 2,3-thioepoxy madol Chemical compound C([C@@H]1CC2)[C@@H]3S[C@@H]3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 UPLPHRJJTCUQAY-WIRWPRASSA-N 0.000 claims 1
- XFCMNSHQOZQILR-UHFFFAOYSA-N 2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOC(=O)C(C)=C XFCMNSHQOZQILR-UHFFFAOYSA-N 0.000 claims 1
- ULUOXCRNSRVJPE-MJRHPTFMSA-N 2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]propanoyl]amino]acetic acid Chemical compound C([C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(O)=O)C1=CN=CN1 ULUOXCRNSRVJPE-MJRHPTFMSA-N 0.000 claims 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims 1
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 1
- 108010011619 6-Phytase Proteins 0.000 claims 1
- 206010000060 Abdominal distension Diseases 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 241000186042 Actinomyces bovis Species 0.000 claims 1
- 229930024421 Adenine Natural products 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 241000270728 Alligator Species 0.000 claims 1
- 241001541997 Allionia Species 0.000 claims 1
- 241000792874 Allocasuarina Species 0.000 claims 1
- 241000219496 Alnus Species 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 claims 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 claims 1
- 101710106364 Apoptosis inhibitor 1 Proteins 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 241000512259 Ascophyllum nodosum Species 0.000 claims 1
- 244000003416 Asparagus officinalis Species 0.000 claims 1
- 235000005340 Asparagus officinalis Nutrition 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 229930192334 Auxin Natural products 0.000 claims 1
- 244000075850 Avena orientalis Species 0.000 claims 1
- 235000007319 Avena orientalis Nutrition 0.000 claims 1
- 241000589154 Azotobacter group Species 0.000 claims 1
- 102100027955 BAG family molecular chaperone regulator 4 Human genes 0.000 claims 1
- 101710089799 BAG family molecular chaperone regulator 4 Proteins 0.000 claims 1
- 241000206761 Bacillariophyta Species 0.000 claims 1
- 108010062877 Bacteriocins Proteins 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 108010001572 Basic-Leucine Zipper Transcription Factors Proteins 0.000 claims 1
- 102000000806 Basic-Leucine Zipper Transcription Factors Human genes 0.000 claims 1
- 235000021537 Beetroot Nutrition 0.000 claims 1
- 235000018185 Betula X alpestris Nutrition 0.000 claims 1
- 235000018212 Betula X uliginosa Nutrition 0.000 claims 1
- 241001474374 Blennius Species 0.000 claims 1
- 208000035049 Blood-Borne Infections Diseases 0.000 claims 1
- 241000219198 Brassica Species 0.000 claims 1
- 235000003351 Brassica cretica Nutrition 0.000 claims 1
- 240000002791 Brassica napus Species 0.000 claims 1
- 235000011293 Brassica napus Nutrition 0.000 claims 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 claims 1
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 claims 1
- 235000003343 Brassica rupestris Nutrition 0.000 claims 1
- 206010006326 Breath odour Diseases 0.000 claims 1
- 241000193417 Brevibacillus laterosporus Species 0.000 claims 1
- 241000273930 Brevoortia tyrannus Species 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 1
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 claims 1
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- 241000220442 Cajanus Species 0.000 claims 1
- 241000220450 Cajanus cajan Species 0.000 claims 1
- 235000010773 Cajanus indicus Nutrition 0.000 claims 1
- 244000105627 Cajanus indicus Species 0.000 claims 1
- 102000016838 Calbindin 1 Human genes 0.000 claims 1
- 229910021532 Calcite Inorganic materials 0.000 claims 1
- 241000220451 Canavalia Species 0.000 claims 1
- 235000010518 Canavalia gladiata Nutrition 0.000 claims 1
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 241000283707 Capra Species 0.000 claims 1
- 235000002566 Capsicum Nutrition 0.000 claims 1
- 101710086403 Carbonic anhydrase-related protein Proteins 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 108090000397 Caspase 3 Proteins 0.000 claims 1
- 108090000567 Caspase 7 Proteins 0.000 claims 1
- 102100029855 Caspase-3 Human genes 0.000 claims 1
- 102100038902 Caspase-7 Human genes 0.000 claims 1
- 102100026550 Caspase-9 Human genes 0.000 claims 1
- 108090000566 Caspase-9 Proteins 0.000 claims 1
- 241000219501 Casuarina Species 0.000 claims 1
- 241000219500 Casuarinaceae Species 0.000 claims 1
- 241001083940 Ceanothus Species 0.000 claims 1
- 235000014342 Ceanothus Nutrition 0.000 claims 1
- 108010084185 Cellulases Proteins 0.000 claims 1
- 102000005575 Cellulases Human genes 0.000 claims 1
- 235000009006 Cercocarpus ledifolius Nutrition 0.000 claims 1
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- 235000007091 Chlorella pyrenoidosa Nutrition 0.000 claims 1
- 244000249214 Chlorella pyrenoidosa Species 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 241000195628 Chlorophyta Species 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 108091060290 Chromatid Proteins 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 235000010521 Cicer Nutrition 0.000 claims 1
- 241000220455 Cicer Species 0.000 claims 1
- 235000010523 Cicer arietinum Nutrition 0.000 claims 1
- 244000045195 Cicer arietinum Species 0.000 claims 1
- 235000007542 Cichorium intybus Nutrition 0.000 claims 1
- 244000298479 Cichorium intybus Species 0.000 claims 1
- 241000132536 Cirsium Species 0.000 claims 1
- 102100038446 Claudin-5 Human genes 0.000 claims 1
- 108090000582 Claudin-5 Proteins 0.000 claims 1
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 241001572165 Coffea benghalensis Species 0.000 claims 1
- 241001379985 Coffea bonnieri Species 0.000 claims 1
- 241000228000 Coffea congensis Species 0.000 claims 1
- 241000176981 Coffea gallienii Species 0.000 claims 1
- 241000228031 Coffea liberica Species 0.000 claims 1
- 241000176996 Coffea mogeneti Species 0.000 claims 1
- 241000228050 Coffea stenophylla Species 0.000 claims 1
- 241000723375 Colchicum Species 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 241000219046 Colletia Species 0.000 claims 1
- 235000006481 Colocasia esculenta Nutrition 0.000 claims 1
- 244000205754 Colocasia esculenta Species 0.000 claims 1
- 241001115510 Comptonia Species 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 241000218170 Coriaria Species 0.000 claims 1
- 241000218168 Coriariaceae Species 0.000 claims 1
- 235000004885 Cowania mexicana Nutrition 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 244000304337 Cuminum cyminum Species 0.000 claims 1
- 235000007129 Cuminum cyminum Nutrition 0.000 claims 1
- 241000219748 Cyamopsis Species 0.000 claims 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 claims 1
- 241000592295 Cycadophyta Species 0.000 claims 1
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 claims 1
- 102000016736 Cyclin Human genes 0.000 claims 1
- 108050006400 Cyclin Proteins 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 241000252233 Cyprinus carpio Species 0.000 claims 1
- 102100030497 Cytochrome c Human genes 0.000 claims 1
- 108010075031 Cytochromes c Proteins 0.000 claims 1
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 claims 1
- 230000005778 DNA damage Effects 0.000 claims 1
- 231100000277 DNA damage Toxicity 0.000 claims 1
- 101100540419 Danio rerio kdrl gene Proteins 0.000 claims 1
- 241001117810 Datisca Species 0.000 claims 1
- 241001117813 Datiscaceae Species 0.000 claims 1
- 102000010170 Death domains Human genes 0.000 claims 1
- 108050001718 Death domains Proteins 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 claims 1
- 241000229161 Discaria Species 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 claims 1
- 241000229249 Dryas <angiosperm> Species 0.000 claims 1
- 208000027244 Dysbiosis Diseases 0.000 claims 1
- 101710175001 E1B protein, small T-antigen Proteins 0.000 claims 1
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 claims 1
- 241001117772 Elaeagnaceae Species 0.000 claims 1
- 235000017643 Elaeagnus angustifolia Nutrition 0.000 claims 1
- 235000004597 Elaeagnus commutata Nutrition 0.000 claims 1
- 244000016119 Elaeagnus latifolia Species 0.000 claims 1
- 235000001456 Elaeagnus latifolia Nutrition 0.000 claims 1
- 235000007630 Elaeagnus umbellata var parvifolia Nutrition 0.000 claims 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 claims 1
- 102000006402 Endocrine-Gland-Derived Vascular Endothelial Growth Factor Human genes 0.000 claims 1
- 108010044063 Endocrine-Gland-Derived Vascular Endothelial Growth Factor Proteins 0.000 claims 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims 1
- 241000194031 Enterococcus faecium Species 0.000 claims 1
- 206010014896 Enterocolitis haemorrhagic Diseases 0.000 claims 1
- 208000000237 Environmental Illness Diseases 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 102400001368 Epidermal growth factor Human genes 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 235000005280 Erythrina herbacea Nutrition 0.000 claims 1
- 108700039887 Essential Genes Proteins 0.000 claims 1
- 102000007594 Estrogen Receptor alpha Human genes 0.000 claims 1
- 108010007005 Estrogen Receptor alpha Proteins 0.000 claims 1
- 102000000509 Estrogen Receptor beta Human genes 0.000 claims 1
- 108010041356 Estrogen Receptor beta Proteins 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 101150064015 FAS gene Proteins 0.000 claims 1
- 241000220485 Fabaceae Species 0.000 claims 1
- 241000510678 Falcaria vulgaris Species 0.000 claims 1
- 208000021663 Female sexual arousal disease Diseases 0.000 claims 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims 1
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- 241000187809 Frankia Species 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 239000005792 Geraniol Substances 0.000 claims 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 claims 1
- 241001315191 Gladiata Species 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 102000006771 Gonadotropins Human genes 0.000 claims 1
- 108010086677 Gonadotropins Proteins 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 241001107136 Gunnera Species 0.000 claims 1
- 241000792872 Gymnostoma Species 0.000 claims 1
- 102000005623 HSP27 Heat-Shock Proteins Human genes 0.000 claims 1
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 claims 1
- 108010027814 HSP72 Heat-Shock Proteins Proteins 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 206010061192 Haemorrhagic fever Diseases 0.000 claims 1
- 240000008669 Hedera helix Species 0.000 claims 1
- 235000003230 Helianthus tuberosus Nutrition 0.000 claims 1
- 240000008892 Helianthus tuberosus Species 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 241000229143 Hippophae Species 0.000 claims 1
- 235000003935 Hippophae Nutrition 0.000 claims 1
- 240000000950 Hippophae rhamnoides Species 0.000 claims 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 claims 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims 1
- 101000585555 Homo sapiens PCNA-associated factor Proteins 0.000 claims 1
- 101000742579 Homo sapiens Vascular endothelial growth factor B Proteins 0.000 claims 1
- 101000742599 Homo sapiens Vascular endothelial growth factor D Proteins 0.000 claims 1
- 240000005979 Hordeum vulgare Species 0.000 claims 1
- 235000007340 Hordeum vulgare Nutrition 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 1
- 241000257303 Hymenoptera Species 0.000 claims 1
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 208000000269 Hyperkinesis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 208000002979 Influenza in Birds Diseases 0.000 claims 1
- 102100023915 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 101150088608 Kdr gene Proteins 0.000 claims 1
- 241000049594 Kentrothamnus Species 0.000 claims 1
- 102100020880 Kit ligand Human genes 0.000 claims 1
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 239000004201 L-cysteine Substances 0.000 claims 1
- 235000013878 L-cysteine Nutrition 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 1
- VVNCNSJFMMFHPL-GSVOUGTGSA-N L-penicillamine Chemical compound CC(C)(S)[C@H](N)C(O)=O VVNCNSJFMMFHPL-GSVOUGTGSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 108010084772 LIM Domain Proteins Proteins 0.000 claims 1
- 102000005633 LIM Domain Proteins Human genes 0.000 claims 1
- 108010059881 Lactase Proteins 0.000 claims 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims 1
- 235000013958 Lactobacillus casei Nutrition 0.000 claims 1
- 241000186840 Lactobacillus fermentum Species 0.000 claims 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 201000010538 Lactose Intolerance Diseases 0.000 claims 1
- 241000282838 Lama Species 0.000 claims 1
- 235000019687 Lamb Nutrition 0.000 claims 1
- 201000008197 Laryngitis Diseases 0.000 claims 1
- 241000219729 Lathyrus Species 0.000 claims 1
- 206010024264 Lethargy Diseases 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 241000894731 Lobaria Species 0.000 claims 1
- 235000008755 Lupinus mutabilis Nutrition 0.000 claims 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 241000219816 Macrotyloma Species 0.000 claims 1
- 235000012549 Macrotyloma uniflorum Nutrition 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 235000014435 Mentha Nutrition 0.000 claims 1
- 241001072983 Mentha Species 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 241000191938 Micrococcus luteus Species 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010061291 Mineral deficiency Diseases 0.000 claims 1
- 241000237852 Mollusca Species 0.000 claims 1
- JJWSNOOGIUMOEE-UHFFFAOYSA-N Monomethylmercury Chemical compound [Hg]C JJWSNOOGIUMOEE-UHFFFAOYSA-N 0.000 claims 1
- 241000122904 Mucuna Species 0.000 claims 1
- 244000111261 Mucuna pruriens Species 0.000 claims 1
- 235000008540 Mucuna pruriens var utilis Nutrition 0.000 claims 1
- 241001534756 Mungos Species 0.000 claims 1
- 240000005561 Musa balbisiana Species 0.000 claims 1
- 241000219433 Myrica Species 0.000 claims 1
- 241001115514 Myricaceae Species 0.000 claims 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 1
- 241000588645 Neisseria sicca Species 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 101710138657 Neurotoxin Proteins 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 241000192656 Nostoc Species 0.000 claims 1
- 108010027206 Nucleopolyhedrovirus inhibitor of apoptosis Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 206010031009 Oral pain Diseases 0.000 claims 1
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 1
- 102100029879 PCNA-associated factor Human genes 0.000 claims 1
- 101150062285 PGF gene Proteins 0.000 claims 1
- 240000004371 Panax ginseng Species 0.000 claims 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims 1
- 235000003140 Panax quinquefolius Nutrition 0.000 claims 1
- 241000588912 Pantoea agglomerans Species 0.000 claims 1
- 235000008753 Papaver somniferum Nutrition 0.000 claims 1
- 241000193157 Paraclostridium bifermentans Species 0.000 claims 1
- 239000006002 Pepper Substances 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 241000192033 Peptostreptococcus sp. Species 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 241000219833 Phaseolus Species 0.000 claims 1
- 240000001956 Phaseolus acutifolius Species 0.000 claims 1
- 235000008527 Phaseolus acutifolius var tenuifolius Nutrition 0.000 claims 1
- 235000006089 Phaseolus angularis Nutrition 0.000 claims 1
- 235000010632 Phaseolus coccineus Nutrition 0.000 claims 1
- 235000010617 Phaseolus lunatus Nutrition 0.000 claims 1
- 244000042209 Phaseolus multiflorus Species 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims 1
- 240000004760 Pimpinella anisum Species 0.000 claims 1
- 235000016761 Piper aduncum Nutrition 0.000 claims 1
- 235000017804 Piper guineense Nutrition 0.000 claims 1
- 240000003889 Piper guineense Species 0.000 claims 1
- 235000008184 Piper nigrum Nutrition 0.000 claims 1
- 102100035194 Placenta growth factor Human genes 0.000 claims 1
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 102000002273 Polycomb Repressive Complex 1 Human genes 0.000 claims 1
- 108010000598 Polycomb Repressive Complex 1 Proteins 0.000 claims 1
- 108010022429 Polycomb-Group Proteins Proteins 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 claims 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 claims 1
- 108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 claims 1
- 102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 claims 1
- 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 claims 1
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 claims 1
- 241000219845 Psophocarpus Species 0.000 claims 1
- 235000014465 Psophocarpus palustris Nutrition 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims 1
- 208000005587 Refsum Disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 241000049527 Retanilla Species 0.000 claims 1
- 241000220317 Rosa Species 0.000 claims 1
- 235000004789 Rosa xanthina Nutrition 0.000 claims 1
- 241000220222 Rosaceae Species 0.000 claims 1
- 240000007651 Rubus glaucus Species 0.000 claims 1
- 101100465401 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SCL1 gene Proteins 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims 1
- 241001037421 Sarcina sp. Species 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 244000082988 Secale cereale Species 0.000 claims 1
- 235000007238 Secale cereale Nutrition 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 241000607694 Serratia odorifera Species 0.000 claims 1
- 241000533293 Sesbania emerus Species 0.000 claims 1
- 235000006449 Shepherdia argentea Nutrition 0.000 claims 1
- 108010017898 Shiga Toxins Proteins 0.000 claims 1
- 241000607762 Shigella flexneri Species 0.000 claims 1
- 244000272459 Silybum marianum Species 0.000 claims 1
- 240000003768 Solanum lycopersicum Species 0.000 claims 1
- 244000061457 Solanum nigrum Species 0.000 claims 1
- 235000000342 Solanum rostratum Nutrition 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims 1
- 208000011641 Spinocerebellar disease Diseases 0.000 claims 1
- 108010039445 Stem Cell Factor Proteins 0.000 claims 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims 1
- 239000005864 Sulphur Substances 0.000 claims 1
- 102100037219 Syntenin-1 Human genes 0.000 claims 1
- 108010083130 Syntenins Proteins 0.000 claims 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 241000492514 Tetragonolobus Species 0.000 claims 1
- 240000002657 Thymus vulgaris Species 0.000 claims 1
- 235000007303 Thymus vulgaris Nutrition 0.000 claims 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
- 206010044314 Tracheobronchitis Diseases 0.000 claims 1
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 claims 1
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 241000229167 Trevoa Species 0.000 claims 1
- 241000223261 Trichoderma viride Species 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 235000007264 Triticum durum Nutrition 0.000 claims 1
- 240000002805 Triticum turgidum Species 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims 1
- 101150095130 URAD gene Proteins 0.000 claims 1
- 102100024205 Ubiquitin carboxyl-terminal hydrolase MINDY-3 Human genes 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 235000009108 Urtica dioica Nutrition 0.000 claims 1
- 241000218215 Urticaceae Species 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 235000009499 Vanilla fragrans Nutrition 0.000 claims 1
- 244000263375 Vanilla tahitensis Species 0.000 claims 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 208000001407 Vascular Headaches Diseases 0.000 claims 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
- 241000219873 Vicia Species 0.000 claims 1
- 235000010725 Vigna aconitifolia Nutrition 0.000 claims 1
- 244000042325 Vigna aconitifolia Species 0.000 claims 1
- 240000007098 Vigna angularis Species 0.000 claims 1
- 235000010711 Vigna angularis Nutrition 0.000 claims 1
- 244000042295 Vigna mungo Species 0.000 claims 1
- 235000010716 Vigna mungo Nutrition 0.000 claims 1
- 240000004922 Vigna radiata Species 0.000 claims 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 claims 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 claims 1
- 235000010726 Vigna sinensis Nutrition 0.000 claims 1
- 235000011453 Vigna umbellata Nutrition 0.000 claims 1
- 244000042314 Vigna unguiculata Species 0.000 claims 1
- 244000240068 Vigna unguiculata ssp sesquipedalis Species 0.000 claims 1
- 235000005755 Vigna unguiculata ssp. sesquipedalis Nutrition 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 229930003451 Vitamin B1 Natural products 0.000 claims 1
- 235000009754 Vitis X bourquina Nutrition 0.000 claims 1
- 235000012333 Vitis X labruscana Nutrition 0.000 claims 1
- 240000006365 Vitis vinifera Species 0.000 claims 1
- 235000014787 Vitis vinifera Nutrition 0.000 claims 1
- 241000272195 Vultur Species 0.000 claims 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims 1
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims 1
- 229960004373 acetylcholine Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000006978 adaptation Effects 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- 208000030597 adult Refsum disease Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 239000013572 airborne allergen Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 238000012867 alanine scanning Methods 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 210000002226 anterior horn cell Anatomy 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 238000009360 aquaculture Methods 0.000 claims 1
- 244000144974 aquaculture Species 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 239000010426 asphalt Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 239000002363 auxin Substances 0.000 claims 1
- 206010064097 avian influenza Diseases 0.000 claims 1
- 108010042854 bacteria histone-like protein HU Proteins 0.000 claims 1
- 235000021015 bananas Nutrition 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 102000055102 bcl-2-Associated X Human genes 0.000 claims 1
- 108700000707 bcl-2-Associated X Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 claims 1
- 230000010234 biliary secretion Effects 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims 1
- 235000005774 blackeyed pea Nutrition 0.000 claims 1
- 210000004952 blastocoel Anatomy 0.000 claims 1
- 208000024330 bloating Diseases 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 230000036770 blood supply Effects 0.000 claims 1
- 230000004641 brain development Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000011449 brick Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000004566 building material Substances 0.000 claims 1
- 229960002092 busulfan Drugs 0.000 claims 1
- 239000001201 calcium disodium ethylene diamine tetra-acetate Substances 0.000 claims 1
- 235000011188 calcium disodium ethylene diamine tetraacetate Nutrition 0.000 claims 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-L calcium;disodium;2-[2-[bis(carboxylatomethyl)azaniumyl]ethyl-(carboxylatomethyl)azaniumyl]acetate Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-L 0.000 claims 1
- 208000001969 capillary hemangioma Diseases 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 238000004177 carbon cycle Methods 0.000 claims 1
- 239000011852 carbon nanoparticle Substances 0.000 claims 1
- 239000002041 carbon nanotube Substances 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 238000012219 cassette mutagenesis Methods 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 230000011712 cell development Effects 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 239000006285 cell suspension Substances 0.000 claims 1
- 229940106157 cellulase Drugs 0.000 claims 1
- 210000003793 centrosome Anatomy 0.000 claims 1
- 239000004464 cereal grain Substances 0.000 claims 1
- 235000013339 cereals Nutrition 0.000 claims 1
- 210000001638 cerebellum Anatomy 0.000 claims 1
- 235000013351 cheese Nutrition 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 210000004756 chromatid Anatomy 0.000 claims 1
- 229910052804 chromium Inorganic materials 0.000 claims 1
- 229940117229 cialis Drugs 0.000 claims 1
- 230000001886 ciliary effect Effects 0.000 claims 1
- 235000000484 citronellol Nutrition 0.000 claims 1
- 238000004140 cleaning Methods 0.000 claims 1
- 238000009535 clinical urine test Methods 0.000 claims 1
- 239000003245 coal Substances 0.000 claims 1
- 229940110456 cocoa butter Drugs 0.000 claims 1
- 235000019868 cocoa butter Nutrition 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 229920002770 condensed tannin Polymers 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 230000008473 connective tissue growth Effects 0.000 claims 1
- 238000010411 cooking Methods 0.000 claims 1
- 239000001359 coriandrum sativum l. oleoresin Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000002594 corticospinal effect Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 108091007930 cytoplasmic receptors Proteins 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 231100000517 death Toxicity 0.000 claims 1
- 230000004040 defense response to microbe Effects 0.000 claims 1
- 230000018044 dehydration Effects 0.000 claims 1
- 238000006297 dehydration reaction Methods 0.000 claims 1
- 238000002716 delivery method Methods 0.000 claims 1
- 208000017004 dementia pugilistica Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000009568 diazotrophic growth Effects 0.000 claims 1
- 235000021004 dietary regimen Nutrition 0.000 claims 1
- 102000038379 digestive enzymes Human genes 0.000 claims 1
- 108091007734 digestive enzymes Proteins 0.000 claims 1
- 108700003601 dimethylglycine Proteins 0.000 claims 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 230000009429 distress Effects 0.000 claims 1
- 238000009826 distribution Methods 0.000 claims 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 1
- 238000005553 drilling Methods 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 230000007140 dysbiosis Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 210000005069 ears Anatomy 0.000 claims 1
- 210000002969 egg yolk Anatomy 0.000 claims 1
- 235000013345 egg yolk Nutrition 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 230000007515 enzymatic degradation Effects 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 230000007608 epigenetic mechanism Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000008472 epithelial growth Effects 0.000 claims 1
- 230000008029 eradication Effects 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000002474 experimental method Methods 0.000 claims 1
- 210000003722 extracellular fluid Anatomy 0.000 claims 1
- 210000001723 extracellular space Anatomy 0.000 claims 1
- 230000004438 eyesight Effects 0.000 claims 1
- 239000002979 fabric softener Substances 0.000 claims 1
- 239000006052 feed supplement Substances 0.000 claims 1
- 235000021107 fermented food Nutrition 0.000 claims 1
- 239000002871 fertility agent Substances 0.000 claims 1
- 230000004720 fertilization Effects 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000010579 first pass effect Methods 0.000 claims 1
- 206010016766 flatulence Diseases 0.000 claims 1
- 229930003935 flavonoid Natural products 0.000 claims 1
- 150000002215 flavonoids Chemical class 0.000 claims 1
- 235000017173 flavonoids Nutrition 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- 239000011888 foil Substances 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 239000013568 food allergen Substances 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 235000013350 formula milk Nutrition 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 239000002509 fulvic acid Substances 0.000 claims 1
- 229940095100 fulvic acid Drugs 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000001156 gastric mucosa Anatomy 0.000 claims 1
- 244000000036 gastrointestinal pathogen Species 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 229940113224 gelatin pill Drugs 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 1
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 238000012268 genome sequencing Methods 0.000 claims 1
- 229940113087 geraniol Drugs 0.000 claims 1
- HIGQPQRQIQDZMP-DHZHZOJOSA-N geranyl acetate Chemical compound CC(C)=CCC\C(C)=C\COC(C)=O HIGQPQRQIQDZMP-DHZHZOJOSA-N 0.000 claims 1
- 235000008434 ginseng Nutrition 0.000 claims 1
- 210000001703 glandular epithelial cell Anatomy 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 claims 1
- 229960002849 glucosamine sulfate Drugs 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 1
- 239000002622 gonadotropin Substances 0.000 claims 1
- 230000036449 good health Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 235000020072 grain neutral spirit Nutrition 0.000 claims 1
- 235000021384 green leafy vegetables Nutrition 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000012447 hatching Effects 0.000 claims 1
- 230000007407 health benefit Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 108010002430 hemicellulase Proteins 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 230000011132 hemopoiesis Effects 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 230000010224 hepatic metabolism Effects 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 229960002591 hydroxyproline Drugs 0.000 claims 1
- 230000003483 hypokinetic effect Effects 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 230000008105 immune reaction Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims 1
- 230000006882 induction of apoptosis Effects 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000009309 intensive farming Methods 0.000 claims 1
- 229940100601 interleukin-6 Drugs 0.000 claims 1
- 230000007413 intestinal health Effects 0.000 claims 1
- 210000005061 intracellular organelle Anatomy 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 230000000622 irritating effect Effects 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000002147 killing effect Effects 0.000 claims 1
- 210000002415 kinetochore Anatomy 0.000 claims 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims 1
- 229940017800 lactobacillus casei Drugs 0.000 claims 1
- 229940072205 lactobacillus plantarum Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 206010024378 leukocytosis Diseases 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 230000000670 limiting effect Effects 0.000 claims 1
- 238000007443 liposuction Methods 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000003908 liver function Effects 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 230000008376 long-term health Effects 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 231100000053 low toxicity Toxicity 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 230000005291 magnetic effect Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 229910052748 manganese Inorganic materials 0.000 claims 1
- 238000013507 mapping Methods 0.000 claims 1
- 229960003987 melatonin Drugs 0.000 claims 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims 1
- 239000000155 melt Substances 0.000 claims 1
- 230000003923 mental ability Effects 0.000 claims 1
- 201000003102 mental depression Diseases 0.000 claims 1
- 150000002730 mercury Chemical class 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000007102 metabolic function Effects 0.000 claims 1
- 230000037353 metabolic pathway Effects 0.000 claims 1
- 150000002736 metal compounds Chemical class 0.000 claims 1
- 230000031864 metaphase Effects 0.000 claims 1
- 210000001724 microfibril Anatomy 0.000 claims 1
- 244000005706 microflora Species 0.000 claims 1
- 239000012982 microporous membrane Substances 0.000 claims 1
- 230000027939 micturition Effects 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 238000005065 mining Methods 0.000 claims 1
- 235000014569 mints Nutrition 0.000 claims 1
- 210000000479 mitotic spindle apparatus Anatomy 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 235000010460 mustard Nutrition 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 239000002581 neurotoxin Substances 0.000 claims 1
- 231100000618 neurotoxin Toxicity 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 150000002823 nitrates Chemical class 0.000 claims 1
- 150000002826 nitrites Chemical class 0.000 claims 1
- 238000004172 nitrogen cycle Methods 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 210000000633 nuclear envelope Anatomy 0.000 claims 1
- 230000000050 nutritive effect Effects 0.000 claims 1
- 229940038580 oat bran Drugs 0.000 claims 1
- 239000004465 oilseed meal Substances 0.000 claims 1
- GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 230000004792 oxidative damage Effects 0.000 claims 1
- 229940124583 pain medication Drugs 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 239000011087 paperboard Substances 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 230000001175 peptic effect Effects 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 claims 1
- 210000001986 peyer's patch Anatomy 0.000 claims 1
- 210000001539 phagocyte Anatomy 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 239000003016 pheromone Substances 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 229940085127 phytase Drugs 0.000 claims 1
- 239000000467 phytic acid Substances 0.000 claims 1
- 229940068041 phytic acid Drugs 0.000 claims 1
- 229930195732 phytohormone Natural products 0.000 claims 1
- 229940023488 pill Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 238000009428 plumbing Methods 0.000 claims 1
- 230000007096 poisonous effect Effects 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 210000004258 portal system Anatomy 0.000 claims 1
- 210000003240 portal vein Anatomy 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 230000003244 pro-oxidative effect Effects 0.000 claims 1
- 235000008428 probiotic yoghurt drink Nutrition 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 150000003212 purines Chemical class 0.000 claims 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 1
- 229960001327 pyridoxal phosphate Drugs 0.000 claims 1
- 238000003908 quality control method Methods 0.000 claims 1
- 235000021013 raspberries Nutrition 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 238000007670 refining Methods 0.000 claims 1
- 238000009877 rendering Methods 0.000 claims 1
- 238000009418 renovation Methods 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 238000012552 review Methods 0.000 claims 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims 1
- 230000001523 saccharolytic effect Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 235000021391 short chain fatty acids Nutrition 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 238000002741 site-directed mutagenesis Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 235000011888 snacks Nutrition 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 230000007480 spreading Effects 0.000 claims 1
- 238000003892 spreading Methods 0.000 claims 1
- 239000005315 stained glass Substances 0.000 claims 1
- 230000037351 starvation Effects 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 230000036561 sun exposure Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 230000001839 systemic circulation Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 claims 1
- 239000008399 tap water Substances 0.000 claims 1
- 235000020679 tap water Nutrition 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims 1
- 230000008471 teeth growth Effects 0.000 claims 1
- 235000008070 tepary bean Nutrition 0.000 claims 1
- 229960003495 thiamine Drugs 0.000 claims 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 239000001585 thymus vulgaris Substances 0.000 claims 1
- 239000010936 titanium Substances 0.000 claims 1
- 229910052719 titanium Inorganic materials 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
- 239000010891 toxic waste Substances 0.000 claims 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 claims 1
- 230000001228 trophic effect Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 230000036325 urinary excretion Effects 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 235000015192 vegetable juice Nutrition 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000010374 vitamin B1 Nutrition 0.000 claims 1
- 239000011691 vitamin B1 Substances 0.000 claims 1
- 235000019163 vitamin B12 Nutrition 0.000 claims 1
- 239000011715 vitamin B12 Substances 0.000 claims 1
- 150000003700 vitamin C derivatives Chemical class 0.000 claims 1
- 229940011671 vitamin b6 Drugs 0.000 claims 1
- 239000000341 volatile oil Substances 0.000 claims 1
- 235000013618 yogurt Nutrition 0.000 claims 1
- 229920002994 synthetic fiber Polymers 0.000 description 19
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 16
- 210000000963 osteoblast Anatomy 0.000 description 16
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 15
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 15
- 208000001132 Osteoporosis Diseases 0.000 description 15
- 229940112869 bone morphogenetic protein Drugs 0.000 description 15
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 15
- 239000007943 implant Substances 0.000 description 14
- 210000000349 chromosome Anatomy 0.000 description 13
- 206010017076 Fracture Diseases 0.000 description 11
- 230000008439 repair process Effects 0.000 description 11
- 235000014653 Carica parviflora Nutrition 0.000 description 10
- 241000243321 Cnidaria Species 0.000 description 10
- 108700020978 Proto-Oncogene Proteins 0.000 description 10
- 102000052575 Proto-Oncogene Human genes 0.000 description 10
- 210000002449 bone cell Anatomy 0.000 description 9
- 208000010392 Bone Fractures Diseases 0.000 description 8
- 239000003462 bioceramic Substances 0.000 description 7
- 230000011164 ossification Effects 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 7
- 208000020084 Bone disease Diseases 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 241001447056 Uristes Species 0.000 description 5
- 235000011010 calcium phosphates Nutrition 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 4
- 208000010191 Osteitis Deformans Diseases 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 239000000316 bone substitute Substances 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 230000022159 cartilage development Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 210000001564 haversian system Anatomy 0.000 description 4
- 210000001624 hip Anatomy 0.000 description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 101800000504 3C-like protease Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241001609030 Brosme brosme Species 0.000 description 3
- 102000003964 Histone deacetylase Human genes 0.000 description 3
- 108090000353 Histone deacetylase Proteins 0.000 description 3
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 208000027868 Paget disease Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000002639 bone cement Substances 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 230000010072 bone remodeling Effects 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000003889 chemical engineering Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 208000027202 mammary Paget disease Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 101800000607 p15 Proteins 0.000 description 3
- 239000003415 peat Substances 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 description 2
- 102100034111 Activin receptor type-1 Human genes 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 2
- 102100028727 Bone morphogenetic protein 15 Human genes 0.000 description 2
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 2
- 102100037597 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283153 Cetacea Species 0.000 description 2
- 108091029523 CpG island Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
- 208000034970 Heterotopic Ossification Diseases 0.000 description 2
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 2
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 description 2
- 101000695360 Homo sapiens Bone morphogenetic protein 15 Proteins 0.000 description 2
- 101000762375 Homo sapiens Bone morphogenetic protein 3 Proteins 0.000 description 2
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 2
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 description 2
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 description 2
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100026818 Inhibin beta E chain Human genes 0.000 description 2
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 101710111489 Neurotrophin 1 Proteins 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 102100029268 Neurotrophin-3 Human genes 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 241000283080 Proboscidea <mammal> Species 0.000 description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
- 101700032040 SMAD1 Proteins 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 241000276707 Tilapia Species 0.000 description 2
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 108010079292 betaglycan Proteins 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940009626 etidronate Drugs 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007941 heterotopic ossification Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 229940097998 neurotrophin 4 Drugs 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000004072 osteoblast differentiation Effects 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 1
- UPMXNNIRAGDFEH-UHFFFAOYSA-N 3,5-dibromo-4-hydroxybenzonitrile Chemical compound OC1=C(Br)C=C(C#N)C=C1Br UPMXNNIRAGDFEH-UHFFFAOYSA-N 0.000 description 1
- 102100034134 Activin receptor type-1B Human genes 0.000 description 1
- 102100021886 Activin receptor type-2A Human genes 0.000 description 1
- 102100027647 Activin receptor type-2B Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 102000004152 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 208000031968 Cadaver Diseases 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- 241000202252 Cerberus Species 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108010066259 Collagraft Proteins 0.000 description 1
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 102100035784 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 235000002723 Dioscorea alata Nutrition 0.000 description 1
- 235000007056 Dioscorea composita Nutrition 0.000 description 1
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 1
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 1
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 1
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 1
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 240000003133 Elaeis guineensis Species 0.000 description 1
- 235000001950 Elaeis guineensis Nutrition 0.000 description 1
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 108010050777 Growth Differentiation Factors Proteins 0.000 description 1
- 102000014015 Growth Differentiation Factors Human genes 0.000 description 1
- 102100040895 Growth/differentiation factor 10 Human genes 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 1
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 1
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 1
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 description 1
- 102100035970 Growth/differentiation factor 9 Human genes 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 1
- 101000970954 Homo sapiens Activin receptor type-2A Proteins 0.000 description 1
- 101000937269 Homo sapiens Activin receptor type-2B Proteins 0.000 description 1
- 101000893552 Homo sapiens Embryonic growth/differentiation factor 1 Proteins 0.000 description 1
- 101000893563 Homo sapiens Growth/differentiation factor 10 Proteins 0.000 description 1
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 1
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 description 1
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 description 1
- 101001023988 Homo sapiens Growth/differentiation factor 5 Proteins 0.000 description 1
- 101001023964 Homo sapiens Growth/differentiation factor 6 Proteins 0.000 description 1
- 101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 description 1
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 1
- 101001075110 Homo sapiens Growth/differentiation factor 9 Proteins 0.000 description 1
- 101001054659 Homo sapiens Latent-transforming growth factor beta-binding protein 1 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000799194 Homo sapiens Serine/threonine-protein kinase receptor R3 Proteins 0.000 description 1
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 1
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 1
- 102100027000 Latent-transforming growth factor beta-binding protein 1 Human genes 0.000 description 1
- 241001503485 Mammuthus Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000121185 Monodon monoceros Species 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 102100030610 Mothers against decapentaplegic homolog 5 Human genes 0.000 description 1
- 101710143113 Mothers against decapentaplegic homolog 5 Proteins 0.000 description 1
- 102100030590 Mothers against decapentaplegic homolog 6 Human genes 0.000 description 1
- 101710143114 Mothers against decapentaplegic homolog 6 Proteins 0.000 description 1
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 description 1
- 102100030607 Mothers against decapentaplegic homolog 9 Human genes 0.000 description 1
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 241000283201 Odobenidae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 101700026522 SMAD7 Proteins 0.000 description 1
- 101700031501 SMAD9 Proteins 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241001062472 Stokellia anisodon Species 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048049 Wrist fracture Diseases 0.000 description 1
- CVTZKFWZDBJAHE-UHFFFAOYSA-N [N].N Chemical compound [N].N CVTZKFWZDBJAHE-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 108700025690 abl Genes Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 108010023079 activin B Proteins 0.000 description 1
- 229940037127 actonel Drugs 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000000868 anti-mullerian hormone Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000005770 birds nest Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 230000004221 bone function Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 108091008816 c-sis Proteins 0.000 description 1
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 1
- 229960004361 calcifediol Drugs 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000019827 calcium polyphosphate Nutrition 0.000 description 1
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 108010008846 chordin Proteins 0.000 description 1
- 102000006533 chordin Human genes 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- GWBBVOVXJZATQQ-UHFFFAOYSA-L etidronate disodium Chemical compound [Na+].[Na+].OP(=O)([O-])C(O)(C)P(O)([O-])=O GWBBVOVXJZATQQ-UHFFFAOYSA-L 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000001497 fibrovascular Effects 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- 229940001490 fosamax Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011507 gypsum plaster Substances 0.000 description 1
- 239000008233 hard water Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000003501 hydroponics Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 108010067471 inhibin A Proteins 0.000 description 1
- 108010067479 inhibin B Proteins 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008182 oocyte development Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000000278 osteoconductive effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000004819 osteoinduction Effects 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000013354 porous framework Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 230000002786 root growth Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000110 selective laser sintering Methods 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 102000009310 vitamin D receptors Human genes 0.000 description 1
- 108050000156 vitamin D receptors Proteins 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000005765 wild carrot Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B3/00—Destroying solid waste or transforming solid waste into something useful or harmless
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09C—RECLAMATION OF CONTAMINATED SOIL
- B09C1/00—Reclamation of contaminated soil
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/20—Organic compounds containing oxygen
- C11D3/22—Carbohydrates or derivatives thereof
- C11D3/222—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin
- C11D3/227—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin with nitrogen-containing groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02W—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO WASTEWATER TREATMENT OR WASTE MANAGEMENT
- Y02W10/00—Technologies for wastewater treatment
- Y02W10/30—Wastewater or sewage treatment systems using renewable energies
- Y02W10/37—Wastewater or sewage treatment systems using renewable energies using solar energy
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Environmental & Geological Engineering (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Soil Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
We could process bio crops such as Jatropha, corn, sugar cane, coconuts and oil palm, as well as any and all organic wastes (including manures, sewage)...
1. Chemical solvents: hexane, benzene...
1. Chemical solvents: hexane, benzene...
2. Soxhlet: chemical solvents, methodology involves repeated washing and/or percolation using hexane and/or petroleum ether (involving reflux in specified glassware).
3. Enzymes (best bred/cloned/synthesized): enzymes break down the cell walls of the bio crops, involving water as solvent assisting in fractionation.
4. Expression (Expeller Press): Mechanical pressing and chemical solvents.
5. Osmotic Shock: fast reduction in osmotic pressure causing the cells to implode/explode, to expel cellular contents including oil.
6. Supercritical fluid: C02, is liquefied under pressure and heated which acts as a solvent that is both in a liquid and a gaseous state.
7. Ultrasonic-assist: sonochemistry, using an ultrasonic reactor, ultrasonic waves make captivation bubbles in a solvent material, the bubbles rupture near the cell walis, it makes shock waves of liquid jets making the cell walls to break down to expel their contents within a solvent.
8. We plan to use our diamond technology for manufacturing larger diamonds, used in conjunction with the pressure/heat to press to crush and breakdown bio crops to release their oils (GP 10%), and any and all waste including garbage, eg.
plastic, rubber, and oil/tar sands (into slag and gasses) we could also combine the use of the pressure/heat smelt metals (steel, aluminium..) heat salt water and use the steam to turn turbines producing energy and then condensating into fresh water, the heat can be powered by mirrors or Tall Gravity to Electricity Invention *underground patented by Gerard Voon) and heat to vibrations to energy technology.
We could do any and all combinations of the 1 to 8 processes above to process for any and all bio-crops and any and all garbage as well as in tandem, we could sequence the processes. (DLD 40% Asia) We could harvest (via from animals and cells tissue to artificial synthesis) 1-alpha-hydroxylase calcidiol to calcitriol, to produce 1,25-dihydroxyvitamin D that bond to Vitamin D
Receptor and retenoid-x receptor (RXR).
We are using the products of VDRE vitamin D response elements namely catheiicidin and defensin beta 2 (Peptides) used as an antibacterial/antiviral/antifungi agents. Including all of the above uses, that are interchangeable with chitosan eg. cleanser -detergent, carpet powder, soap bars, liquid soaps, disinfectants, tooth paste, mouth wash, final stage to clean up industries that use strong microbes (eg. genetically engineered extra tough microbes), -we are also testing these two substances effectiveness against toxins and heavy metals (eg.
binding...).
We plan to use 1,25D as a treatment to cause immune cells take away the cell to cell signalling via secreted cytokines and other factors that cause major inflammations. Diseases that can be treated include, but are not limited to, peripheral - chronic inflammation-related diseases, for example: chronic inflammation; thrombosis; atherosclerosis;
restenosis; chronic venous insufficiency; recurrent bacterial infections; sepsis; cutaneous infections; renal disease; glomerulonephritis; fibrotic lung disease; allergic disease; IBS;
rheumatorid arthritis and acute bronchiolitis. Central nervous system-macroglia and microglia related diseases, for example: neurodegenerative diseases; Alzheimer's disease; Multiple sclerosis;
Parkinson's disease; neuroinflammation; HIV-associated neurological diseases; HIV-associated dementia; CNS bacterial infections; brain Toxoplasma gondii; Acanthamoeba infections;
Listeria infections; prion diseases; subacute spongiform encephalopathies and macular degeneration may also be treated.
We also plan to deactivate, remove, the GADD45x-is gene to try to augment our stem cells to more proliferation, then restore its function once the cells are ready for use.
As well as the above creatures we could use the HOX treatments on (close relatives of the dinosaur precusor), eg. elephants to mammoths, tigers to sabre tooth tigers, alligators/crocodiles, bats, any and all birds.
Any and all methods and techniques for Cloning Elephants, Narwhales, walruses and any and all expensive ivory, teeth, bones (whales), human, skulls, jaws, horns (horns 5%).
We need to determine the precusor cells to the ivory (possible from the jaws, and/or skill and/or dentine surrounded on one side by pulp).
We need to know the signalling mode of these creatures that cause them to grow the ivory (eg. pressure missing, feedback molecules, hormones, substances and their concentrations, produced by the cells external surrounding cells and/or internally within the cells eg. causing the stem cells DNA to line up and the cell to split into two robust (cytoplasm - organelles) divisions)...
We could tissue culture their stem cells (especially from creatures with the best quality ivory) and find the gene(s) and/or chemicals that stimulate the stem cells to specialize into ivory.
One method to enhance growth is to Gerard's patented stem cells recycling method (and perhaps isolation and further culturing the cells with the longest telomeres into new colonies possibly surrounded with dental pulp on one end)... We plan to grow any and all teeth and bones and horns and tusks possibly using precusor cells, (stem cells using my patented cell proliferation techniques possibly bone marrow and red blood cells and plasma).
We could grow teeth, tusks, bones (including whale bones) by differentiating their stem cells via signalling and emulating the necessary factors (environment that) the cells naturally grows in.
We will induce the bone cell differentiation via bone morphogenetic proteins from large numbers of stem cells and/or Germ cells and/or bone marrow derived from the stem cells/germ cells. We could use synthetic matrix/scaffold that are porous, varying shapes and sizes to seed new bone growth. Possibly using coral, ceramic and animal collagen.
We could feed calcium and proteins to prompt and calls on cells such as osteoblasts and other cells to lay down new matrix that mineralizes and forms hydroxyapatite and collagen.
By using a porous matrix/scaffolding we allow blood vessels (and/or synthetic blood and/or liquid/serum tissue culture medium) snake through the bone framework (and/or applied directly to control/manage growth of the teeth/bones/tusks/horns) carrying many different compounds that orchestrate bone remodeling, such as calcitrol (a form of vitamin D-3), caicitonin (a thyroid hormone that prevents bone resorption), parathyroid hormone (which works with calcitrol to regulate calcium and phosphate metabolism), and prostagiandins (fatty acids that perform hormonelike functions).
We could also use foam/polymer/co-polymer to contain the direct tissue culture of bone marrow (and/or precusor stem cells seeded for its own proliferation; also stem cells into bone marrow; and stem cells into red blood cells and plasma at the right time the stem cells are treated with signals, proteins, amino acids ... pressure, hormones, bone morphogenetic protein growth factors), surrounded with surrounded by live vascular tissue, surrounded by medium such as nutrients oxygenated pulsing with nutrients.
Additionally (we could use neurotrophin family includes nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-1 (NT-1), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4) and/or apply with stem cells to apply to patients suffering from spinal cord injury).
REFERRENCE MATERIAL...
TAKEN FROM WIKIPEDIA:
List of Bone Morphogenetic Proteins BMP Known functions Gene Locus *BMP1 does not belong to the TGF-,6 family of proteins. It is a Chromosome: 8;
BMPI metalloprotease that acts on procollagen I, II, and Ill. It is Location:
8p21 involved in cartilage development.
Acts as a disulfide-linked homodimer and induces bone and Chromosome: 20;
BMP2 cartilage formation. It is a candidate as a retinoid mediator. Location:
20p12 Plays a key role in osteoblast differentiation.
Chromosome: 14;
BMP3 Induces bone formation Location: 14p22 BMP4 Regulates the formation of teeth, limbs and bone from Chromosome: 14;
mesoderm. It also plays a role in fracture repair. Location: 14q22-q23 BMP5 Performs functions in cartilage development. Chromosome: 6;
Location: 6p12.1 Chromosome: 6;
BMP6 Plays a role in joint integrity in adults.
Location: 6p12.1 Plays a key role in osteoblast differentiation. It also induces Chromosome:
20;
BMP7 the production of SMAD1. Also key in renal development and Location:
20q13 repair.
BMP8a Involved in bone and cartilage development Chromosome: 1;
Location: 1 p35-p32 BMP8b Expressed in the hippocampus. Chromosome: 1;
Location: 1 p35-p32 BMP10 May play a role in the trabeculation of the embryonic heart. Chromosome:
2;
Location: 2p14 BMP15 May play a role in oocyte and follicular development. Chromosome: X;
Location: Xp11.2 hide]
v=d-e Cell signaiing: TGF beta signaiing pathway TGF beta family (TGF-01, TGF-02, TGF-03) Bone morphogenetic proteins (BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8a, BMP8b, BMP10, BMP15) TGF beta superfamily of ligands Growth differentiation factors (GDF1, GDF2, GDF3, GDF5, GDF6, GDF7, Myostatin/GDF8, GDF9, GDF10, GDF11, GDF15) Other (Activin A and B/inhibin A and B, Anti-mullerian hormone, Nodal) TGFBR1: Activin type 1 receptors (ACVR1, ACVR1B, ACVR1 C) - ACVRL1 - BMPR1 (BMPRIA - BMPR1 B) TGF beta receptors TGFBR2: Activin type 2 receptors (ACVR2A, ACVR2B) TGFBR3: betaglycan TransducerslSMAD R-SMAD (SMAD1, SMAD2, SMAD3, SMAD5, SMAD9) - I-SMAD (SMAD6, SMAD7) - SMAD4 Ligand Inhibitors Cerberus - Chordin - DAN - Decorin - Follistatin -Gremlin - Lefty - LTBP1 - Noggin - THBS1 Coreceptors BAMBI - Cri to Other SARA
Chemical & Engineering News August 25, 1997 Other SARA
Chemical & Engineering News August 25, 1997 Copyright 1997 by the American Chemical Society I l- . . v19"~
BONING UP
At the human body shop, bioceramics or biopolymers combined with bone cells and growth factors are likely to lead the parts list STEPHEN K. RITTER
C&EN Washington A woman struck by a car in Florida loses 3 inches of her crushed lower leg and could be left to live with a drastic disability for the rest of her life. A Detroit teenager with a marble-sized divot in his thigh from the removal of a benign tumor could spend the rest of his life being overly cautious.
But the woman is now back to ballroom dancing, and the teenager is swimming again and plans to go skiing.
These dramatic tales of people who against great odds recovered from accidents or diseases to live reasonably normal lives are examples of the benefits reaped from research that began in the 1980s to characterize with increasing accuracy the content and structure of human bone. The success of this research now is resulting in new drugs and treatments for bone diseases, a host of new synthetic materials to repair bone fractures or to serve as bone replacements, and tissue engineering techniques to induce bone growth from scratch using a patient's own bone ceils.
"There is more activity now in this field than there ever has been before, which I find gratifying," says Ralph E. Holmes, professor of surgery and head of the division of plastic surgery at the University of California, San Diego, Medical Center. Holmes, who invented a scanning electron microscope backscatter imaging technique to quantitatively measure ingrowth of bone in implants, has been a leader during the past 20 years in evaluating many synthetic materials. "I think the current activity is a sign of the maturity of all the sciences involved and a recognition that not just one thing can make bone heal," Holmes observes.
Although bone seems lifeless, it actually is made up of a very alive, porous framework that is constantly rebuilding itself. Bone is a composite material made up of collagen protein fibers threading through hydroxyapatite, Ca5(PO4)30H. Hydroxyapatite makes up about 70% of bone structure and essentially all of the enamel in teeth. The coliagen fibers, a bundled array of cross-linked helical polypeptide strands, provide extra strength, allowing bones to flex under stress.
BENEATH BONE'S HARD EXTERIOR...
Bone tissue replaces itself through the action of cells called osteociasts that produce acids to dissolve (resorb) hydroxyapatite and enzymes to break down collagen. The resulting release of calcium and proteins prompts other cells called osteoblasts to lay down new matrix that mineralizes and forms hydroxyapatite and coliagen. Some growth factors, such as bone morphogenetic proteins, are manufactured by bone cells themselves to either increase or decrease bone remodeling.
Blood vessels snake through the bone framework, too, carrying many different compounds that orchestrate bone remodeling, such as calcitrol (a form of vitamin D-3), calcitonin (a thyroid hormone that prevents bone resorption), parathyroid hormone (which works with calcitrol to regulate caicium and phosphate metabolism), and prostaglandins (fatty acids that perform hormonelike functions). Beneath all of that is the bone marrow that creates the osteoblasts and osteociasts as well as the red and white blood cells.
Skeletal deficiencies from trauma, tumors and bone diseases, or abnormal development frequently require surgical procedures to attempt to restore normal bone function. Although most of these treatments are successful, they all have associated problems and limitations.
For a minor fracture, usually a few weeks in a cast are all that is needed for the bone to repair itself. For a more severe fracture or one in a particularly tricky position, a bone cement or filler may be used to help strengthen the fractured bone so it heals faster. These procedures may or may not require metal hardware such as plates, pins, or screws for extra support.
For severe fractures, a bone graft may be needed. In a typical bone graft, natural bone or a synthetic material is shaped by the surgeon to fit the affected area and held in place with hardware. Over time, the natural bone growth process takes over and at least partially resorbs the grafted bone. Key to the level of resorption is the porosity of the implant material that allows ingrowth of vascularized tissue.
Surgeons have been performing bone grafts for years. The preferred method is a procedure called an autograft, where bone fragments are taken from a patient's own body-usually a hip (iliac crest), the pelvis, or ribs-and affixed to healthy bone. An alternative method, called an allograft, uses bone donated from a cadaver and works nearly as well.
Bone grafts are painful, complicated procedures that generally involve a long recovery period. Drawbacks to autografts are the two surgical procedures needed, meaning longer hospitalization and recovery time, and higher cost. Besides, the body doesn't carry much spare bone.
Allografts eliminate the need for a second surgery, but after sterilization, the donated bone loses much of its strength. In addition, when bone grafts are taken from cadavers, there is the risk of rejection or of transmitted diseases such as hepatitis B or AIDS
caused by infection with the human immunodeficiency virus. Allograft procedures have been on the decline since late 1993 when the Food & Drug Administration issued regulations governing bone and tissue banks because of the risk of transmitting infectious diseases.
A third option, which today is becoming more viable, is use of a synthetic material to replace lost bone. Synthetic materials have the advantage of eliminating the need for surgery to claim bone for the graft procedure, and eliminating the chance for rejection or transmission of infectious disease. An additional benefit is a significant reduction in medical cost and, in general, a faster recovery time.
The ideal bone substitute, according to Holmes, would approximate the autograft, requiring minimally that it be biocompatible and osteoinductive so that the body's natural bone-making process eventually would replace the implanted material. Most synthetic materials, however, are weakly resorbed or do not resorb at all. But low resorption is not necessarily a drawback, he says.
In some applications, such as a long bone fracture, one might hope for complete resorption of a synthetic material. But in other cases, such as reconstruction of the chin, resorption may not be desirable at all. Thus, a combination of autograft and synthetic material with hardware often turns out to be the best solution, Holmes notes.
The driving force to develop new treatments for bone diseases, the fractures associated with them, and fractures from trauma is that they make up an important segment of the health care industry. Americans suffer some 5.6 million fractures, and surgeons perform about 3.1 million orthopedic procedures in the U.S. each year, according to the American Academy of Orthopaedic Surgeons. Industry experts expect these numbers to increase steadily as the general population grows older.
In 1995, the latest year for which statistics are available, there were some 426,000 bone-graft procedures in the U.S., according to Medical Data International (MDI), a market research firm based in Irvine, Calif. That makes bone second only to blood transfusions on the list of transplanted materials.
The worldwide bone-graft market was estimated to be about $800 million annually, about half in the U.S., MDI reports. In 1995, about 58% of bone-graft procedures were autografts, compared with 34% allografts, and 8% synthetic materials, and nearly half of the procedures involved the spine. The percentage of synthetic procedures is expected to rise substantially as new biomaterials continue to come onto the market.
Treating bone diseases When osteociasts dissolve old bone faster than osteoblasts can replace it, the result is osteoporosis. Osteoporosis is characterized by loss of bone density that can lead to debilitating fractures of the hip and spine. The disease usually strikes postmenopausal women (age 50 to 70) as a result of decreased estrogen and progestin levels.
The disease also can occur later in life (after age 75) in women and, as a result of testosterone imbalance, in men.
According to the National Osteoporosis Foundation, an estimated 20 million women in the U.S. have osteoporosis. That number is projected to grow to more than 35 million by 2015.
Furthermore, the financial impact of osteoporosis in the U.S. has been estimated to be almost $14 billion per year in medical costs and lost productivity. These sobering statistics are the driving force for research into drugs to prevent or treat osteoporosis and other bone diseases. Industry analysts expect the global osteoporosis market for pharmaceuticals to reach $5 billion by 2005.
Osteoporosis can be detected by radiological imaging techniques used to measure loss of bone density. Besides prevention through diet, a number of therapies are being used to treat or prevent the disease. Estrogen replacement therapy, approved in 1988 by FDA, is common. Combined estrogen-progestin therapy as well as calcitonin therapy also are being used.
Diphosphonates are a class of compounds that are now becoming available in the U.S. as nonhormonal drugs for prevention of osteoporosis and as a treatment to help prevent bone fractures in patients who already have osteoporosis. The drugs are also proving successful for treatment of Paget's disease of bone (a chronic dissolving of normal bone followed by disorganized, enlarged, and weakened bone formation) and heterotopic ossification (abnormal overgrowth of bone, usually at postoperative sites such as the hip).
Although the exact mechanism of action of diphosphonates is unclear, they accumulate on bone surfaces and inhibit osteoclast resorption, allowing the bone-formation process to dominate.
DIPHOSPHONATES HELP BOOST BONE DENSITY
The use of diphosphonates to treat bone disease was first advanced by emeritus research chemist M. David Francis and coworkers at Procter & Gamble in Cincinnati.
Francis' other research accomplishments include discovering the benefits of adding fluoride salts to toothpaste to prevent tooth decay and adding pyrophosphate (P407 4-) for tartar control (C&EN, March 11, 1996, page 34).
Francis led the development of etidronate (disodium 1-hydroxyethane-1,1-diphosphonate), a compound that Procter & Gamble originally had looked at as a detergent additive to chelate calcium and other hard-water ions. Etidronate, now marketed by Procter &
Gamble as Didronel, is used in the U.S. and abroad to treat Paget's disease and heterotopic ossification.
Procter & Gambie also markets Didronel in 17 countries for osteoporosis.
However, in April of this year, Merck announced that it had become the first company to receive final U.S. approval for a diphosphonate to help prevent or treat osteoporosis.
Alendronate (sodium 4-amino-l-hydroxybutylidene-1,1-diphosphonate) is now marketed in 49 countries as Fosamax.
FDA's decision to clear the drug, according to the company, was based primarily on two-year results of an ongoing six-year study of more than 1,600 women ages 45 to 59.
The drug is working as well as hormone replacement therapy to increase bone mass at the hip and spine, while a placebo group is showing a gradual loss of bone mass.
Procter & Gamble has another diphosphonate compound, risedronate (sodium 2-(3-pyridinyl)-1-hydroxyethylidene-1,1-diphosphonate), that is in late-stage Phase III clinical trials for treatment of osteoporosis and Paget's disease. In March, the company filed a new-drug application with FDA for treatment of Paget's disease, and plans to file another application for treatment of osteoporosis in 1998. In May, Procter & Gamble announced it was forming a global alliance with Hoechst Marion Roussel-the pharmaceutical company of Germany's Hoechst-to commercialize the new drug under the name Actonel.
Mending and making bones Poly(methyl methacrylate), an old standard, has been used for decades as a synthetic filler to repair skeletal defects and affix metal implants to bone. Usually methyl methacrylate is polymerized in situ at the site where additional bone is needed. The polymer hardens to become stronger than bone and is generally a good substitute.
One of the advantages of poly(methyl methacrylate) as well as similar types of bone fillers and cements is that they can be injected through the skin. But there are a couple of problems critical to the use of these materials. One is that they usually must cure in situ and in doing so can generate heat that could damage surrounding soft tissues. Another, and perhaps more important issue, is that most of the materials are minimally degradable or don't degrade at all, nor can they support ingrowth of new bone tissue.
The concept of developing materials that are biocompatible and can at least be partially resorbed in the natural bone-growth process grew out of the ground-breaking research in the 1960s by Marshall R. Urist, a professor of orthopedic surgery at the University of California, Los Angeles.
Urist was the first researcher to conclusively demonstrate the phenomenon of osteoinduction, or the natural process of bone desorption and formation. For more than a century, surgeons had recognized the ability of demineralized bone to aid bone healing. But it was Urist's work on implanting demineralized bone segments into animals and being able to induce new bone growth within the implants that led him to conclude in 1965 that cells in the bone matrix stimulated cells at an implant site to differentiate into osteoblasts and osteoclasts. He later showed that bone morphogenetic proteins are the sole inducers of bone cell differentiation. His original paper reporting those findings was recently reprinted as a landmark paper in the Journal of NIH Research [9, 43 (1997)].
Urist's findings coupled with better diagnostic techniques subsequently gave rise to a greater understanding of bone structure and the bone-formation process. This understanding, in turn, led to the development of a host of calcium-based synthetic bone products designed to mimic natural bone and to actually be resorbed by the body. It has been only recently, after many years of animal trials, that these materials have advanced to the point that they are acceptable for use in humans and are starting to gain FDA approval.
One company well ahead in the synthetic bone implant market is Interpore International of Irvine, Calif. In November 1992, Interpore became the first company to receive FDA approval for a synthetic bone-void filler.
The company's Pro Osteon hydroxyapatite is made from coral through a thermochemical process developed in the 1970s. Currently, it is the only synthetic product on the market that has a porous infrastructure similar to natural bone. The interconnected structure of the coral remains intact throughout processing, providing a matrix through which blood vessels and new bone tissue can grow.
INTERPORE'S SYNTHETIC BONE GRAFT...
Interpore acquires between 2 and 4 tons of coral each year from atolls in the Pacific and Indian Oceans to make its product, less than 1% of the total annual amount of coral imported into the U.S., the company says. The amount of coral harvested for import is controlled by the Convention on International Trade of Endangered Species of Wild Fauna &
Flora (CITES) and is generally agreed upon by ecologists to present little threat to fragile reefs as long as the coral is harvested in ways that sustain the reefs as living structures. One coral "head" weighing 150 to 200 lb provides enough material for several hundred bone grafts.
The synthetic material is prepared by heating the coral-which is essentially calcium carbonate-with ammonium phosphate at more than 200 C for 24 to 60 hours to obtain about 95% hydroxyapatite. The material is processed into block or granular form and sterilized by gamma radiation.
Used similarly to natural bone in autograft procedures, the synthetic material has about the same length of healing time. A surgeon can shape a block of the material, for example, to fit into a fracture crevice or a carved out portion of a long bone. The graft area is then stabilized with a metal plate and screws, which later can be removed.
The natural porosity of the material does have the drawback of reducing its strength, notes David C. Mercer, Interpore's president and chief executive officer. But the porous structure provides room for bone tissue to immediately grow into the pores of the implant. However, the material is only partially resorbed and replaced by natural bone. The company is now evaluating in preclinical studies a related new product that has a higher resorption rate.
Pro Osteon is currently approved for nonweight-bearing treatment of fractures at the wide end of long bones and for jaw and reconstructive facial surgery, according to Mercer.
However, the material has been used in many cases to replace a short section of a long bone, he says. In such cases, the limb must be immobilized for a long period-perhaps several years-to ensure new bone growth has become strong enough to support weight.
Sales of Pro Osteon have increased steadily since 1992, reaching $11.7 million in 1996, up 47% from the previous year. Sales in the first half of 1997 continue to be strong, increasing 13% from last year's first half to $6.3 million. lnterpore also has approval to sell its bone substitute in 41 countries and began international marketing in 1995.
Although synthetic biomaterials on the market or under development work well for their intended functions, none has yet proven to be sufficiently strong or able to be processed into a large enough piece to stand in as a complete replacement for long bones.
Research by University of Texas, Austin, chemistry professor Richard J. Lagow, however, appears to have come the closest to that goal. Lagow makes a high-purity hydroxyapatite from scratch by reacting calcium metal, calcium hydroxide, and phosphoric acid at 700 to 850 C. Lagow also has come up with analogous high molecular weight linear calcium polyphosphates by reacting hydroxyapatite with phosphoric acid. The success of his research has led to the creation of a small Austin-based company, called OsteoMedica Inc., to develop the synthetic materials as potential complete bone substitutes.
Key to developing these compounds for implant materials, Lagow says, is their high purity, which does not retard bone growth. Also important, he says, is holding the reaction temperature below the 1,200 C temperature at which calcium phosphate fuses into a ceramic.
Besides controlling bulk size and shape, during his proprietary synthesis and processing method, Lagow can moderate the interconnecting porosity of the synthetic material-in the range of 150- to 400-pm pores-to match the density of different types of bone.
"Interconnecting means that the body can vascularize it quickly and bone can then grow into the material much faster because there is a greater surface area for the osteoblasts and osteoclasts to work," Lagow notes. "Otherwise, the osteociasts must tunnel through the bone matrix to resorb the synthetic material, which is a much slower process."
Lagow has collaborated with UT Austin chemical engineering professor Joel W.
Barlow and others to develop a selective laser sintering technology that they have patented to fabricate complex bone shapes from the calcium phosphate materials.
Barlow and his research group developed a technique whereby they use a spray drier to coat hydroxyapatite or calcium phosphate powders with a poly(methyl methacrylate) that acts as a binder. The materials readily fuse in the sintering process but maintain their interconnecting pore structure. And, unlike other bioceramics being investigated as bone substitutes, they retain their high strength during processing, Lagow says.
LAGOW S METHOD TO SYNTHESIZE...
The laser can be guided to form intricate bone shapes by computer, using data sources such as magnetic resonance imaging or computed tomography. The molded ceramic is then heated to remove the polymer and further processed. Thus far, the researchers have been able to generate a wide range of bone sizes and shapes. The technology has since been licensed to BioMedical Enterprises Inc., San Antonio, which is pursuing biocompatability studies of fabricated calcium phosphate implants.
OsteoMedica's goal is eventually to provide surgeons with synthetic molded bone "blanks"
that can be custom shaped to fit a patient's needs. The company's bioceramic, called Megag raft 1000, so far has been successful in tests replacing tibia sections in rabbits and other animals.
And in a very successful study on dogs, sections of the radius were replaced with the synthetic bone. After 11 months, support plates and screws were removed, and the dogs eventually regained full use of their legs. One of the most promising aspects of the study was that, some three years after the time of the implant, the synthetic material was completely resorbed- results that haven't been reported for other synthetic materials.
OsteoMedica is preparing to begin clinical trials in humans for spinal fusions in the U.K.
and Australia, where regulatory requirements aren't as stringent as in the U.S.
"Being able to synthesize novel hydroxyapatite material to make it accessible to higher bone ingrowth and remodeling rate is a critical step," says UC San Diego's Holmes, who has evaluated both Interpore's and OsteoMedica's products. While he finds both materials work well for their intended use, a product such as OsteoMedica's hydroxyapatite being available in different pore sizes would be particularly useful for a wide range of applications to control the level of resorption, he notes. "Wi'th a range of porosities and resorption rates, surgeons could learn to choose the synthetic material for a particular application much in the way they choose a suture material."
Glen O'Sullivan, an assistant professor of orthopedics at Stanford University Medical Center, also has used lnterpore's product in his patients and has worked on a clinical study of spinal fusions in sheep using OsteoMedica's material. He, too, finds both materials perform well for their designed use.
"One advantage of OsteoMedica's product is it is one of the hardest materials," O'Sullivan notes. "For example, lnterpore's material can be crumbled between the fingers, while OsteoMedica's is strong enough to drill holes in it. This makes OsteoMedica's a good candidate for use in the spinal column, whereas Interpore's would not be-and it isn't approved by FDA for that."
Holmes and O'Sullivan agree that there isn't one material that is going to be suitable for all applications. "With any of these new products," O'Sullivan says, "one likes to be optimistic, but the hopes and expectations may not always pan out for all applications."
It makes sense, he adds, that FDA only approves what might appear to be broadly applicable bioceramic materials for a narrow range of applications.
There are perhaps dozens of calcium-based synthetic materials in addition to Interpore's and OsteoMedica's that have received approval for use in the past couple of years or are anticipating approval soon. In 1996, for example, FDA approved OsteoSet, a calcium sulfate (plaster of paris) bone-void filler developed by Wright Medical Technology, Arlington, Tenn., that is reasonably resorbed by the body in as little as eight weeks. Another product cleared in 1996 by FDA for repair of cranial defects is a hydroxyapatite bone cement developed by American Dental Association Health Foundation researchers called BoneSource.
The material will be manufactured by OsteoGenics Inc. and distributed by Howmedica Leibinger, a division of Pfizer.
An injectable bone cement developed by Norian Corp., Cupertino, Calif., is described by the company as a biocompatible, moldable compound made by mixing calcium phosphate, tricalcium phosphate, and calcium carbonate with sodium phosphate solution into a toothpastelike substance. Norian currently has approval to market its Skeletal Repair System in Europe and Canada, and is working toward regulatory approval in Japan and the U.S., mainly for treatment of wrist and hip fractures.
New directions In 1993, FDA approved one of the first bone graft substitutes that capitalized on a new concept for products to facilitate bone repair. Collagraft, marketed by Bristol-Myers Squibb subsidiary Zimmer Inc., Warsaw, Ind., is a hydroxyapatite/tricalcium phosphate and bovine collagen that must be mixed with a patient's own bone marrow.
In late 1996, Interpore signed a license and development agreement with Quantic Biomedical, San Rafael, Calif., for a technology to use a gellike material containing bone growth factors from a patient's own blood that can be combined with its coral-based Pro Osteon to provide accelerated bone growth. Preclinical feasibility trials are expected to begin by the end of this year.
These examples illustrate the impact that the "delayed discovery" of bone morphogenetic proteins (BMPs) has had in opening the research community to a new direction:
the concept that BMPs, bone cells, and various hormones could form the basis of an engineered system for bone repair that includes bioceramics or biopolymers. In essence, the world of bioceramics is being wed to the world of tissue engineering.
Although Urist's work on osteoinductivity was definitive, most researchers weren't convinced until BMPs actually began to be cloned by recombinant DNA methods some 20 years after his landmark research paper.
In 1988, the first group to clone a BMP was that of senior director John M.
Wozney at biotechnology company Genetics Institute, Andover, Mass. [Science, 242, 1528 (1988)].
Today, one of Genetics Institute's molecules, BMP2, is in clinical trials for fracture repair, spinal fusion, and other possible applications. Several other biotechnology and pharmaceutical companies are testing the more than 30 BMPs cloned thus far for potential use in bone- and tooth-mending applications. "BMPs are destined to bring osteogenesis under the control of surgeons before the turn of the century," Urist noted in a commentary on his landmark paper.
"Despite the great advances in the synthetic materials, one still needs the bone cells,"
O'Sullivan states. "Bone cells are needed in the implant material and you want a means of stimulating bone cell activity. This is where research with BMPs is really going to take off."
O'Sullivan notes that even during autograft procedures, surgeons attempt to aspirate bone celis from adjacent bone to incorporate into the implanted bone, and sometimes use material extracted from presurgical blood donation by the patient to help induce implant bone growth and resorption.
O'Sullivan points out that a critical step remaining for BMPs is to find the optimum carrier for implantation. Although bioceramics likely will work well, he says, they do have the problem of slow resorption. Thus many researchers believe that biodegradable polymers will work best as delivery devices for human growth factors, he says.
One of the leaders in the biodegradable polymer area is Antonios G. Mikos, an associate professor in the department of chemical engineering and the Institute of Biosciences &
Bioengineering at Rice University, Houston. "The advantage of using polymers is that one can very accurately engineer their mechanical properties and degradation characteristics,"
he explains. The size and shape of the scaffold can be made to order as well, depending on which bone a potential patient may need.
Mikos and his research group are working on strategies to naturally grow bone from scratch either in vitro or in vivo by seeding natural or synthetic polymer scaffolds with bone cells or to use the scaffolds as conduits to induce new bone growth from surrounding tissues. Several substrate materials are being investigated by a number of researchers, Mikos notes, including poly(a-hydroxy esters), polyanhydrides, polyimides, polyphosphazenes, and collagen.
The success of such strategies is dependent on the scaffold material's being biocompatible, osteoconductive, and quickly degradable into products that can be metabolized or excreted, he explains. For example, poly(lactic-co-glycolic acid) breaks down to lactic acid and glycolic acid, which are metabolized in the body and excreted as carbon dioxide and water.
Osteoblast transplantation onto a polymer scaffold would eliminate the problem of donor scarcity, immune rejection, and pathogen transfer by taking the needed cells from a patient's own body, Mikos points out. Although osteoblasts may be obtained by a variety of methods, including bone chips from an injury site or enzymatic digestion of harvested bone, the most desirable method would be to obtain the cells from the patient's own bone marrow.
Osteoblasts obtained from bone marrow, for example, can also be expanded in tissue culture in a lab and seeded onto a polymer scaffold for implantation.
Poly(lactic-co-glycolic acid) has been extensively investigated as a material for tissue-engineering scaffolds because it already has been approved by FDA for use in surgical sutures, can be made with controlled pore size, and degrades well. The first such scaffolds were designed by biomedical and chemical engineering professor Robert S.
Langer at Massachusetts Institute of Technology and Joseph P. Vacanti of Harvard Medical School in the late 1980s to create an in vitro environment that enables cells to organize themselves to form functioning tissues. Langer and Vacanti prepared crude scaffolds by bonding together poly(lactic-co-glycolic acid) fibers into a two-dimensional network.
In 1991, working with Langer and Vacanti, Mikos (then at MIT) further developed the polymer scaffolds by incorporating sodium chloride crystals into the copolymer matrix by adding crystals to a solution of the dissolved polymer. The salt crystals were later leached out, leaving behind a porous polymer matrix. Mikos was able to control porosity and pore size by varying the concentration and size of the crystals.
In another technique, Mikos extruded polymer fibers and aligned them in the shape of the desired scaffold. He embedded the arrangement in a polymer with a higher melting point and bound the scaffold together by heating. After cooling, he selectively dissolved the embedding medium, leaving behind an interconnected, highly porous structure.
Mikos, graduate student Susan L. Ishaug-Riley, and coworkers have recently conducted feasibility studies to show that bone formation in vitro and in vivo is possible by culturing rat osteoblasts in three-dimensional poly(lactic-co-glycolic acid) foams of different pore sizes (shown on the cover of this issue).
In one study, the polymer foams supported the proliferation of the seeded rat osteoblasts in --i vitro to form a calcified bonelike tissue after two months [J. Biomed. Mater.
Res., 36, (1997)].
The goal of the study was to gain a better understanding of the important parameters in the design of an osteoblast foam-culture system before attempting osteoblast transplantation in vivo.
In a subsequent in vivo study, rat bone marrow osteoblasts were seeded onto polymer foams and implanted into the rat mesentery (the membrane of the abdominal cavity) [J. Biomed.
Mater. Res., 36, 1 (1997)]. Growth of islands of mineralized bonelike tissue in the foam surrounded by fibrovascular tissue was observed within one week and had significant penetration of bone tissue into the scaffold after seven weeks.
The findings were encouraging, the researchers note, because they indicate that the regenerative potential of the seeded polymer scaffolds for new bone growth with transplanted cells and secreted bone growth factors may further induce bone growth from adjacent bone.
Ishaug-Riley received a student outstanding research award from the Society for Biomaterials for the in vivo study at the society's 23rd annual meeting in New Orleans in May.
Osteoblast transplantation is not a straightforward approach, Mikos says, noting that because bone is highly vascularized, it is not possible to engineer and grow a complete bone or bone fragment in vitro and transplant it. "The maximum thickness of new bone one can create in vitro is a few hundred micrometers, which is not significant for clinical applications.
However, the goal is to form new bone tissue in vivo and not in vitro. Then, vascularization becomes equally important to bone formation and necessary for regeneration."
A critical issue for cell transplantation is which phenotype of transplanted cell should be used. "It is not clear if one should transplant osteoblasts or preosteoblasts or progenitor cells," he says.
Mikos believes it will be possible in the next decade for tissue-engineered implants to be used for the reconstruction of skeletal deformities resulting from trauma, tumors, or abnormal development. "I hope that new cell-based therapies will be developed for the treatment of osteoarthritis and osteoporosis based on combinations of degradable biomaterials, growth factors, and cells," he says. "Yet, the main drawback with new polymers is the time and effort needed to get FDA approval for their use."
O'Sullivan is optimistic about the prospects of tissue engineering in bone repair, but also cautious about a couple of potentially critical problems. FDA currently is not certain about how to regulate tissue-engineered products, he says. (A problem with tissue cultures is potential contamination with a fungus, bacteria, or mold.) "And it will be interesting to see if the new technology will become available in an affordable manner, given that the couple of companies working on BMPs have spent a tremendous amount of money during the past few years to develop a research infrastructure." He thinks the BMP companies will end up controiling the technology development path for the synthetic implant companies.
"The next step is going to be a fine balance between cost and whether the outcome is going to be worth it."
n coral that is converted to hydroxyapatite and processed into block or granular form. X-ray ima )one fragment was removed and replaced by the synthetic material. Metal plates and screws ob -rt the ankle until it heals.
hemCenter ^Pubs Div. Home Page We are so looking at cloning fish (especially high in omega 3) and the cells that produce or are rich in omega 3 for food any and all varieties, any and all climates for sushi, chinese seafood cuisine, fish and chips and any and all cuisine, including pelletisizing for food for livestock, also cloning the silivary glands that produce bird's nest soup, and jellyfish dishes, as well as clone any and all livestock (including chicken GP 33%), for flesh as well as fur and for leather and skin...
(3.5%) Growing com on the top layer could package (hereinafter, package/packed refers to biodegreadable absorbant yet stiff enough to support planst such as corn) large tight rooting and the stalk stands up - packed surrounding the roots is enough soil and/or peat and/or manure/compost/partially treated sewage and any and all organic wastes and/or chitin/chitosan to provide for the corn (and/or any and all plants to last through maturation -the packages fit in holes in large styrafoam trays and/or lava rock, and a further layer of lava rock below. Underneath the lava rock is a perforated strong waterproof material (eg. PVC) to hold up the two layers above and finally the bottom is a catch basin, where we could grow lobsters/crawdads/crayfish/tilapia/any and all shell fish/and any and all fishes and any and all water creatures; the entire system could be flushed with UV treated salt water and re-circulated UV treated salt water and low concentration feed tea manure...Alternatively if the tea manure has too much nitrogen, we could skip the middle layer of lava rock and rather plant the com in tight packages with enough peat and top soil in the rooting package surrounded by either a thick layer of styrafoam with holes that fit the rooting packages, and or lava rock to keep the corn from tipping and then place a membrane -multiple layer (eg.
sealing above the perforated strong waterproof material eg. PVC) to keep the nitrogen out, from entering the catch basin where the lobsters/crawdads/crayfish/tilapia/any and all shell fish/and any and all fishes are housed or more importantly to keep the salt water below from tainting the corps above, unless the farmed creatures below are fresh water species.
Alternatively, we could design the system where water does not pass freely between the crops hydroponics' in packages surrounding the stalks of eg. corn we could put bags of algae (that are passed with tea manure) above and the farmed water boume species below we could recycle water, where nitrogen-ammonia water caused by feces/uneaten are treated with UV and then micro organisms in sand and membrane to take out the salt which produces fresh water that is re-circulated to the plants/crops above, then the opposite the water from the crops (that have nitrogen removed by the roots of the crops) can be mixed in salt if for salt water re-circulation. This rotational re-circulation, may create symbiotic synergies. We could grow these stacked farming systems on further floors up all the way up tall buildings... possibly with TALL GRAVITY TO ELECTRICITY INVENTION buried underground to provide energy. We could also grow root foods in third world countries (as well as rice) such as yam, sweet potatoes and potatoes which may be higher yield than rice - in its ability to fill stomachs (even gingseng)... by packing the area surrounding the roots with a large footprint of tightly peat/top soiVmanure/slightly treated sewage/compost/and and all organic waste, perhaps surrounded by a burlap (or biodegradable - any and all covers) to wrap, and placed in a hydroponic solution (eg. tea manure; possibly supplement with phosphorous/potassium and vitamins), surrounded by support such as thick styrafoam flats to support the stock and lava rock surrounding the packaged roots - with ample packaging of root growth space so as not to impede the growth of root crops - possibly in sky scrapper green houses.
We could also methylation, imprinting to increase harvests of any and all crops including any and all bio crops.
We could coat any and all seeds (especially bio crops seeds) as well as pack chitin/chitosan around roots.
In all of the above we use chitin and chitosan interchangeably.
The some of the following can be interchangeably between any and all creatures and any and all plants.
We are culturing stem cells (using testing for the best timing and sequences...) and enhancing their proliferation by using GM-CSF (granulocyte-macrophage colony-stimulating factor) + fetal bovine serum (FBS) (and/or any other mediums) to methylate in the p15 CpG
island. Viable cells were responsible for this epigenetic change. Following the GM-CSF + FBS application the culture was added to inhibitors for DNA
methyltransferase (DNMT) and histone deacetylase (HDAC) caused the demethylation of nearly all CpG sites in the p15 CpG island on every allele sequenced. GM-CSF may be able to induce de novo methylation of the p15 gene, using HDAC(s) as well as DNMT(s).
Taken Wikipedia:
Neoplastic tumors often contain more than one type of cell, but their initiation and continued growth is usually dependent on a single population of neoplastic cells. These cells are usually presumed to be clonal - that is, they are descended from a single progenitor cell.
The neoplastic cells typically bear common eg netic or epigenetic abnormalities, an evidence of clonality. For some types of neoplasm, e.g. lymphoma and leukemia, the demonstration of clonality is now considered to be necessary (though not sufficient) to define a cellular proliferation as neoplastic.
Nocodazole and Colchicine have the opposite effect, blocking the polymerization of tubulin into microtubules, we could try these drugs to increase the proliferation of stem cells.
We are also using proto-oncogenes to increase stem cell proliferation (see below taken from Wikepedia).
Proto-oncogene A proto-oncogene is a normal gene that can become an oncogene due to mutations or increased expression. Proto-oncogenes code for proteins that help to regulate cell growth and differentiation. Proto-oncogenes are often involved in signal transduction and execution of mitogenic signals, usually through their protein products. Upon activafion, a proto-oncogene (or its product) becomes a tumor inducing agent, an oncogene.u Examples of proto-oncogenes include RAS, WNT, MYC, ERK and TRK.
edit Activation The proto-oncogene can become an oncogene by a relatively small modification of its original function. There are three basic activation types:
= A mutation within a proto-oncogene can cause a change in the protein structure, causing o an increase in protein (enzyme) activity o a loss of regulation = An increase in protein concentration, caused by o an increase of protein expression (through misregulation) o an increase of protein stability, prolonging its existence and thus its activity in the cell o a gene duplication (one type of chromosome abnormality), resulting in an increased amount of protein in the cell = A chromosomal translocation (another type of chromosome abnormaiity), causing o an increased gene expression in the wrong cell type or at wrong times o the expression of a constitutively active hybrid protein. This type of aberration in a dividing stem cell in the bone marrow leads to adult leukemia Mutations in microRNAs can lead to activation of oncogenes.v New research indicates that small RNAs 21-25 nucleotides in length called microRNAs (miRNAs) can control expression of these genes by downregulating them.r7l edit Proto-Oncogenes There are several systems for classifying oncogenes, 8 9 but there is not yet a widely accepted standard. They are sometimes grouped both spatially (moving from outside the cell inwards) and chronologically (paralielling the "normal" process of signal transduction). There are several categories that are commonly used:
Category Examples Description Usually secreted by specialized cells to induce cell proliferation in themselves, nearby cells, or distant Growth factors, or c-Sis cells. An oncogene may cause a cell mitogens to secrete growth factors even though it does not normally do so. It will thereby induce its own uncontrolled proliferation (autocrine IOog), and proliferation of neighboring cells. It may also cause production of growth hormones in other parts of the body.
Kinases add phosphate groups to other proteins to turn them on or off.
Receptor kinases add phosphate groups to receptor proteins at the epidermal growth factor receptor surface of the cell (which receive (EGFR), platelet-derived growth protein signals from outside the cell Receptor tyrosine factor receptor (PDGFR), and and transmit them to the inside of kinases vascular endothelial growth factor the cell). Tyrosine kinases add receptor (VEGFR), HER2/neu phosphate groups to the amino acid tyrosine in the target protein. They can cause cancer by turning the receptor permanently on (constitutively), even without signals from outside the cell.
Src-family, Syk-ZAP-70 family, and Cytoplasmic BTK family of tyrosine kinases, the _ tyrosine kinases Abl gene in CML -Philadelphia chromosome Cytoplasmic Serine/threonine Raf kinase, and cyclin-dependent kinases and their kinases (through overexpression).
regulatory subunits Regulatory Ras protein GTPases -Transcription -MYC- gene factors We plan to add Cargo transport In the cell, small molecules such as gases and glucose diffuse to where they are needed.
Large molecules synthesised in the cell body, intracellular components such as vesicles, and organelles such as mitochondria are too large (and the c osol too crowded) to diffuse to their destinations. Motor proteins fulfill the role of transporting large cargo about the cell to
plastic, rubber, and oil/tar sands (into slag and gasses) we could also combine the use of the pressure/heat smelt metals (steel, aluminium..) heat salt water and use the steam to turn turbines producing energy and then condensating into fresh water, the heat can be powered by mirrors or Tall Gravity to Electricity Invention *underground patented by Gerard Voon) and heat to vibrations to energy technology.
We could do any and all combinations of the 1 to 8 processes above to process for any and all bio-crops and any and all garbage as well as in tandem, we could sequence the processes. (DLD 40% Asia) We could harvest (via from animals and cells tissue to artificial synthesis) 1-alpha-hydroxylase calcidiol to calcitriol, to produce 1,25-dihydroxyvitamin D that bond to Vitamin D
Receptor and retenoid-x receptor (RXR).
We are using the products of VDRE vitamin D response elements namely catheiicidin and defensin beta 2 (Peptides) used as an antibacterial/antiviral/antifungi agents. Including all of the above uses, that are interchangeable with chitosan eg. cleanser -detergent, carpet powder, soap bars, liquid soaps, disinfectants, tooth paste, mouth wash, final stage to clean up industries that use strong microbes (eg. genetically engineered extra tough microbes), -we are also testing these two substances effectiveness against toxins and heavy metals (eg.
binding...).
We plan to use 1,25D as a treatment to cause immune cells take away the cell to cell signalling via secreted cytokines and other factors that cause major inflammations. Diseases that can be treated include, but are not limited to, peripheral - chronic inflammation-related diseases, for example: chronic inflammation; thrombosis; atherosclerosis;
restenosis; chronic venous insufficiency; recurrent bacterial infections; sepsis; cutaneous infections; renal disease; glomerulonephritis; fibrotic lung disease; allergic disease; IBS;
rheumatorid arthritis and acute bronchiolitis. Central nervous system-macroglia and microglia related diseases, for example: neurodegenerative diseases; Alzheimer's disease; Multiple sclerosis;
Parkinson's disease; neuroinflammation; HIV-associated neurological diseases; HIV-associated dementia; CNS bacterial infections; brain Toxoplasma gondii; Acanthamoeba infections;
Listeria infections; prion diseases; subacute spongiform encephalopathies and macular degeneration may also be treated.
We also plan to deactivate, remove, the GADD45x-is gene to try to augment our stem cells to more proliferation, then restore its function once the cells are ready for use.
As well as the above creatures we could use the HOX treatments on (close relatives of the dinosaur precusor), eg. elephants to mammoths, tigers to sabre tooth tigers, alligators/crocodiles, bats, any and all birds.
Any and all methods and techniques for Cloning Elephants, Narwhales, walruses and any and all expensive ivory, teeth, bones (whales), human, skulls, jaws, horns (horns 5%).
We need to determine the precusor cells to the ivory (possible from the jaws, and/or skill and/or dentine surrounded on one side by pulp).
We need to know the signalling mode of these creatures that cause them to grow the ivory (eg. pressure missing, feedback molecules, hormones, substances and their concentrations, produced by the cells external surrounding cells and/or internally within the cells eg. causing the stem cells DNA to line up and the cell to split into two robust (cytoplasm - organelles) divisions)...
We could tissue culture their stem cells (especially from creatures with the best quality ivory) and find the gene(s) and/or chemicals that stimulate the stem cells to specialize into ivory.
One method to enhance growth is to Gerard's patented stem cells recycling method (and perhaps isolation and further culturing the cells with the longest telomeres into new colonies possibly surrounded with dental pulp on one end)... We plan to grow any and all teeth and bones and horns and tusks possibly using precusor cells, (stem cells using my patented cell proliferation techniques possibly bone marrow and red blood cells and plasma).
We could grow teeth, tusks, bones (including whale bones) by differentiating their stem cells via signalling and emulating the necessary factors (environment that) the cells naturally grows in.
We will induce the bone cell differentiation via bone morphogenetic proteins from large numbers of stem cells and/or Germ cells and/or bone marrow derived from the stem cells/germ cells. We could use synthetic matrix/scaffold that are porous, varying shapes and sizes to seed new bone growth. Possibly using coral, ceramic and animal collagen.
We could feed calcium and proteins to prompt and calls on cells such as osteoblasts and other cells to lay down new matrix that mineralizes and forms hydroxyapatite and collagen.
By using a porous matrix/scaffolding we allow blood vessels (and/or synthetic blood and/or liquid/serum tissue culture medium) snake through the bone framework (and/or applied directly to control/manage growth of the teeth/bones/tusks/horns) carrying many different compounds that orchestrate bone remodeling, such as calcitrol (a form of vitamin D-3), caicitonin (a thyroid hormone that prevents bone resorption), parathyroid hormone (which works with calcitrol to regulate calcium and phosphate metabolism), and prostagiandins (fatty acids that perform hormonelike functions).
We could also use foam/polymer/co-polymer to contain the direct tissue culture of bone marrow (and/or precusor stem cells seeded for its own proliferation; also stem cells into bone marrow; and stem cells into red blood cells and plasma at the right time the stem cells are treated with signals, proteins, amino acids ... pressure, hormones, bone morphogenetic protein growth factors), surrounded with surrounded by live vascular tissue, surrounded by medium such as nutrients oxygenated pulsing with nutrients.
Additionally (we could use neurotrophin family includes nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-1 (NT-1), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4) and/or apply with stem cells to apply to patients suffering from spinal cord injury).
REFERRENCE MATERIAL...
TAKEN FROM WIKIPEDIA:
List of Bone Morphogenetic Proteins BMP Known functions Gene Locus *BMP1 does not belong to the TGF-,6 family of proteins. It is a Chromosome: 8;
BMPI metalloprotease that acts on procollagen I, II, and Ill. It is Location:
8p21 involved in cartilage development.
Acts as a disulfide-linked homodimer and induces bone and Chromosome: 20;
BMP2 cartilage formation. It is a candidate as a retinoid mediator. Location:
20p12 Plays a key role in osteoblast differentiation.
Chromosome: 14;
BMP3 Induces bone formation Location: 14p22 BMP4 Regulates the formation of teeth, limbs and bone from Chromosome: 14;
mesoderm. It also plays a role in fracture repair. Location: 14q22-q23 BMP5 Performs functions in cartilage development. Chromosome: 6;
Location: 6p12.1 Chromosome: 6;
BMP6 Plays a role in joint integrity in adults.
Location: 6p12.1 Plays a key role in osteoblast differentiation. It also induces Chromosome:
20;
BMP7 the production of SMAD1. Also key in renal development and Location:
20q13 repair.
BMP8a Involved in bone and cartilage development Chromosome: 1;
Location: 1 p35-p32 BMP8b Expressed in the hippocampus. Chromosome: 1;
Location: 1 p35-p32 BMP10 May play a role in the trabeculation of the embryonic heart. Chromosome:
2;
Location: 2p14 BMP15 May play a role in oocyte and follicular development. Chromosome: X;
Location: Xp11.2 hide]
v=d-e Cell signaiing: TGF beta signaiing pathway TGF beta family (TGF-01, TGF-02, TGF-03) Bone morphogenetic proteins (BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8a, BMP8b, BMP10, BMP15) TGF beta superfamily of ligands Growth differentiation factors (GDF1, GDF2, GDF3, GDF5, GDF6, GDF7, Myostatin/GDF8, GDF9, GDF10, GDF11, GDF15) Other (Activin A and B/inhibin A and B, Anti-mullerian hormone, Nodal) TGFBR1: Activin type 1 receptors (ACVR1, ACVR1B, ACVR1 C) - ACVRL1 - BMPR1 (BMPRIA - BMPR1 B) TGF beta receptors TGFBR2: Activin type 2 receptors (ACVR2A, ACVR2B) TGFBR3: betaglycan TransducerslSMAD R-SMAD (SMAD1, SMAD2, SMAD3, SMAD5, SMAD9) - I-SMAD (SMAD6, SMAD7) - SMAD4 Ligand Inhibitors Cerberus - Chordin - DAN - Decorin - Follistatin -Gremlin - Lefty - LTBP1 - Noggin - THBS1 Coreceptors BAMBI - Cri to Other SARA
Chemical & Engineering News August 25, 1997 Other SARA
Chemical & Engineering News August 25, 1997 Copyright 1997 by the American Chemical Society I l- . . v19"~
BONING UP
At the human body shop, bioceramics or biopolymers combined with bone cells and growth factors are likely to lead the parts list STEPHEN K. RITTER
C&EN Washington A woman struck by a car in Florida loses 3 inches of her crushed lower leg and could be left to live with a drastic disability for the rest of her life. A Detroit teenager with a marble-sized divot in his thigh from the removal of a benign tumor could spend the rest of his life being overly cautious.
But the woman is now back to ballroom dancing, and the teenager is swimming again and plans to go skiing.
These dramatic tales of people who against great odds recovered from accidents or diseases to live reasonably normal lives are examples of the benefits reaped from research that began in the 1980s to characterize with increasing accuracy the content and structure of human bone. The success of this research now is resulting in new drugs and treatments for bone diseases, a host of new synthetic materials to repair bone fractures or to serve as bone replacements, and tissue engineering techniques to induce bone growth from scratch using a patient's own bone ceils.
"There is more activity now in this field than there ever has been before, which I find gratifying," says Ralph E. Holmes, professor of surgery and head of the division of plastic surgery at the University of California, San Diego, Medical Center. Holmes, who invented a scanning electron microscope backscatter imaging technique to quantitatively measure ingrowth of bone in implants, has been a leader during the past 20 years in evaluating many synthetic materials. "I think the current activity is a sign of the maturity of all the sciences involved and a recognition that not just one thing can make bone heal," Holmes observes.
Although bone seems lifeless, it actually is made up of a very alive, porous framework that is constantly rebuilding itself. Bone is a composite material made up of collagen protein fibers threading through hydroxyapatite, Ca5(PO4)30H. Hydroxyapatite makes up about 70% of bone structure and essentially all of the enamel in teeth. The coliagen fibers, a bundled array of cross-linked helical polypeptide strands, provide extra strength, allowing bones to flex under stress.
BENEATH BONE'S HARD EXTERIOR...
Bone tissue replaces itself through the action of cells called osteociasts that produce acids to dissolve (resorb) hydroxyapatite and enzymes to break down collagen. The resulting release of calcium and proteins prompts other cells called osteoblasts to lay down new matrix that mineralizes and forms hydroxyapatite and coliagen. Some growth factors, such as bone morphogenetic proteins, are manufactured by bone cells themselves to either increase or decrease bone remodeling.
Blood vessels snake through the bone framework, too, carrying many different compounds that orchestrate bone remodeling, such as calcitrol (a form of vitamin D-3), calcitonin (a thyroid hormone that prevents bone resorption), parathyroid hormone (which works with calcitrol to regulate caicium and phosphate metabolism), and prostaglandins (fatty acids that perform hormonelike functions). Beneath all of that is the bone marrow that creates the osteoblasts and osteociasts as well as the red and white blood cells.
Skeletal deficiencies from trauma, tumors and bone diseases, or abnormal development frequently require surgical procedures to attempt to restore normal bone function. Although most of these treatments are successful, they all have associated problems and limitations.
For a minor fracture, usually a few weeks in a cast are all that is needed for the bone to repair itself. For a more severe fracture or one in a particularly tricky position, a bone cement or filler may be used to help strengthen the fractured bone so it heals faster. These procedures may or may not require metal hardware such as plates, pins, or screws for extra support.
For severe fractures, a bone graft may be needed. In a typical bone graft, natural bone or a synthetic material is shaped by the surgeon to fit the affected area and held in place with hardware. Over time, the natural bone growth process takes over and at least partially resorbs the grafted bone. Key to the level of resorption is the porosity of the implant material that allows ingrowth of vascularized tissue.
Surgeons have been performing bone grafts for years. The preferred method is a procedure called an autograft, where bone fragments are taken from a patient's own body-usually a hip (iliac crest), the pelvis, or ribs-and affixed to healthy bone. An alternative method, called an allograft, uses bone donated from a cadaver and works nearly as well.
Bone grafts are painful, complicated procedures that generally involve a long recovery period. Drawbacks to autografts are the two surgical procedures needed, meaning longer hospitalization and recovery time, and higher cost. Besides, the body doesn't carry much spare bone.
Allografts eliminate the need for a second surgery, but after sterilization, the donated bone loses much of its strength. In addition, when bone grafts are taken from cadavers, there is the risk of rejection or of transmitted diseases such as hepatitis B or AIDS
caused by infection with the human immunodeficiency virus. Allograft procedures have been on the decline since late 1993 when the Food & Drug Administration issued regulations governing bone and tissue banks because of the risk of transmitting infectious diseases.
A third option, which today is becoming more viable, is use of a synthetic material to replace lost bone. Synthetic materials have the advantage of eliminating the need for surgery to claim bone for the graft procedure, and eliminating the chance for rejection or transmission of infectious disease. An additional benefit is a significant reduction in medical cost and, in general, a faster recovery time.
The ideal bone substitute, according to Holmes, would approximate the autograft, requiring minimally that it be biocompatible and osteoinductive so that the body's natural bone-making process eventually would replace the implanted material. Most synthetic materials, however, are weakly resorbed or do not resorb at all. But low resorption is not necessarily a drawback, he says.
In some applications, such as a long bone fracture, one might hope for complete resorption of a synthetic material. But in other cases, such as reconstruction of the chin, resorption may not be desirable at all. Thus, a combination of autograft and synthetic material with hardware often turns out to be the best solution, Holmes notes.
The driving force to develop new treatments for bone diseases, the fractures associated with them, and fractures from trauma is that they make up an important segment of the health care industry. Americans suffer some 5.6 million fractures, and surgeons perform about 3.1 million orthopedic procedures in the U.S. each year, according to the American Academy of Orthopaedic Surgeons. Industry experts expect these numbers to increase steadily as the general population grows older.
In 1995, the latest year for which statistics are available, there were some 426,000 bone-graft procedures in the U.S., according to Medical Data International (MDI), a market research firm based in Irvine, Calif. That makes bone second only to blood transfusions on the list of transplanted materials.
The worldwide bone-graft market was estimated to be about $800 million annually, about half in the U.S., MDI reports. In 1995, about 58% of bone-graft procedures were autografts, compared with 34% allografts, and 8% synthetic materials, and nearly half of the procedures involved the spine. The percentage of synthetic procedures is expected to rise substantially as new biomaterials continue to come onto the market.
Treating bone diseases When osteociasts dissolve old bone faster than osteoblasts can replace it, the result is osteoporosis. Osteoporosis is characterized by loss of bone density that can lead to debilitating fractures of the hip and spine. The disease usually strikes postmenopausal women (age 50 to 70) as a result of decreased estrogen and progestin levels.
The disease also can occur later in life (after age 75) in women and, as a result of testosterone imbalance, in men.
According to the National Osteoporosis Foundation, an estimated 20 million women in the U.S. have osteoporosis. That number is projected to grow to more than 35 million by 2015.
Furthermore, the financial impact of osteoporosis in the U.S. has been estimated to be almost $14 billion per year in medical costs and lost productivity. These sobering statistics are the driving force for research into drugs to prevent or treat osteoporosis and other bone diseases. Industry analysts expect the global osteoporosis market for pharmaceuticals to reach $5 billion by 2005.
Osteoporosis can be detected by radiological imaging techniques used to measure loss of bone density. Besides prevention through diet, a number of therapies are being used to treat or prevent the disease. Estrogen replacement therapy, approved in 1988 by FDA, is common. Combined estrogen-progestin therapy as well as calcitonin therapy also are being used.
Diphosphonates are a class of compounds that are now becoming available in the U.S. as nonhormonal drugs for prevention of osteoporosis and as a treatment to help prevent bone fractures in patients who already have osteoporosis. The drugs are also proving successful for treatment of Paget's disease of bone (a chronic dissolving of normal bone followed by disorganized, enlarged, and weakened bone formation) and heterotopic ossification (abnormal overgrowth of bone, usually at postoperative sites such as the hip).
Although the exact mechanism of action of diphosphonates is unclear, they accumulate on bone surfaces and inhibit osteoclast resorption, allowing the bone-formation process to dominate.
DIPHOSPHONATES HELP BOOST BONE DENSITY
The use of diphosphonates to treat bone disease was first advanced by emeritus research chemist M. David Francis and coworkers at Procter & Gamble in Cincinnati.
Francis' other research accomplishments include discovering the benefits of adding fluoride salts to toothpaste to prevent tooth decay and adding pyrophosphate (P407 4-) for tartar control (C&EN, March 11, 1996, page 34).
Francis led the development of etidronate (disodium 1-hydroxyethane-1,1-diphosphonate), a compound that Procter & Gamble originally had looked at as a detergent additive to chelate calcium and other hard-water ions. Etidronate, now marketed by Procter &
Gamble as Didronel, is used in the U.S. and abroad to treat Paget's disease and heterotopic ossification.
Procter & Gambie also markets Didronel in 17 countries for osteoporosis.
However, in April of this year, Merck announced that it had become the first company to receive final U.S. approval for a diphosphonate to help prevent or treat osteoporosis.
Alendronate (sodium 4-amino-l-hydroxybutylidene-1,1-diphosphonate) is now marketed in 49 countries as Fosamax.
FDA's decision to clear the drug, according to the company, was based primarily on two-year results of an ongoing six-year study of more than 1,600 women ages 45 to 59.
The drug is working as well as hormone replacement therapy to increase bone mass at the hip and spine, while a placebo group is showing a gradual loss of bone mass.
Procter & Gamble has another diphosphonate compound, risedronate (sodium 2-(3-pyridinyl)-1-hydroxyethylidene-1,1-diphosphonate), that is in late-stage Phase III clinical trials for treatment of osteoporosis and Paget's disease. In March, the company filed a new-drug application with FDA for treatment of Paget's disease, and plans to file another application for treatment of osteoporosis in 1998. In May, Procter & Gamble announced it was forming a global alliance with Hoechst Marion Roussel-the pharmaceutical company of Germany's Hoechst-to commercialize the new drug under the name Actonel.
Mending and making bones Poly(methyl methacrylate), an old standard, has been used for decades as a synthetic filler to repair skeletal defects and affix metal implants to bone. Usually methyl methacrylate is polymerized in situ at the site where additional bone is needed. The polymer hardens to become stronger than bone and is generally a good substitute.
One of the advantages of poly(methyl methacrylate) as well as similar types of bone fillers and cements is that they can be injected through the skin. But there are a couple of problems critical to the use of these materials. One is that they usually must cure in situ and in doing so can generate heat that could damage surrounding soft tissues. Another, and perhaps more important issue, is that most of the materials are minimally degradable or don't degrade at all, nor can they support ingrowth of new bone tissue.
The concept of developing materials that are biocompatible and can at least be partially resorbed in the natural bone-growth process grew out of the ground-breaking research in the 1960s by Marshall R. Urist, a professor of orthopedic surgery at the University of California, Los Angeles.
Urist was the first researcher to conclusively demonstrate the phenomenon of osteoinduction, or the natural process of bone desorption and formation. For more than a century, surgeons had recognized the ability of demineralized bone to aid bone healing. But it was Urist's work on implanting demineralized bone segments into animals and being able to induce new bone growth within the implants that led him to conclude in 1965 that cells in the bone matrix stimulated cells at an implant site to differentiate into osteoblasts and osteoclasts. He later showed that bone morphogenetic proteins are the sole inducers of bone cell differentiation. His original paper reporting those findings was recently reprinted as a landmark paper in the Journal of NIH Research [9, 43 (1997)].
Urist's findings coupled with better diagnostic techniques subsequently gave rise to a greater understanding of bone structure and the bone-formation process. This understanding, in turn, led to the development of a host of calcium-based synthetic bone products designed to mimic natural bone and to actually be resorbed by the body. It has been only recently, after many years of animal trials, that these materials have advanced to the point that they are acceptable for use in humans and are starting to gain FDA approval.
One company well ahead in the synthetic bone implant market is Interpore International of Irvine, Calif. In November 1992, Interpore became the first company to receive FDA approval for a synthetic bone-void filler.
The company's Pro Osteon hydroxyapatite is made from coral through a thermochemical process developed in the 1970s. Currently, it is the only synthetic product on the market that has a porous infrastructure similar to natural bone. The interconnected structure of the coral remains intact throughout processing, providing a matrix through which blood vessels and new bone tissue can grow.
INTERPORE'S SYNTHETIC BONE GRAFT...
Interpore acquires between 2 and 4 tons of coral each year from atolls in the Pacific and Indian Oceans to make its product, less than 1% of the total annual amount of coral imported into the U.S., the company says. The amount of coral harvested for import is controlled by the Convention on International Trade of Endangered Species of Wild Fauna &
Flora (CITES) and is generally agreed upon by ecologists to present little threat to fragile reefs as long as the coral is harvested in ways that sustain the reefs as living structures. One coral "head" weighing 150 to 200 lb provides enough material for several hundred bone grafts.
The synthetic material is prepared by heating the coral-which is essentially calcium carbonate-with ammonium phosphate at more than 200 C for 24 to 60 hours to obtain about 95% hydroxyapatite. The material is processed into block or granular form and sterilized by gamma radiation.
Used similarly to natural bone in autograft procedures, the synthetic material has about the same length of healing time. A surgeon can shape a block of the material, for example, to fit into a fracture crevice or a carved out portion of a long bone. The graft area is then stabilized with a metal plate and screws, which later can be removed.
The natural porosity of the material does have the drawback of reducing its strength, notes David C. Mercer, Interpore's president and chief executive officer. But the porous structure provides room for bone tissue to immediately grow into the pores of the implant. However, the material is only partially resorbed and replaced by natural bone. The company is now evaluating in preclinical studies a related new product that has a higher resorption rate.
Pro Osteon is currently approved for nonweight-bearing treatment of fractures at the wide end of long bones and for jaw and reconstructive facial surgery, according to Mercer.
However, the material has been used in many cases to replace a short section of a long bone, he says. In such cases, the limb must be immobilized for a long period-perhaps several years-to ensure new bone growth has become strong enough to support weight.
Sales of Pro Osteon have increased steadily since 1992, reaching $11.7 million in 1996, up 47% from the previous year. Sales in the first half of 1997 continue to be strong, increasing 13% from last year's first half to $6.3 million. lnterpore also has approval to sell its bone substitute in 41 countries and began international marketing in 1995.
Although synthetic biomaterials on the market or under development work well for their intended functions, none has yet proven to be sufficiently strong or able to be processed into a large enough piece to stand in as a complete replacement for long bones.
Research by University of Texas, Austin, chemistry professor Richard J. Lagow, however, appears to have come the closest to that goal. Lagow makes a high-purity hydroxyapatite from scratch by reacting calcium metal, calcium hydroxide, and phosphoric acid at 700 to 850 C. Lagow also has come up with analogous high molecular weight linear calcium polyphosphates by reacting hydroxyapatite with phosphoric acid. The success of his research has led to the creation of a small Austin-based company, called OsteoMedica Inc., to develop the synthetic materials as potential complete bone substitutes.
Key to developing these compounds for implant materials, Lagow says, is their high purity, which does not retard bone growth. Also important, he says, is holding the reaction temperature below the 1,200 C temperature at which calcium phosphate fuses into a ceramic.
Besides controlling bulk size and shape, during his proprietary synthesis and processing method, Lagow can moderate the interconnecting porosity of the synthetic material-in the range of 150- to 400-pm pores-to match the density of different types of bone.
"Interconnecting means that the body can vascularize it quickly and bone can then grow into the material much faster because there is a greater surface area for the osteoblasts and osteoclasts to work," Lagow notes. "Otherwise, the osteociasts must tunnel through the bone matrix to resorb the synthetic material, which is a much slower process."
Lagow has collaborated with UT Austin chemical engineering professor Joel W.
Barlow and others to develop a selective laser sintering technology that they have patented to fabricate complex bone shapes from the calcium phosphate materials.
Barlow and his research group developed a technique whereby they use a spray drier to coat hydroxyapatite or calcium phosphate powders with a poly(methyl methacrylate) that acts as a binder. The materials readily fuse in the sintering process but maintain their interconnecting pore structure. And, unlike other bioceramics being investigated as bone substitutes, they retain their high strength during processing, Lagow says.
LAGOW S METHOD TO SYNTHESIZE...
The laser can be guided to form intricate bone shapes by computer, using data sources such as magnetic resonance imaging or computed tomography. The molded ceramic is then heated to remove the polymer and further processed. Thus far, the researchers have been able to generate a wide range of bone sizes and shapes. The technology has since been licensed to BioMedical Enterprises Inc., San Antonio, which is pursuing biocompatability studies of fabricated calcium phosphate implants.
OsteoMedica's goal is eventually to provide surgeons with synthetic molded bone "blanks"
that can be custom shaped to fit a patient's needs. The company's bioceramic, called Megag raft 1000, so far has been successful in tests replacing tibia sections in rabbits and other animals.
And in a very successful study on dogs, sections of the radius were replaced with the synthetic bone. After 11 months, support plates and screws were removed, and the dogs eventually regained full use of their legs. One of the most promising aspects of the study was that, some three years after the time of the implant, the synthetic material was completely resorbed- results that haven't been reported for other synthetic materials.
OsteoMedica is preparing to begin clinical trials in humans for spinal fusions in the U.K.
and Australia, where regulatory requirements aren't as stringent as in the U.S.
"Being able to synthesize novel hydroxyapatite material to make it accessible to higher bone ingrowth and remodeling rate is a critical step," says UC San Diego's Holmes, who has evaluated both Interpore's and OsteoMedica's products. While he finds both materials work well for their intended use, a product such as OsteoMedica's hydroxyapatite being available in different pore sizes would be particularly useful for a wide range of applications to control the level of resorption, he notes. "Wi'th a range of porosities and resorption rates, surgeons could learn to choose the synthetic material for a particular application much in the way they choose a suture material."
Glen O'Sullivan, an assistant professor of orthopedics at Stanford University Medical Center, also has used lnterpore's product in his patients and has worked on a clinical study of spinal fusions in sheep using OsteoMedica's material. He, too, finds both materials perform well for their designed use.
"One advantage of OsteoMedica's product is it is one of the hardest materials," O'Sullivan notes. "For example, lnterpore's material can be crumbled between the fingers, while OsteoMedica's is strong enough to drill holes in it. This makes OsteoMedica's a good candidate for use in the spinal column, whereas Interpore's would not be-and it isn't approved by FDA for that."
Holmes and O'Sullivan agree that there isn't one material that is going to be suitable for all applications. "With any of these new products," O'Sullivan says, "one likes to be optimistic, but the hopes and expectations may not always pan out for all applications."
It makes sense, he adds, that FDA only approves what might appear to be broadly applicable bioceramic materials for a narrow range of applications.
There are perhaps dozens of calcium-based synthetic materials in addition to Interpore's and OsteoMedica's that have received approval for use in the past couple of years or are anticipating approval soon. In 1996, for example, FDA approved OsteoSet, a calcium sulfate (plaster of paris) bone-void filler developed by Wright Medical Technology, Arlington, Tenn., that is reasonably resorbed by the body in as little as eight weeks. Another product cleared in 1996 by FDA for repair of cranial defects is a hydroxyapatite bone cement developed by American Dental Association Health Foundation researchers called BoneSource.
The material will be manufactured by OsteoGenics Inc. and distributed by Howmedica Leibinger, a division of Pfizer.
An injectable bone cement developed by Norian Corp., Cupertino, Calif., is described by the company as a biocompatible, moldable compound made by mixing calcium phosphate, tricalcium phosphate, and calcium carbonate with sodium phosphate solution into a toothpastelike substance. Norian currently has approval to market its Skeletal Repair System in Europe and Canada, and is working toward regulatory approval in Japan and the U.S., mainly for treatment of wrist and hip fractures.
New directions In 1993, FDA approved one of the first bone graft substitutes that capitalized on a new concept for products to facilitate bone repair. Collagraft, marketed by Bristol-Myers Squibb subsidiary Zimmer Inc., Warsaw, Ind., is a hydroxyapatite/tricalcium phosphate and bovine collagen that must be mixed with a patient's own bone marrow.
In late 1996, Interpore signed a license and development agreement with Quantic Biomedical, San Rafael, Calif., for a technology to use a gellike material containing bone growth factors from a patient's own blood that can be combined with its coral-based Pro Osteon to provide accelerated bone growth. Preclinical feasibility trials are expected to begin by the end of this year.
These examples illustrate the impact that the "delayed discovery" of bone morphogenetic proteins (BMPs) has had in opening the research community to a new direction:
the concept that BMPs, bone cells, and various hormones could form the basis of an engineered system for bone repair that includes bioceramics or biopolymers. In essence, the world of bioceramics is being wed to the world of tissue engineering.
Although Urist's work on osteoinductivity was definitive, most researchers weren't convinced until BMPs actually began to be cloned by recombinant DNA methods some 20 years after his landmark research paper.
In 1988, the first group to clone a BMP was that of senior director John M.
Wozney at biotechnology company Genetics Institute, Andover, Mass. [Science, 242, 1528 (1988)].
Today, one of Genetics Institute's molecules, BMP2, is in clinical trials for fracture repair, spinal fusion, and other possible applications. Several other biotechnology and pharmaceutical companies are testing the more than 30 BMPs cloned thus far for potential use in bone- and tooth-mending applications. "BMPs are destined to bring osteogenesis under the control of surgeons before the turn of the century," Urist noted in a commentary on his landmark paper.
"Despite the great advances in the synthetic materials, one still needs the bone cells,"
O'Sullivan states. "Bone cells are needed in the implant material and you want a means of stimulating bone cell activity. This is where research with BMPs is really going to take off."
O'Sullivan notes that even during autograft procedures, surgeons attempt to aspirate bone celis from adjacent bone to incorporate into the implanted bone, and sometimes use material extracted from presurgical blood donation by the patient to help induce implant bone growth and resorption.
O'Sullivan points out that a critical step remaining for BMPs is to find the optimum carrier for implantation. Although bioceramics likely will work well, he says, they do have the problem of slow resorption. Thus many researchers believe that biodegradable polymers will work best as delivery devices for human growth factors, he says.
One of the leaders in the biodegradable polymer area is Antonios G. Mikos, an associate professor in the department of chemical engineering and the Institute of Biosciences &
Bioengineering at Rice University, Houston. "The advantage of using polymers is that one can very accurately engineer their mechanical properties and degradation characteristics,"
he explains. The size and shape of the scaffold can be made to order as well, depending on which bone a potential patient may need.
Mikos and his research group are working on strategies to naturally grow bone from scratch either in vitro or in vivo by seeding natural or synthetic polymer scaffolds with bone cells or to use the scaffolds as conduits to induce new bone growth from surrounding tissues. Several substrate materials are being investigated by a number of researchers, Mikos notes, including poly(a-hydroxy esters), polyanhydrides, polyimides, polyphosphazenes, and collagen.
The success of such strategies is dependent on the scaffold material's being biocompatible, osteoconductive, and quickly degradable into products that can be metabolized or excreted, he explains. For example, poly(lactic-co-glycolic acid) breaks down to lactic acid and glycolic acid, which are metabolized in the body and excreted as carbon dioxide and water.
Osteoblast transplantation onto a polymer scaffold would eliminate the problem of donor scarcity, immune rejection, and pathogen transfer by taking the needed cells from a patient's own body, Mikos points out. Although osteoblasts may be obtained by a variety of methods, including bone chips from an injury site or enzymatic digestion of harvested bone, the most desirable method would be to obtain the cells from the patient's own bone marrow.
Osteoblasts obtained from bone marrow, for example, can also be expanded in tissue culture in a lab and seeded onto a polymer scaffold for implantation.
Poly(lactic-co-glycolic acid) has been extensively investigated as a material for tissue-engineering scaffolds because it already has been approved by FDA for use in surgical sutures, can be made with controlled pore size, and degrades well. The first such scaffolds were designed by biomedical and chemical engineering professor Robert S.
Langer at Massachusetts Institute of Technology and Joseph P. Vacanti of Harvard Medical School in the late 1980s to create an in vitro environment that enables cells to organize themselves to form functioning tissues. Langer and Vacanti prepared crude scaffolds by bonding together poly(lactic-co-glycolic acid) fibers into a two-dimensional network.
In 1991, working with Langer and Vacanti, Mikos (then at MIT) further developed the polymer scaffolds by incorporating sodium chloride crystals into the copolymer matrix by adding crystals to a solution of the dissolved polymer. The salt crystals were later leached out, leaving behind a porous polymer matrix. Mikos was able to control porosity and pore size by varying the concentration and size of the crystals.
In another technique, Mikos extruded polymer fibers and aligned them in the shape of the desired scaffold. He embedded the arrangement in a polymer with a higher melting point and bound the scaffold together by heating. After cooling, he selectively dissolved the embedding medium, leaving behind an interconnected, highly porous structure.
Mikos, graduate student Susan L. Ishaug-Riley, and coworkers have recently conducted feasibility studies to show that bone formation in vitro and in vivo is possible by culturing rat osteoblasts in three-dimensional poly(lactic-co-glycolic acid) foams of different pore sizes (shown on the cover of this issue).
In one study, the polymer foams supported the proliferation of the seeded rat osteoblasts in --i vitro to form a calcified bonelike tissue after two months [J. Biomed. Mater.
Res., 36, (1997)].
The goal of the study was to gain a better understanding of the important parameters in the design of an osteoblast foam-culture system before attempting osteoblast transplantation in vivo.
In a subsequent in vivo study, rat bone marrow osteoblasts were seeded onto polymer foams and implanted into the rat mesentery (the membrane of the abdominal cavity) [J. Biomed.
Mater. Res., 36, 1 (1997)]. Growth of islands of mineralized bonelike tissue in the foam surrounded by fibrovascular tissue was observed within one week and had significant penetration of bone tissue into the scaffold after seven weeks.
The findings were encouraging, the researchers note, because they indicate that the regenerative potential of the seeded polymer scaffolds for new bone growth with transplanted cells and secreted bone growth factors may further induce bone growth from adjacent bone.
Ishaug-Riley received a student outstanding research award from the Society for Biomaterials for the in vivo study at the society's 23rd annual meeting in New Orleans in May.
Osteoblast transplantation is not a straightforward approach, Mikos says, noting that because bone is highly vascularized, it is not possible to engineer and grow a complete bone or bone fragment in vitro and transplant it. "The maximum thickness of new bone one can create in vitro is a few hundred micrometers, which is not significant for clinical applications.
However, the goal is to form new bone tissue in vivo and not in vitro. Then, vascularization becomes equally important to bone formation and necessary for regeneration."
A critical issue for cell transplantation is which phenotype of transplanted cell should be used. "It is not clear if one should transplant osteoblasts or preosteoblasts or progenitor cells," he says.
Mikos believes it will be possible in the next decade for tissue-engineered implants to be used for the reconstruction of skeletal deformities resulting from trauma, tumors, or abnormal development. "I hope that new cell-based therapies will be developed for the treatment of osteoarthritis and osteoporosis based on combinations of degradable biomaterials, growth factors, and cells," he says. "Yet, the main drawback with new polymers is the time and effort needed to get FDA approval for their use."
O'Sullivan is optimistic about the prospects of tissue engineering in bone repair, but also cautious about a couple of potentially critical problems. FDA currently is not certain about how to regulate tissue-engineered products, he says. (A problem with tissue cultures is potential contamination with a fungus, bacteria, or mold.) "And it will be interesting to see if the new technology will become available in an affordable manner, given that the couple of companies working on BMPs have spent a tremendous amount of money during the past few years to develop a research infrastructure." He thinks the BMP companies will end up controiling the technology development path for the synthetic implant companies.
"The next step is going to be a fine balance between cost and whether the outcome is going to be worth it."
n coral that is converted to hydroxyapatite and processed into block or granular form. X-ray ima )one fragment was removed and replaced by the synthetic material. Metal plates and screws ob -rt the ankle until it heals.
hemCenter ^Pubs Div. Home Page We are so looking at cloning fish (especially high in omega 3) and the cells that produce or are rich in omega 3 for food any and all varieties, any and all climates for sushi, chinese seafood cuisine, fish and chips and any and all cuisine, including pelletisizing for food for livestock, also cloning the silivary glands that produce bird's nest soup, and jellyfish dishes, as well as clone any and all livestock (including chicken GP 33%), for flesh as well as fur and for leather and skin...
(3.5%) Growing com on the top layer could package (hereinafter, package/packed refers to biodegreadable absorbant yet stiff enough to support planst such as corn) large tight rooting and the stalk stands up - packed surrounding the roots is enough soil and/or peat and/or manure/compost/partially treated sewage and any and all organic wastes and/or chitin/chitosan to provide for the corn (and/or any and all plants to last through maturation -the packages fit in holes in large styrafoam trays and/or lava rock, and a further layer of lava rock below. Underneath the lava rock is a perforated strong waterproof material (eg. PVC) to hold up the two layers above and finally the bottom is a catch basin, where we could grow lobsters/crawdads/crayfish/tilapia/any and all shell fish/and any and all fishes and any and all water creatures; the entire system could be flushed with UV treated salt water and re-circulated UV treated salt water and low concentration feed tea manure...Alternatively if the tea manure has too much nitrogen, we could skip the middle layer of lava rock and rather plant the com in tight packages with enough peat and top soil in the rooting package surrounded by either a thick layer of styrafoam with holes that fit the rooting packages, and or lava rock to keep the corn from tipping and then place a membrane -multiple layer (eg.
sealing above the perforated strong waterproof material eg. PVC) to keep the nitrogen out, from entering the catch basin where the lobsters/crawdads/crayfish/tilapia/any and all shell fish/and any and all fishes are housed or more importantly to keep the salt water below from tainting the corps above, unless the farmed creatures below are fresh water species.
Alternatively, we could design the system where water does not pass freely between the crops hydroponics' in packages surrounding the stalks of eg. corn we could put bags of algae (that are passed with tea manure) above and the farmed water boume species below we could recycle water, where nitrogen-ammonia water caused by feces/uneaten are treated with UV and then micro organisms in sand and membrane to take out the salt which produces fresh water that is re-circulated to the plants/crops above, then the opposite the water from the crops (that have nitrogen removed by the roots of the crops) can be mixed in salt if for salt water re-circulation. This rotational re-circulation, may create symbiotic synergies. We could grow these stacked farming systems on further floors up all the way up tall buildings... possibly with TALL GRAVITY TO ELECTRICITY INVENTION buried underground to provide energy. We could also grow root foods in third world countries (as well as rice) such as yam, sweet potatoes and potatoes which may be higher yield than rice - in its ability to fill stomachs (even gingseng)... by packing the area surrounding the roots with a large footprint of tightly peat/top soiVmanure/slightly treated sewage/compost/and and all organic waste, perhaps surrounded by a burlap (or biodegradable - any and all covers) to wrap, and placed in a hydroponic solution (eg. tea manure; possibly supplement with phosphorous/potassium and vitamins), surrounded by support such as thick styrafoam flats to support the stock and lava rock surrounding the packaged roots - with ample packaging of root growth space so as not to impede the growth of root crops - possibly in sky scrapper green houses.
We could also methylation, imprinting to increase harvests of any and all crops including any and all bio crops.
We could coat any and all seeds (especially bio crops seeds) as well as pack chitin/chitosan around roots.
In all of the above we use chitin and chitosan interchangeably.
The some of the following can be interchangeably between any and all creatures and any and all plants.
We are culturing stem cells (using testing for the best timing and sequences...) and enhancing their proliferation by using GM-CSF (granulocyte-macrophage colony-stimulating factor) + fetal bovine serum (FBS) (and/or any other mediums) to methylate in the p15 CpG
island. Viable cells were responsible for this epigenetic change. Following the GM-CSF + FBS application the culture was added to inhibitors for DNA
methyltransferase (DNMT) and histone deacetylase (HDAC) caused the demethylation of nearly all CpG sites in the p15 CpG island on every allele sequenced. GM-CSF may be able to induce de novo methylation of the p15 gene, using HDAC(s) as well as DNMT(s).
Taken Wikipedia:
Neoplastic tumors often contain more than one type of cell, but their initiation and continued growth is usually dependent on a single population of neoplastic cells. These cells are usually presumed to be clonal - that is, they are descended from a single progenitor cell.
The neoplastic cells typically bear common eg netic or epigenetic abnormalities, an evidence of clonality. For some types of neoplasm, e.g. lymphoma and leukemia, the demonstration of clonality is now considered to be necessary (though not sufficient) to define a cellular proliferation as neoplastic.
Nocodazole and Colchicine have the opposite effect, blocking the polymerization of tubulin into microtubules, we could try these drugs to increase the proliferation of stem cells.
We are also using proto-oncogenes to increase stem cell proliferation (see below taken from Wikepedia).
Proto-oncogene A proto-oncogene is a normal gene that can become an oncogene due to mutations or increased expression. Proto-oncogenes code for proteins that help to regulate cell growth and differentiation. Proto-oncogenes are often involved in signal transduction and execution of mitogenic signals, usually through their protein products. Upon activafion, a proto-oncogene (or its product) becomes a tumor inducing agent, an oncogene.u Examples of proto-oncogenes include RAS, WNT, MYC, ERK and TRK.
edit Activation The proto-oncogene can become an oncogene by a relatively small modification of its original function. There are three basic activation types:
= A mutation within a proto-oncogene can cause a change in the protein structure, causing o an increase in protein (enzyme) activity o a loss of regulation = An increase in protein concentration, caused by o an increase of protein expression (through misregulation) o an increase of protein stability, prolonging its existence and thus its activity in the cell o a gene duplication (one type of chromosome abnormality), resulting in an increased amount of protein in the cell = A chromosomal translocation (another type of chromosome abnormaiity), causing o an increased gene expression in the wrong cell type or at wrong times o the expression of a constitutively active hybrid protein. This type of aberration in a dividing stem cell in the bone marrow leads to adult leukemia Mutations in microRNAs can lead to activation of oncogenes.v New research indicates that small RNAs 21-25 nucleotides in length called microRNAs (miRNAs) can control expression of these genes by downregulating them.r7l edit Proto-Oncogenes There are several systems for classifying oncogenes, 8 9 but there is not yet a widely accepted standard. They are sometimes grouped both spatially (moving from outside the cell inwards) and chronologically (paralielling the "normal" process of signal transduction). There are several categories that are commonly used:
Category Examples Description Usually secreted by specialized cells to induce cell proliferation in themselves, nearby cells, or distant Growth factors, or c-Sis cells. An oncogene may cause a cell mitogens to secrete growth factors even though it does not normally do so. It will thereby induce its own uncontrolled proliferation (autocrine IOog), and proliferation of neighboring cells. It may also cause production of growth hormones in other parts of the body.
Kinases add phosphate groups to other proteins to turn them on or off.
Receptor kinases add phosphate groups to receptor proteins at the epidermal growth factor receptor surface of the cell (which receive (EGFR), platelet-derived growth protein signals from outside the cell Receptor tyrosine factor receptor (PDGFR), and and transmit them to the inside of kinases vascular endothelial growth factor the cell). Tyrosine kinases add receptor (VEGFR), HER2/neu phosphate groups to the amino acid tyrosine in the target protein. They can cause cancer by turning the receptor permanently on (constitutively), even without signals from outside the cell.
Src-family, Syk-ZAP-70 family, and Cytoplasmic BTK family of tyrosine kinases, the _ tyrosine kinases Abl gene in CML -Philadelphia chromosome Cytoplasmic Serine/threonine Raf kinase, and cyclin-dependent kinases and their kinases (through overexpression).
regulatory subunits Regulatory Ras protein GTPases -Transcription -MYC- gene factors We plan to add Cargo transport In the cell, small molecules such as gases and glucose diffuse to where they are needed.
Large molecules synthesised in the cell body, intracellular components such as vesicles, and organelles such as mitochondria are too large (and the c osol too crowded) to diffuse to their destinations. Motor proteins fulfill the role of transporting large cargo about the cell to
Claims (12)
Any and all Uses for chitosan's antibacterial properties and its low toxicity for human and creatures ingestion.
We can use it as a spray (eg. mix with drinks in hepatitis prevalent countries), flavoured and/or unflavoured (no taste) - an additive to any and all foods mixtures and/or beverages, as well as spray on cup (prevention e.coli, salmonella, avian flu) spray a film on masks for any and/or all diseases that are airborne, including diseases that are spread by fluid transfer.
We could also inject this substance via empty T-cells (and other immune cells eg.
macrophages, phagocytes and lymph) that bind to HIV AIDS, filling these immune cells whose membrane proteins bind with HIV AIDS cells and deliver chitosan (same as cancer and any and all diseases whose infection method can be identified to bind with the immune cells membranes between proteins and receptors to deliver chitosan to kill the diseases and then we could repopulate the disease battle zone with stem cells (possibly use HOX genes and/or building blocks of HOX) and differentiated stem cells appropriate to the battle zone.
The delivery of these concoctions can be via multi micro syringes to ensure neither too much and/or too little of the concoctions to the map of the infected battle zone.
We can use the above for any and all uses to kill off bacteria and/or viruses.
(Jz 0.7%) We could use the chitosan in conjunction with zeolite, semi-permeable membrane, and test for heavy metals - if there is high amount of heavy metals in a batch we could plasma torch the batch to burn for energy.
We could use it for sewage/tea manure and/or all organic wastes. We could also use it to caked/coated onto a multi level horizontal/vertical matrix/scaffold to soak in reservoir tanks, until the water has reached safe levels.
We could use it to develop fluoride and/or chlorine and/or paste.
We could develop jugs where caked on perforated blocks drip off and mix with the chitosan cleansing the water. (Tea Bags - 25% GP), Powder and/or dissolving pill.
Also a large diameter straw with permeable caked/coated on dyed (to indicate level filtration ability remaining) chitosan. And even polluted rivers and/or lakes and/or wells and/or cisterns...whereby a large amount of chitosan is slowly discharged (and since chitosan is a renewable resource, we can mass produce the substance.
We could dye all the chitosan to observe the remaining concentrations.
(DLD Asia 40%) Also to add to polluted water sources.
Also Salt Water to Energy and Fresh Water Technologies.
We could also rear any and/or all chitosan sources such as crayfish/crawdads, in multiple levels of tanks in huge underground bunkers, possibly growing algae and other biocrops and/or any and/or all energy sources eg. solar, wind mills, TALL GARVITY TO
ELECTRICITY INVENTION...
We could also build aquariums (tanks/reservoirs) with a sunken floor to drain through pipe that is covered by a rubber stopper (like toilet stoppers), so that by lifting the stopper (flushing action) the stopper lid opens to the spout/pipe.
The spout/pipe immediately under the stopper has a grill/sift with small enough holes to avoid the fish/crawdads...falling through.
We can use a squeegee/rake to sweep the uneaten food and/or feces, down the spout/pipe, where these material is drained away.
We could add calcium and/or chitin, to the water when the creatures are moulting.
We could try to clone chitosan the stem cells and differentiate into the layer cells (precusor cells to the chitosan shell (GP 1%)) under moulting that produce chitosan exoskeleton.
And/or produce molecules that have the same basic structure as chitosan.
Chitin (C8H13O5N)n is a long-chain polymer of a N-acetylglucosamine.
Chitosan can also be used as scaffolding for stem cell, and differentiated planted artificially grown organs.
Chitosan could also be distributed in powdered and/or sprayed form to stop red tide.
Chitosan used for any and all detergents and/or oil/tar sands bitumen separator, (tailings ponds GP 13.5%), any and all industrial uses especially food and beverage industries, wet and dry tissue and toilet paper, (paper towel 13.5% GP), film lined any and all bags - paper to garbage bags. Pulp and Paper (eg. card boxes) made with less need for poisonous preservatives. We could use the chitosan for (refining any and all petroleum and bio fuels GP 10%).
Chitosan might also be used as a spray on preservatives such as wood, any and all spray on applications (2.5%).
Chitosan could also be used as soaps for animals. Chitosan could also be added to (compost?), and/or an additives wet vacuums, and/or wet air filters (with removable cartridges Jeff 1%), it could also be caked on/coated on any and all seeds, especially bio crops, and/or chitosan could be used at the end of the need for micro organisms, as a way of treating the micro organisms out the fermentation process to kill off potential microbial threats.
Chitosan could be used in powdered form to treat foot odour, dry and remove odour from shoes and/boots that are wet inside (ski/snowboard boots), kitchen clothing, fabric softener, carpet powder, spray/powder for any and all home uses on furniture/fruit bowl...any and/or all hospital uses, and office, and leisure (eg. where hepatitis, dengue fever, hemorrhagic fever ...
On another note, we plan to genetically bioengineer potatoes, and yams, and sweet potatoes, and taro roots to third world countries, where rice paddies costs are going up, and rice farming polluting the water supply (runoff from fertilizer and pesticides) and rice farming carries waterborne diseases such as malaria. Furthermore potatoes are probably more productive in terms of bulk value) as well potato farming is the USA is suffering from low cost, meaning it is a cheaper source of food for developing nations struggling to put food on the table.
We could use chitosan to refine any and all oil and gases We could also create cardboard boxes and biodegradable bags and wrapping -which can be made in different sizes and durability with a paper/cardboard box/bag and wrapping maker that is like a printer controlled by the computers, especially where the material contained is perishable foods, (eg. inner lining of candies, and snack foods).
We could make chitosan tooth paste and mouth wash, and/or gum and/or candy mints for fresh breath.
We could use chitosan and its properties to make a healthier palm oil and any and all oil (cooking products GP 0.1%).
We could use chitosan to clean up any and all hazardous materials. And use to clean up contaminated lands; land fills, slow dissolving slow delivery to aquaculture pens possibly hoses with sprinkling.
Hoses/trickling/sprinkling (eg. capillaries that reach the width/length of shellfish commercial farms that release) the chitosan in agriculture as well as farming feed.
As a an additional farming note we plan grow mass quantities of potatoes in developing countries where land is cheap, and rice prices are rising, while potato profits in decreasing in America are lowering. Potatoes are possibly more productive in terms of filling the stomach with less land. Potatoes use less water loss to evaporation. Rice fields can cause water borne diseases (including parasites and malaria). We could build green houses whose roofs are shaped like a spout/funnel that drains rain into a tank. We could also use Gerard Voon's salt to fresh water and energy invention to provide water. Local sources of water could be filtered with chitosan.
We are considering growing hydropohnically grown potatoes plants in floating trays. We will deliver into the water and/or substrate chitosan to prevent rot. We might recover the chitosan via, membrane, filter and/or drying. We can grow craysish/crawdads under the floating platforms, the walls need to be higher and transparent to keep the crayfish/crawdads from escaping, yet not interefere with light on the potato plants above. We could use tea manure for the fertilization of tanks, and for germinating tanks, no fertilizer, where the crayfish/crawdads are safest.
(GP 1%) We might also grow flats of algae (of optimal depths) with chitosan mixing in tea manure to harvest bio fuel.
If we make the floating platform tall enough to support the neck we could grow corn and/or any and all bio crops and high profit crops (eg. ice wine). We could even incorporate these hydroponic platforms into multiple level glass sky scrapper buildings. We could rotate these flats of floating platforms in circles (GP 1% solely) to get better sun exposure - more even or slow/stop/reverse to give certain regions more light. We could put in the centre of the building a Gerard Voon's patented TALL GRAVITY TO ELECTRICITY INVENTION
(and/or any and all building such as offices/condos/hotels/resorts/apartments at its centre GP 5%) and industrial uses for the centre as well and top levels buildings of underground shopping malls) whereby any and all crops are on multiple level floating platform flats that rotate around the buildings. We could also incorporate windmills on top or sides of the building.
We could rotate the entire platforms deck/level spinning around to get the most of the sun relative to the different needs of the platforms.
We could also build these spinning farms on platforms in the sea/oceans including polluted places.
We could also grow jacobra in hot dry climates by using low water required substrates such as lava rock and foam.
We could even use lattice skeletal structure of the building that are open walls, in climates that are non-extreme with the transparent roofs that funnel/spout the water down to a tank/reservoir.
We could use the centre/core of the building to chum the corn and microbes to (churn) ferment and produce ethanol. We plan to use sound and magnetics in pulses to stimulate/induce the micro organisms to (possibly imitating pulsating sounds that cause optimal metabolism and temperature and timing possibly in cycles so the micro organisms are pushed in the extreme one way at the cost/price of their long term health) to grow, proliferate and produce enzymes that ferment the corn.
We could use plasma torch/laser to burn any and all wastes, such as coal effluent, pulp and paper discharge (where the liquid discharge can be bound to chitosan and then dried and burnt with plasma torch/laser), any and all hazardous waste and all industrial/raw and all along the development stream of wastes produced (GP 1%) including recycling.
We could tie-in developers to be green (recycling) by identifying any and all parts taking apart and all buildings (sky/scrappers, houses, condominiums...) before demolition and/or renovation and refurbish their appliances/computers/televisions/audio/video/electronics furniture and the building materials like bricks separated from the dry wall and wooden doors/frames, walls... Some of the material can be refurbished (eg. computer with CD - for education, Internet (to learn about anything and everything from the world's knowledge) and email (to make friends even business connections worldwide) and Word capabilities (to be able to communicate and express in the Arts, Business, Science... papers of your ideas and understanding, perhaps internet web page designing program) and supplied to the poor worldwide.
We could also try to increase proliferation of stem cells by administering the ambilify drug, viagra and/or cialis...
We could have any and all plants uptake chitosan to fight fungi, rot, disease, toxins and heavy metals and produce long shelf life in fruits and vegetables and their by products.
We plan to take the homeodomain protein (genes) WUSHEL (WUS), LEAFY (LFY), and AGAMOUS (AG) to cultivate and grow stem cells of (high value plants - biofuel crops, ginseng, coffee, tea, rare plants).We are also testing GARP and bZIP. And explore phytohormone cytokinin, transcriptional network and factors and how these processes regulate proliferation.
Growth hormone cytokinin is at most effective when WUSCHEL stops the ARR genes feedback loop.
Ethylene is a major factor that drives the plant cells to proliferate.
We also plan to use epigenetic mechanisms which have had some success in non-plant stem cell proliferation.
The purpose of cloning is to try to grow valuable fruits and vegetables by, 1.) tissue culture of the stem cells and then differentiating them into desired cells (fruits and/or vegetables, kernels), 2.) multiplication effect from less starter cells needed to grow next generation's crop size (eg. rather than planting kernel by kemel, one kemel's many stem cells can be used to produce multiplications of starter plants for next generation crops), 3.) hybridization, isolating stem cells from the most productive and best characteristics for suited purposes of such crops.
We could also grow potatoes in our towers (glass sky scrappers), our plan is to submerge the potatoes und a platform with a hole so the stem can grow above, and we add chitosan in the medium below to prevent fungi and rot.
We plan to use pressure and temperature - to manure/sewage/any and all organic waste /tea manure... (possibly a vacuum surrounding the targeted raw materials) to create nitrogen, that can be used as fertilizer.
We can use the following for nitrogen fixation, including legume family Fabaceae:
Family. Genera Betulaceae (Birch): Alnus (Alder) Casuarinaceae (she-oaks):
Allocasuarina Casuarina Gymnostoma Coriariaceae: Coriaria Datiscaceae: Datisca Elaeagnaceae (oleaster):
Elaeagnus (silverberry) Hippophae (sea-buckthorn) Shepherdia (buffaloberries) Myricaceae:
Morella arborea Myrica Comptonia Rhamnaceae (buckthorn):
Ceanothus Colletia Discaria Kentrothamnus Retanilla Trevoa Rosaceae (rose):
Cercocarpus (mountain mahogany) Chamaebatia (mountain misery) Purshia (bitterbrush or cliff-rose) Dryas (Taken from Wikipedia) There are also several nitrogen-fixing symbiotic associations that involve cyanobacteria (such as Nostoc). These include some lichens such as Lobaria and Peltiqera:
.cndot. Mosquito fern (Azolla species) .cndot. Cycads .cndot. Gunnera Microorganisms that fix nitrogen .cndot. Diazotrophs .cndot. Cyanobacteria .cndot. Azotobacteraceae .cndot. Rhizobia .cndot. Frankia We could also develop microbes (and/or any and all enzymes) to combat bad breath, microbes for fermentation (gasses and/or sugars/carbohydrates/cellulose to ethanol and/or compost...any/and all waste organic (eg sewage; manure) and any and all -mixed with temperature (mirrors cheaper and plasma torch augmentation - eg. if ore heat is needed and/or days that are not sunny) and heat for oil/tar sands - to eliminate difficult to process waste, seriously unwanted and of little recycling value we could plasma torch it (with Gerard Voon's TALL GARVITY TO ELECTRICITY INVENTION V - generating the energy to power the plasma torch).
Microbial growth requires cell signalling when there is a quorum (to grow large colonies of microbes one needs to start with a grouping of the microbes), and biofilms that appear at the same time are an indiicator if not a cause if not and an affect. In humans, in the case of infections, bio films can block the immune cells from reacing the perpertrating microbes.
Perhaps by adding Dermatix or other scar removing substances, the patient could have their biofilm removed, and then stem cells and localized differentiated cells (probably from the stem cell stock) can be injected possibly with chitosan, to repopulate the and clean up the infection site.
We could use genetic circuits on any and all genes of any and all creatures.
There are four main chemicals; A for adenine; C for cytosine; G guanine; T thymine.
We could use DNA synthesizers.
Using mixed chemicals (solvents) that form molecules ... that create short strings to short strings to longer chains, and joined into doubel stranded DNA and copied.
In addition we could use furanone from a long-leaf sea weed to prevent the microbes from building biofilm. This substance can be used for out breaks of antibiotic resistant infections, including digestive and any and all illnesses or unwanted presence of biofilms, for human and any and all creatures, applications, mix with stem cells, localized differentiated cells, chitosan Even cancer, possibly inflamatory over active immune systems...(or under active immune systems).
Nitrogen Fixation by Cyanobacteria Cyanobacteria inhabit nearly all illuminated environments on Earth and play key roles in the carbon and nitrogen cycle of the biosphere. Generally, cyanobacteria are able to utilize a variety of inorganic and organic sources of combined nitrogen, like nitrate, nitrite, ammonium, urea or some amino acids. Several cyanobacterial strains are also capable of diazotrophic growth. Genome sequencing has provided a large amount of information on the genetic basis of nitrogen metabolism and its control in different cyanobacteria.
Comparative genomics, together with functional studies, has led to a significant advance in this field over the past years. 2-oxoglutarate has turned out to be the central signalling molecule reflecting the carbon/nitrogen balance of cyanobacteria. Central players of nitrogen control are the global transcriptional factor NtcA, which controls the expression of many genes involved in nitrogen metabolism, as well as the P II signalling protein, which fine-tunes cellular activities in response to changing C/N conditions. These two proteins are sensors of the cellular 2-oxoglutarate level and have been conserved in all cyanobacteria. In contrast, the adaptation to nitrogen starvation involves heterogeneous responses in different strains Nitrogen fixations can be used to extract nitrogen from sewage/manure/any and all organic wastes to have a purer/ cleaner fertilizer, that can as a final step be mixed with chitosan to eliminate microbes. We could synthesize the genes (and/or clone the entire microbe) responsibly for most effective nitrogen fixing as well ethanol from cellulose as well a s bio crops... We could also use the gene synthesis technique, to create new life of any and all forms, differentiate stem cell pools into required specialized cells. And/or reprogram old cells to revert to precursor and/or stem cells (eg. HOX, Homeodomain cells) perhaps replenish the telomerase. We could examine the tole of telomerase with and without endings to see if the reason a stem cells stops proliferating is directly caused by telomerase shortening or if its shortening with age is only another age related coincidence.
For Inflamatory diseases (antagonists) formyl peptide receptor like 1 receptor (FPRL
1),whereby CCR1 ligand and CKB8-1 recruits monocytes and neutrophils and FRPL1 attracts monocytes, dendritic cells, and resting lymphocytes. Mix the CCR1 and FRPL1 and CKB8-1 to recruit/attract immune cells to the infected sites.
One application is to take a large population of stem cells and differentiate them (or tissue culture) them into White cells, T-cells, macrophages, phagocytosis, (possibly) B-cells, cytotoxic, and remove the contents from these cells and refill them with (electro shock, laser fuse and/or micro syringe) material that would be toxic fluid and/or salts and/or chitosan that enter the virus AIDS/HIV virus until the virus bursts...
The AIDS/HIV has proteins, sugar-contains theglycoprotein gp 120 on its envelope, "recognizes" a protein on helper T-cells, macrophages, phagocytosis, (possibly) B-cells, cytotoxic named CD4, and physically associates with it. The CD4 [Cluster of Differentiation Antigen No. 4] protein is a normal part of a helper (both Th1 and Th2) T-cell's membrane.
Thus, CD4 is a specific receptor for HIV.
Besides AIDS, formyl peptide receptor like 1 receptor (FPRL 1),whereby CCR1 ligand and CKB8-1 recruits can be used with stem cell line grown immune cells (of variety and amount most effective for the procedure) and micro inject into any and all bacteria/virus infected regions of the body (to recruit/atract immune cells to), as well we could put chitosan into the mix to help kill microbes). We need to study the genes that activate and deactivate inflammation to treat diseases that are inflammatory related.
Diseases that can be treated include, but are not limited to, peripheral -chronic inflammation-related diseases, for example: chronic inflammation; thrombosis;
atherosclerosis; restenosis;
chronic venous insufficiency; recurrent bacterial infections; sepsis;
cutaneous infections;
renal disease; glomerulonephritis; fibrotic lung disease; allergic disease;
IBS; rheumatorid arthritis and acute bronchiolitis. Central nervous system-macroglia and microglia related diseases, for example: neurodegenerative diseases; Alzheimer's disease;
Multiple sclerosis;
Parkinson's disease; neuroinflammation; HIV-associated neurological diseases;
HIV-associated dementia; CNS bacterial infections; brain Toxoplasma gondii; Acanthamoeba infections; Listeria infections; prion diseases; subacute spongiform encephalopathies and macular degeneration may also be treated.
We plan to test the chemokine receptors eg. CCR1, CCR2, CCR5, CCR8, CXR2 and CXCR4 as well as cytokines to act as targeting mechanisms for immune cells.
We plan to try either or both Dermatix or scar removing products or furanone to try to remove the plaque/fiber tangles from Alzheimer's patients, then repopolate the area with 1. stem cells, 2. neutrophins, 3. localized differentiated cell types, 4. stimulus pulsating electrode, all these techniques are also applicable for Mad Cow Disease, Parkinsons Disease -acetylcholine, norepinephrine, serotonin, soma-tostatin as well as melatonin, these treatments can also be used for patients with spinal cord illnesses treating their neurons and dendrites.
Gene therapies can be transfection, viral infection, microinjection, or fusion of vesciles.
Proteins including anti-inflammatory (to treat inflamatory related illinesses) ctyokines, growth factors/antioxidants protect neurons when present in the extracellular space (the presence of a screctory signal sequence) the protein protects when inside a neuron - eg.
protein is an antioxidant that localizes to an intracellular organelle. Neuron uptakes of these proteins are known as protein tranduction domain. Further conversion of stem cell into neurons include...nerve growth factor (NGF), glial-derived neutrophic factor (GDNF), hepatocyte growth factor (HGF), brain-derived neutrotrophic factor (BDNF), ciliary neutrotrophic factor (CNTF), fibrobalst growth factor 2 (FGF-2), neutrophin 3 (NT 3) and transforming growth factor B (TGF-B). We are using these factors to enhance proliferation and cloning (including stem cells).
We plan to use binding proteins calbindin D28K, to proliferate any and/all of our cell cultures (especially stem cells and cloning) and all treatments from excitotoxins, pro-oxidants, serum withdrawl, also from B-amyloid, excitotoxins, hypogiycaemia, cynaide, as well as helping metabolism, ATP concentrations and mitochondrial potential.
The inhibitor of apoptosis proteins (IAPs) are a family of antiapoptotic proteins that bind and inhibit caspases 3, 7, and/or 9. We plan to use IAP's to proliferate any and all cells including stem cells, differentiated cells of any kind, including immune cells for fighting diseases, brain damage...The IAP proteins contain a BIR (baculovirus IAP repeat) a domain next to the amino-terminus. The BIR domain can bind some caspases. A large proportion of the IAP
family of proteins block proteolytic activation of caspase-3 and -7. XIAP, cIAP-1 and cIAP-2 appear to block cytochrome c-induced activation of caspase-9, thereby preventing initiation of the caspase cascade. IAP-1 and cIAP-2 were first identified as components in the cytosolic death domain-induced complex associated with the TNF family of receptors, they may inhibit apoptosis by additional mechanisms. We plan to use these mechanisms to proliferate cells (especially stem cells and cloning).
Other antiatpotopic, via cdk inhibitor include flavonoid derative that inhibits cdk 1, 2 and 4.
Olomoucine and roscovitine which are purine derivatives that inhibit cdk1, 2 and 5 and also early response kinase 1 and/or MAP kinase activities. These substances are effective in saving and perhaps increasing proliferation (eg. stem cells or at least CGN
and cloning) of trophic factor deprivation and DNA damage. Particularly induced by KCL
withdrawl.
FLIP/FLAME is highly homologous to caspase-8. It does not, however, contain the active site required for proteolytic activity. FLIP appears to compete with caspase-8 for binding to the cytosolic receptor complex, thereby preventing the activation of the caspase cascade in response to members of the TNF family of ligands. The exact in vivo influence of the IAP
family of proteins on apoptosis. Using this mechanism we plan to augment proliferation of cells (especially stem cells and cloning).
The IE1 and IE2 proteins each inhibit the induction of apoptosis by tumor necrosis factor alpha or by the E1B 19-kDa-protein-deficient adenovirus but not by irradiation with UV light.
We plan to use IE1 and IE2 proteins to proliferate any and all cells including stem cells and cloning, differentiated cells of any kind, including immune cells for fighting diseases, brain damage...
The 14-3-3 protein is also associated to proliferate cells, eg. stem cells and cloning, differentiated cells, immune cells, bone, neurons...
We are also using Heat Shock Protein 27 and 72 and 70 and 54 to make cells (eg. stem cells and cloning) proliferate.
We are also using BAG-4, BAG proteins, EBV-EBER, Imp-1, ki-67, bcl-2, survivin, Bax, fas, c-myc, and p53 to make cells (eg. stem cells and cloning) proliferate.
In mammal cells, survivin colocalizes with the mitotic apparatus including B
tubulin, microtubules, centrosomes, and kinetochores. Inhibition of survivin with anti-survivin antibody results in delayed metaphase and produces mitotic cells with shorter and less dense mitotic spindles to be used for cell culture (stem cells and cloning).
For females we might try to obtain more eggs from females by managing the c-jun protein, c-fos protein, estrogen receptors alpha and beta (ER-.alpha. and ER-.beta.), progesterone receptor (PR), and Ki-67for their roles in proliferation (including stem cells and cloning)and apoptosis of glandular epithelial cells.
We are also using III collagen (eg. coated dishes), together with ascorbic cid and ascorbic 2-phosphate and long effecting vitamin C derivative and also epidermal growth factor (to further proliferate cells culture (especially stem cells and cloning).
We are also using Polycomb Group gene complexes (PcG) to proliferate cell culture (eg.
stem cells and cloning), once we want to use the stem cells and cloning for patient treatment (eg. body parts), we can silence the PcG by using multiprotein complex PRC1, PRC2 and PhoRC...
We are studying using amino acids and glucose and water...
We also plan to develop microbes (eg. pre/pro-biotics) that act on the mouth breath and flatulence to remove the bad odours (perhaps mixed with zeolite - eg. powdered and/or pre-mixed with liquids).
Amino acid classes Class Amino acids hydrophobic Norleucine, Met, Ala, Val, Leu, Ile neutral hydrophilic Cys, Ser, Thr acidic Asp, Glu basic Asn, Gln, His, Lys, Arg disrupt chain conformation Gly, Pro aromatic Trp, Tyr, Phe The variant polypeptides can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis (Carter, 1986; Zoller and Smith, 1987), cassette mutagenesis, restriction selection mutagenesis (Wells et al. , 1985) or other known techniques can be performed on the cloned DNA to produce the SHAAGtide variant DNA (Ausubel et al. , 1987; Sambrook, 1989).
STEM CELL PROLIFERATION (as an aside we could put high levels of zinc into the stem cell nutrient solution/tissue culture/medium to increase appetite and faster growth as well Vitamin E is known for keeping seniors healthier and may help to keep stem cells or microbe cells to further proliferate...).
I) We plan to batch cells at different stages of stem cell development by using protein kinase enzymes to catalyze phosphate group from ATP to a target protein to activate or deactivate specific proteins.
We plan to pulse regulatory proteins called cyclins to dependent kinases to work in rhythm with MPF (maturation promoting factor) that will recycle the sequence of events during cell cycle.
As well stem cells that are full enough of cytoplasm to reach the threshold volume to genome ration, is also being tested.
We plan to use Bio Flip Chip (BFC), a microfabricated polymer chip containing thousands of microwells (for example if we centrifuge the microbes found in a termite's gut and put into well foring colonies and tissue culture then when there are multiple identical cells (stem cells) we simply screen the DNA of from a single cell from the colony the seed cell would possess (selected after verified testing) the phenotypes that are the most productive/efficient cost and difficulty and hardiness to produce butanol and survive the toxins), and with gelatin, a 3-D
substrate, and even another layer of cells.
We are testing the effects of SHP2-mediated activation of the MAP kinase cascade in regards to proliferation of stem cells.
II) We could take a somatic DNA from a female (and/or female) and micro inject, electro fuse, and/or laser fuse/heat shock into any female's egg that has had its DNA
removed or a fertilized egg that has had its DNA removed. The idea is that the cytoplasm has reached its threshold volume to genome ration, (eg. one theory is that there is enough key organelles -that can't be easily duplicated that exists in duplicate in the parent cell;
to migrate to each polar end of the division).
III) We could protoplast fuse adult somatic cells (from where there are large collections like the skin and the gut) with stem cells that have stopped proliferating or replace micro inject adult DNA into stem that have stopped proliferating and have had their DNA
removed, and electrofuse/laserfuse/heat shock, the cytoplasm to fuse to the new DNA, perhaps the adult DNA is longer, thinner than the stem cells' own DNA which have been continuing to divide for some time (and therefore having inadequate inputs (in the necessary conditions eg. DNA
length and width) to provide for the process to naturally and properly complete into further stem cell proliferation via chromatid duplication... We might also try micro injection removal of cytoplasm from an egg (fertilized and/or fertilized), suck up the top pole and lower poles' cytoplasm separately and micro injection remove either and adult cell (somatic) and/or stem cells that have stopped proliferating - most of its cytoplasm, leaving the DNA
intact then reinjecting the cytoplasm from the egg into the top and the lower pole of the cells that are no longer proliferating until the cytoplasm has reached its threshold volume to genome ration.
Another option is to take stem cells that have stopped proliferating and inject trying both top and bottom cytoplasm injection (where the cytoplasm comes form any source -though we think the most reproductive cytoplasm come form the egg), to replenish the cytoplasm material in the proper distribution, so that the two new cells both contain the main organelles structures distributed evenly between the two, while micro injecting cytoplasm allows the cytoplasm to reach it volume to genome ratio.
We could microinject/electro fuse/laser fuse/heat shock human DNA into pigs and fast dividing bacteria and/or lamas emus. Or better yet First we tackle the ability of microbes (yeast) (especially the strong performing - measured by the durability of the cellulose) to breakdown (eg. cow's gut, that breaks down straw);
found in termites' and/or cow's and/or lamb's and/or goats' and any and all digestive systems that are good at breaking down cellulose guts.
Second, we mix these corn (biocrops) and possibly supplements of vitamins and necessary nutrients not found in the bio crops that are important to the health and productivity as well as oxycyte or other artificial blood to deliver oxygen, nutrients and remove carbon dioxide and regulating PH and also regulating temperature - possibly by cycles of the microbes to produce butanol. We take the microbes that survive the butanol toxins (given this proven track record - the secret is to isolate and breed microbes that 1. survive butanol toxins and 2.
are the most productive in turning bio crops into biofuel; both in time (how fast), and ration of inputs (costliness) to outputs. We can tissue culture the optimal microbes and/or inject their DNA into other microbes that are plentiful and prolific or non proven but easily available (removing the host cells' DNA in the case that these optimal microbes stop proliferating and then adding the proven DNA into unproven or more prolific or more plentiful host cells that have had their DNA removed). And/or we could protoplast fuse the cells with the best phenotypes (prolific, hardy - not requiring constant/difficult care including survival in butanol toxins, productive, efficient. Furthermore using the stem cells (tissue culture) stock of termite and/or cow gut microbes (are proven) to survive the butanol toxins, and are effective (productive) and hardy, we could identify the types of microbes and study their genes in comparison to the less successful genes to identify the type the genes that make the good microbes versus the unwanted microbes. As well the microbes that are more effective and productive, could be used to produce their enzymes, whether organically stimulated and/or harvested for their molecular make-up and artificial synthesis.
One option is to gather a good number of microbes from the termites' and/or cows' gut, then centrifuge the microbes, tissue culture and/or each cell into colonies (and/or stem cells if necessary; if can serve an advantageous purpose) then use a assembly line (eg.
electron) microscopic viewer (perhaps with thermal sensor - if we need to see inside the makeup of the cells, the content, organelles, shape, sizes to identify them) and Artificial Intelligence or computer that can pick out and identify differentiating microbe cells by running the tests below... 1) common reactions, 2) antibody tests, 3) DNA, PCR probes and primers.
A Brookhaven team has developed just such a technique, which they call "single point genome signature tagging." Using enzymes that recognize specific sequences in the genetic code, they chop the microbial genomes into small segments that contain identifier genes common to all microbial species, plus enough unique genetic information to tell the microbes apart.
In one example, the scientists cut and splice pieces of DNA to produce "tags"
that contain 16 "letters" of genetic code somewhat "upstream" from the beginning of the gene that codes for a piece of the ribosome - the highly conserved "single point" reference gene.
By sequencing these tags and comparing the sequenced code with databases of known bacterial genomes, the Brookhaven team determined that this specific 16-letter region contains enough unique genetic information to successfully identify all community members down to the genus level, and most to the species level as well.
"Sequencing is expensive, so the shorter the section you can sequence and still get useful information, the better," van der Lelie said. "In fact, because these tags are so short, we 'glue' 10 to 30 of them together to sequence all at one time, making this a highly efficient, cost-effective technique."
For tag sequences that can't be matched to an already sequenced bacterial genome (of which there are only a couple hundred), the scientists can use the tag as a primer to sequence the entire attached ribosomal gene. This gene is about 1400 genetic-code-letters long, so this is a more time-consuming and expensive task. But since ribosomal genes have been sequenced and cataloged from more than 100,000 bacterial species, this "ribotyping"
technique makes use of a vast database for comparison.
Then test out the (strengths) effectiveness of each type of microbe and the specific enzymes that each microbe produces, and to artificially synthesize (duplicate) the enzyme in the laboratory - eg. by its molecular makeup and the catalyst conditions of the amino acids and their areas of linkages - maybe eventually synthesizing enzumes that are even more productive and hardier).
Another possibility is to take ant microbes from the termites' stomachs and try injecting their DNA into either cow's microbes found in their stomach and/or grow the ants microbes directly in the cow's stomach, (where removal of other microbes in the cow's stomach might be warranted to reduce competition for proliferation) and/or create a synthetic cow's stomach and/or grow under tissue culture (eg. fibroblasts... ). We could create artificial elements of the termite or and/or cows' stomachs, including pressure, PH, temperature...to breed the microbes Known micro-organisms such as bacteria, protozoa, and fungi enzyme feed supplements containing fungal cellulase produced by Trichoderma viride cellulase enzyme.
Using the same single point genome signature tagging technique, we could apply it to stem cells, we compare the genome of stem cells using enzymes that recognizes specific sequences in genetic code, then chop the stem cells' genes into small segments that contain identifier genes common to all close species (or of single individual to single type of stem cell to single stem cell) of the stem cells in question and compare stem cells' genes at their most proliferative and when they are no longer proliferative (but not yet specialized), and we chop off the genes that are common (eg. both activated and/or both deactivated) to both the two types of stem cells and focus on the genes that are active in one and inactive in the other.
We could also these techniques for any and all health solutions by 1) ruling out all segments of (genetic related) diseases (bacteria and/or viruses) and/or desired phenotype genetic traits (eg. tall height, intelligence...), by by using enzymes that recognize specific sequences of genetic code, then chop the genes into small segments that contain identifier genes common to all close species (or a single individual to another individual or even the same individual where one cell has cancer and the other does not) we chop off the genes that are common to both then we focus on the genes that are active in one and the same gene is inactive in the other Using enzymes that recognize specific sequences in the genetic code, they chop the microbial genomes into small segments that contain identifier genes common to all microbial species, plus enough unique genetic information to tell the microbes apart.
We could micro inject human DNA into pigs fertilized and/or unfertilized eggs (of which the host has had its DNA removed).
Tissue Culture Medium should include:
20 amino acids include Essential. Aarginine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine.
Non-Essential Alanine, Aspartic Acid, Citruiline, Cystine, Glutamic Acid, Glycine, Proline, Hydroxyproline, Serine, Tyrosine Vitamins A (vision, bone growth, epithelial growth), D (bone growth), E
(membrane structure, antioxidant, immune functions), K (blood clotting), B1 (carbohydrate and fat metabolism), B2 (energy metabolism and normal growth), Niacin (co-enzyme for energy metabolism) Major needed minerals are - Ca, P, Na, K, Mg, S, Cl (electrolytes and metabolism) Minor minerals - B, Co, Cr, F, Fe, Mn, SE, Si. . (co-enzymes and building blocks of proteins) We are also protoplast fusing corn to jatropha, to produce the phenotype of drought (low water consumption) resistant crop whose mass (eg corn may be more productive, eg input to levels of outputs) and also the husk and cellulose because of the jatropha may be more easily fermented We will also try protoplast and/or/also micro injection DNA
into DNA ovum cells that we tissue culture removed cells between the two plants above algae, coconuts, sugar cane, and palm oil We are looking at cloning corn and bio fuel plants involving callus, auxin, and cytokinin We are looking at cloning implanting coffee DNA (from the animals that eat selected coffee bean - connoisseurs) into vanilla or other aromatic and flavourful seeds (that are safe for human consumption) Included are Colchicum seed, Thistle seed, Cumin seed, Anis seed, Coriander seed, Poppy seed, Pepper seed, Thyme seed, Species Coffea arabica -Arabica Coffee Coffea benghalensis -Bengal coffee Coffea canephora - Robusta coffee Coffea congensis - Congo coffee Coffea dewevrei -Excelsa coffee Coffea excelsa -Liberian coffee Coffea gallienii Coffea bonnieri Coffea mogeneti Coffea liberica -Liberian coffee Coffea stenophylla -Sierra Leonian coffee Types of beans .cndot. Vicia ~ Faba or broad bean Vica faba or broad beans, known in the US as fava beans .cndot. Vigna ~ Aconitifolia or Moth bean ~ Angularis or azuki bean ~ mungo or urad bean ~ radiata or mung bean ~ umbellatta or rice bean ~ unguiculata or cowpea (includes the black-eyed pea, yardlong bean and others) .cndot. Cicer ~ arietinum or chickpea .cndot. Pisum ~ sativum or pea .cndot. Lathyrus .cndot. Lathyrus sativus (Indian pea) .cndot. Lathyrus tuberosus (Tuberous pea) .cndot. Lens ~ culinaris or lentil Lentils .cndot. Lablab ~ purpureus or hyacinth bean ~ Phaseolus ~ acutifolius or tepary bean ~ coccineus or runner bean ~ lunatus or lima bean ~ vulgaris or common bean (includes the pinto bean, kidney bean and many others) .cndot. Glycine ~ max or soybean .cndot. Psophocarpus ~ tetragonolobus or winged bean Psophocarpus tetragonolobus (winged bean) .cndot. Cajanus ~ cajan or pigeon pea .cndot. Stizolobium ~ spp or velvet bean .cndot. Cyamopsis ~ tetragonoloba or guar .cndot. Canavalia ~ ensiformis or jack bean ~ gladiata or sword bean .cndot. Macrotyloma ~ M. uniflorum or horse gram .cndot. Lupinus or Lupin ~ L. mutabilis or tarwi .cndot. Ervthrina ~ E. herbacea or Coral bean We could use different sound vibrations to stimulate responses for any and all living organisms. The sound can be pulsed in micro and macro rthyhm/cyclical.
For example in the case of stem cell proliferation, if we could 1) record the vibrations made by the cells at their most proliferative - and healthy (eg. blastocyst) stage the replay when their proliferation has stopped, 2) trial and/or error of various sounds (eg.
woofer), genre of music, chanting.
Also the sound could be recorded from the human body (or neural; mind sound;
electrode receptors) when they overcome disease, and then replayed for patients who might benefit from these bodily vibrations and/or trial and error of various sound, genre of music, chanting;
these includes all disease such as cancer or even plaque on the teeth (less effective at corroding teeth and gums), if we could aim the sound at the area of infection, and disrupt the regulation of its processes (eg. proliferation and/or metabolism...), inhibit spreading and inhibiting serious harm (additionally to treat cancer we could inject enzymes into a retro virus that interacts with the cancer cells and wreaks havoc with the cancer cells within its cell membrane) We could record a colonies' sounds for desirable microbes (could some microbes be complementary in nature, requiring the active - eg. cell signalling, products of one microbe to make another microbe more effective) when they were healthy - without the stress of the butonal toxin.
Additionally, we could record the sound made either a fetus (growing limbs from the blastema and/or stem cells) and/or a salamanders' sound when regenerating its limb and/or trial and error of sounds to help amputees to grow new limbs (see below).
Perhaps humans could regrow limbs and organs by growing using a blastema (stem cells) with the Human HOX genes and pressure that is found in that area of the body as well as cell signalling, with new doses of stem cells to be added as the stem cells migrate and form the different stages of embryonic development of the limb and/or organ.
The other option is to inject the stem cells together with activated HOX genes regularly (perhaps by Intra Venous drip GP; GV) and in time before scarring even use topical and/or abrasive dermal removal of scar tissue, even shave of the overgrown tissue in preparation for the mixture of stem cells with activated HOX gene to create a human blastema as well as cell signalling. The stem cells with activated HOX genes can be added directly to the (eg.
removed area - limb) as the progress of migration and distal tip, stage by stage embryogenesis converts and/or causes the stem cells to produce the limb/organs that is just in time method, so there is no excess or not enough stem cells with the activated HOX genes to cause unwanted growth or in the case of not enough administration scar tissue may form or the regeneration may be instructed to stop due to lack of stem cells with activated HOX
genes by whatever the body's recognition is, ...and also where the best place to administer the concoction, and amounts...
Furthermore through any and/or all gene therapies we could activate the HOX
genes in stem cells to further proliferate them.
Humans generally contain homeobox genes in four clusters:
There is also a "distal-less homeobox" family: DLX1, DLX2, DLX3, DLX4, DLX, and DLX6.
"HESX homeobox 1" is also known as HESX1.
Short stature homeobox gene is also known as SHOX.
Tissue culture stem cells in direct contact with BMEC monolayers, or physically separated by microporous membrane. In unstimulated condition BMEC monolayers constitutively produce interleukin-6, Kit- ligand, granulocyte colony-stimulating factor, and granulocyte macrophage colony-stimulating factor.
Microbes from a pig's stomach and/or a vulture's stomach (that can survive, thrive even in such a rotten toxic environment) for their enzymes to process organic, restaurant waste, rotten organic garbage, offal, (especially manures and sewage) and compost as well. Some areas to start with include; Actinomyces bovis, Lactobacillus cellobiosus, Micrococcus luteus, Neisseria sicca, Clostridium bifermentans, Enterobacter agglomerans, Peptostreptococcus sp., Sarcina sp., Serratia odorifera, and Shigella flexneri Lactobacillus acidophilus, Streptococcus faecium, and Saccharomyces cerevisiae. We could also test these microbes with cellulose and producing butonal or any and all biofuels. We could also test the effectiveness of termite and cow gut microbes in processing organic wastes (eg. eg. sewage and manures). We could combine the rotten toxic waste microbes of vultures and swine with the cellulose enzyme break down of cows and termite microbes and apply to both manure and cellulose digestion. We could protoplast fuse such as Bio Flip Chip (BFC), a microfabricated polymer chip containing thousands of microwells that align together two types of microbes (selected based on ideal phenotype criteria, such as vulture's gut microbes hardiness to toxins and termite's voracious ability to break down even wood).
We are testing the use of .beta.-glucanase and pentosanases mixed to degrade the .beta.-glucans and pentosans (complex carbohydrates that interfere with digestibility of other nutrients), in grains (especially corn)...
We are testing phytase for it's enzyme that cleaves the ortho-phosphate groups from phytic acid (phytate), the major source of phosphorus in cereal grains and oilseed meals (and/or all bio fuel crops, eg. corn, and/or organic wastes..including wood waste).
probiotics,"
Some enzymes we will test specifically in the molecular design of cellulases, hemicellulases, and proteases of a form (related and/or mutated) that come from microbes that are the best performing (see the criteria above).
We will also lower the PH. . I believe to be conducive for good microbes to flourish.
Citric acid, fumaric acid, or formic acid are used in digestion; probably by helping the good bacteria thrive.
Inorganic acids, such as phosphoric acid and, in some instances, hydrochloric acid, also have been found to help digestion.
We are experimenting SCFAs with saccharolytic fermentation which involves acetic acid, propionic acid, and butyric acid. Gases as well as organic acids like lactic acid are also produced by saccahrolytic fermentation. Acetic acid is used by muscle, propionic acid helps the liver produce ATP, and butyric acid provides energy to gut cells and may prevent cancer (University of Glasgow. 2005, Gibson RG. 2004, Beaugerie L and Petit JC.
2004).
We are already tissuing culturing cells (microbes) in:
We then set up the medium we are considering several alternatives or combination (even all together).
(Passaging of cells are used to further proliferate stem cells) Accutase (Innovative Cell Technologies Inc., distributed by PAA) and triturated approximately 10 times using a pipette.
Then, the cell suspension was incubated. Dissociated cells were centrifuged at 120 rcf and resuspended. An aliquot was counted by trypan blue exclusion assay in a hemocytometer to determine the amount of viable cells. Cells (105) were plated in T75 culture flasks for long-term passaging (culture medium (coated with fibronectin/lanmine) per flask).
All media contained 1-glutamine, penicillin/streptomycin, heparin (Sigma), bFGF (R&D
Systems), and EGF (R&D Systems). A total of 104 cells per well were seeded in 12-well plates in a volume of 1 ml and grown under standard conditions. After a few days the grown stem cells were counted and dissociated by Accutase, and viable cells were counted by trypan blue exclusion assay in a hemocytometer.
One of the problem we foresee, after identyfing then producing the microbes enzymes easily, in large amounts and cheaply is that corn husks and leaves is fiberous so it is harder to digest, stretching the time needed to digest, these microbes may go hungry and start to starve if they aren't getting enough nutrients over the time it takes to digest the fiberous cellulose - if this is the case we may have to mix in carbohydrates and other nutrients found in the cell culture medium above.
Treatment Options - Treatment Information During treatment for intestinal yeast and/or bacterial overgrowth it is essential that probiotic bacteria are consumed concurrently to restore the proper balance of organisms in the gut.
When you undergo anti-fungal and/or anti-bacterial therapy when the pathogenic organisms are killed off space within the intestines and along the intestinal wall becomes available for colonization by other organisms. Taking probiotic supplements enhances the chances of these new colonies being made up of beneficial bacteria rather than more pathogenic types Also of importance to sufferers of environmental illnesses is the fact that recent research has shown that the gut flora is directly linked to the development of allergies to both food and airborne allergens and that improving gut flora could potentially reduce the number and severity of allergies1,2.
At first the range of probiotic products on the market will likely seem overwhelming and you won't know whether you are getting a good product or not until you learn a little bit more about the subject. The information below will explain a bit about probiotic bacteria, otherwise known as'beneficial bacteria' or 'friendly bacteria', and provide some basic pointers on what to look for in a probiotic product.
Types of Probiotic Bacteria The most numerous arobiotic bacteria normally inhabiting the small intestine are species of Lactobacilli. In the colon the majority are mainly Bifidobacteria. Most probiotic products consist of one or more species of bacteria from one or both of these types.
Some products available mainly in europe may also contain certain beneficial species of E.coli but these are rare at this time.
Let's take a look at some of the most well researched probiotic bacteria and those found most commonly in probiotic supplements.
Lactobacillus Acidophilus By far the most well known species of probiotic bacteria is Lactobacillus acidophilus which has led many people to refer to probiotics simply as "acidophilus". This status is not without reason as the acidophilus species is the most prevalent in the human intestine and has been the most widely studied probiotic bacteria with research starting on L.acidophilus as long ago as 1925. The best researched single strain of acidophilus is probably the DDS-1 strain. This strain amongst other benefits has been shown to stimulate the immune system, (WE COULD USE THIS BACTERIA FOR HIV/AIDS PATIENTS AND OTHER IMMUNE
DEFFIENCY PROBLEMS ANYWHERE WHERE IMMUNE SYSTEM IS COMPROMISED) increasing levels of interleukin-1 alpha (IL-1 alpha) and (WE COULD USE THIS
BACTERIA
KEEP STEM CEALLS FROM DIFFERENTIATING - WHERE ONE POSSIBLE THEORY IS
THAT IF THE STEM CELLS DON'T DIFFERENTIATE THEY WILL CONTINUE TO
PROLIFERATE AND ALSO TO BALANCE OUT THE DANGERS OF STEM CELLS
BECOMING TUMOURS) (WE COULD ALSO USE THIS BACTERIA MULTIPLE NEEDLE
MICRO INJECT AND/OR RETRO VIRUS IT INTO THE TUMOURS) (ANOTHER USE IS
TO TREAT THE DIFFERENTIATED STEM CELL BACTERIA BEFORE THE CELLS
ENTER THE BODY TO COUNTER ANY CANCER TENDENCIES) (FINALLY WE COULD
EITHER MULTIPLE MICRO INJECT AND/OR DELIVER VIA RETRO VIRUS FILLED WITH
THIS BACTERIA AT THE SAME TIME A CHEMOTHERAPY PERHAPS EVEN IN THE
SAME RETROVIRUS SHELL TO THE CANCER AREA) tumour necrosis factor-alpha (TNF-alpha) which suppress cancerous tumour growth3. Other research has shown that L.acidophilus DDS-1 also alleviates lactose intolerance by producing significant amounts of the lactose digesting enzyme lactase, inhibits gastrointestinal pathogens by producing antimicrobial substances such as acidophilin and helps alleviate dermatitis and other skin conditions by altering gut flora amongst other things.
Lactobacillus Rhamnosus Lactobacillus rhamnosus is a probiotic bacteria that has been receiving a growing amount of attention as a treatment for many illnesses in the form of the GG strain.
Lactobacillus rhamnosus GG (LGG) now has a wealth of research backing its use, particularly for infectious and allergic conditions. A 2001 study reviewing information regarding probiotics and infectious diseases found that there is a large amount of data showing that Lactobacillus GG is an effective treatment for diarrhea caused by Clostridium difficile infection4. Another study testing the effectiveness of probiotics in preventing allergic illness found that Lactobacillus GG given prenatally to mothers with at least 1 first-degree relative and postnatally for 6 months to their infants reduced the incidence of atopic eczema by half compared to controls5.
Lactobacillus Bulgaricus (Galactooligosaccharides PREBIOTICS FACILITATES THIS
PROBIOTIC) This organism is slightly different to most probiotic bacteria in that it is a 'transient bacteria'.
It is referred to in this way because unlike most probiotic bacteria it doesn't adhere to the intestinal wall and form colonies, rather it simply passes through the digestive system and leaves the body in the stool. It has many beneficial effects as it passes through the digestive tract, however. These include enhancing the digestibility of milk products and other proteins and producing natural antibiotic substances that specifically target pathogenic bacteria whilst sparing friendly species. In this sense L.bulgaricus can be thought of as a helper to colonizing bacteria just as the immune system has T helper cells to support other immune cells. A study published in the World Journal of Gastroenterology showed that L.bulgaricus could suppress inflammatory immune reactions in the intestinal wall thus preventing tissue damage6. In another study a substance produced by (CAN BE USED DEFENSE AGAINST
PATHOGENIC ORGANISMS AND MIXED INTO THE MICROBES USED TO BREAK
DOWN BIOFUEL ORGANIC WASTE (EG. CORN HUSKS) AND SEWAGE AND OTHER
SUCH RELATEED ORGANIC WASTE - HOPEFULLY NOT ATTACKING THE MICROBES
WITH THE MOST WANTED PHENOTYPES, DOING MORE GOOD THAN HARM) L.bulgaricus was shown to stimulate activity in part of the gut immune system called the Peyer's patches which provide defense against pathogenic organisms within the gut7.
Lactobacillus Salivarius L.salivarius has been repeatedly shown to inhibit the bacteria Helicobacter pylori (H.pylori) which is responsible for the creation of peptic ulcers8. H.pylori interferes with stomach acid production and/or produces a toxin that directly contributes to ulcer formation. The usual treatment involves taking antibiotics but H.pylori may become resistant to them and there are side effects of prolonged antibiotic use due to the eradication of beneficial bacteria along with the pathogenic bacteria. It has been discovered that L.salivarius produces large amounts of lactic acid that completely inhibits the growth of H.pylori and reduces the associated inflammatory response. The first bacteriocin (natural antibiotic substance) to be isolated and studied at the genetic level was taken from a strain of L.salivarius9.
Lactobacillus Plantarum This bacteria is the most prevalent species in most naturally fermented foods.
It has the ability to block receptor sites for gram negative bacteria and so is effective as an antibiotic.
It is an important player in (WE COULD USE THIS BACTERIA FOR ANY AND ALL
IMMUNE DEFIENCY PROBLEMS ANYWHERE WHERE THE IMMUNE SYSTEM IS
COMPROMISED) antimicrobial defense and is effective against both extra and intracellular pathogens. L.plantarum is also capable of digesting (WE COULD USE THIS PRODUCT
TO
BREAK DOWN BIO FUEL CROPS WASTE AS WELL AS WOOD WASTES) semi-digestible fibres such as those found in onions, garlic, wheat, oats, rye and yeast. It may therefore help with digestive problems like gas and bloating. Recent research has shown that L.plantarum has the ability to break down bile acids and lower cholesterol10 and is extremely resistant to stress conditions including high temperature and (ESPECIALLY
GOOD FOR BUTANOL PRODUCTION) concentrations of ethanol, extremes of pH and the freeze drying process that would normally kill lactic acid bacteria11.
Lactobacillus Casei This species is commonly found in probiotic dairy foods such as 'live yoghurt', hence the name 'casei' which relates to the milk protein casein. It was reported in Microbiology and Immunology to have the most potent protective activity against the Listeria bacteria. Listeria is potentially lethal with about 30% of victims dying. It is most commonly transmitted through consumption of dairy products and raw vegetables. Like L.salivarius, L.casei, in the form of the shirota strain found in Yakult probiotic yoghurt drinks, has been shown to significantly inhibit the growth of the peptic ulcer causing bacteria H.pylori12. A
probiotic drink containing the shirota strain has also been shown to reduce the severity of constipation as evidenced by both patient response to questionnaires and physical examinations13.
Finally, a study with malnourished mice showed that L.casei (combined with FOS), when given along with a re-nutrition diet, enhanced the immune response and increased resistance to certain pathogenic bacteria in the digestive tract14.
Lactobacillus Sporogenes In a study at the G.B. Pant hospital in New Delhi, India, Lactobacillus sporogenes was able to lower cholesterol levels by 104 points. It produced a highly significant reduction in LDL
cholesterol ('bad cholesterol) levels and a small but significant increase in HDL cholesterol ('good cholesterol'). This study offers the prospect of using L.sporogenes as a side-effect free alternative to drug therapy in the treatment of high cholesterol and heart disease. In a multi-centre double-blind placebo controlled trial, L.sporogenes was found to be nearly twice as effective as placebo in reducing the number of episodes and duration of diarrhea following antibiotic treatment in children15. As well as being used to lower cholesterol, Alternative Medical Review reports that L.sporogenes has been used in the treatment of gut dysbiosis, vaginitis and aphthous stomatitis16.
Bifidobacteria Bifidum (Galactooligosaccharides PREBIOTICS FACILITATES THIS
PROBIOTIC) This bacteria is one of the major constituents of the normal flora in the colon and is the most common Bifidobacteria species found in probiotic products. It is reportedly well tolerated, reduces the (inflammatory response (SEE INFLAMMATORY DISEASES BELOW) in the colon and (COULD BE USED WITH hiv/aids AND OTHER IMMUNE PROBLEMS WHERE
IMMUNE SYSTEM HAS BEEN COMPROMISED) stimulates the body's fluid immunity. A
study carried out at the Women and Children's Hospital of Buffalo, NY showed that B.bifidum can significantly reduce the intestinal concentration of endotoxin, which is made up of the cell walls of (WE COULD USE THIS BACTERIA ON STEM CELLS TO CLEAN
OFF THE THECELL WALLS SO THE STEM CELLS CONTINUE TO PROLIFERATE) (WE
COULD ALSO USE THIS PRODUCT TO CLEAN OFF SCARRING TISSUE) dead bacteria and is toxic if allowed to build up17. In another study B.bifidum of human origin was found to adhere well to the intestinal wall and significantly reduce the ability of pathogenic E.coli to do the same (WE COULD ALSO BE USED ON PATIENTS WHOSE CANCER IS IN
REMISSION TO CLEAN OUT THE REMAINING TOXICITY FROM THE REMAINING
CHEMOTHERAPY)18. Research carried out by the Yakult company who manufacture probiotic drinks showed that their patented strain of B.bifidum had significant (WE COULD
USE THIS PRODUCT IN THE MEDIUM AND/OR MICRO INJECT INTO THE CELL
ESPECIALLY THE NUCLEUS TO TRY TO KEEP STEM CELLS PROLIFERATING) anti-oxidant action and was able to protect the intestinal lining from lipid peroxidation in iron overloaded mice19.
Bifidobacteria Longum (Galactooligosaccharides PREBIOTICS FACILITATES THIS
PROBIOTIC) B.longum is another species of Bifidobacteria commonly found in probiotic products. It is reportedly able to eliminate the (CAN BE USED TO CLEAN OUT NITRATES FROM THE
WATER TABLE NEAR FARMS) nitrates commonly found in foods ingested by humans.
Levels of nitrate commonly ingested by humans are unable to kill this species.
B.longum has been shown to inhibit the action of vero cytotoxin produced by some strains of E.coli which can cause hemorrhagic colitis and hemolytic uremic syndrome in humans.
(WE ARE
LOOKING AT USING THIS BINDING TO TOXIN EFFECT FOR BINDING TO ANY AND
ALL TOXINS, POISONS...USEFUL IN SEWAGE TREATMENT). It achieves this by producing substances that bind to the vero cytotoxins20. B.longum has also been shown to have a protective effect against infection with Salmonella Typhimurium, possibly due to an anti-inflammatory action21 (SEE INFLAMMATORY DISEASES BELOW).
Bifidobacteria Infantis (Galactooligosaccharides PREBIOTICS FACILITATES THIS
PROBIOTIC) B.infantis is known to have an inhibitory action on invasive pathogenic bacteria such as E.coli. Research has shown that it achieves this inhibition through more than one mechanism which explains why it is effective against a range of pathogens.
Inflammatory bowel disease (IBD) is thought to be caused by organisms called bacteroides which are a normal component of the gut flora. B.infantis has the ability to highly reduce the growth of bacteroides and also significantly inhibit the inflammatory response (see inflammatory diseases below) caused by them in the gut lining22. Other research using formulations containing B.infantis has found it to useful for treating irritable bowel syndrome (IBS) and diarrhea. Of all the strains of bacteria in the formulation B.infantis was found be one of the species that had colonized the intestines of patients to the highest degree23.
Streptococcus Thermophilus Like L.casei, this bacteria has been shown to (COULD STEMS STOP IN THEIR
PROLIFERATION BECAUSE THEY HAVE BEGUN TO ATROPHY - IF YES THEN
PERHAPS THIS BACTERIA MAY WORK TO AID FURTHER STEM CELL
PROLIFERATION) aid recovery from malnutrition due to short-term fasting and reduce the associated intestinal atrophy in animal studies24. S.thermophilus is also known to have powerful antioxidant activity, protecting the body from dangerous free radicals which increase in the body due to aging, stress, sugar, antibiotics and other chemicals and toxins It has also been shown to have (WE ALSO THEORIZE THAT PERHAPS THIS
BACTERIA'S ABILITY TO FIGHT CANCER OF WHICH WE ARE CLAIMING ITS USE FOR
ALL CANCERS, ADDITIONALLY WE WILL TRY TO USE THIS BACTERIA TO CAUSE
CELLS FROM DIFFERENTIATING INTO CANCER CELLS USING THIS MECHANISM TO
PREVENT STEM CELLS FROM DIFFERENTIATING LEAVING PLURIPOTENT AND
FURTHERMORE ABLE TO CONTINUE TO PROLIFERATE) (ANOTHER USE IS TO
TREAT THE DIFFERENTIATED STEM CELL PRODUCT BEFORE THE CELLS ENTER
THE BODY TO COUNTER ANY CANCER TENDENCIES) (FINALLY WE COULD EITHER
MULTIPLE MICRO INJECT AND/OR DELIVER VIA RETRO VIRUS FILLED WITH THIS
BACTERIA AT THE SAME TIME A CHEMOTHERAPY PERHAPS EVEN IN THE SAME
RETROVIRUS SHELL TO THE CANCER AREA) anti-tumour activity which is especially effective against colon cancer cells.
Homeostatic Soil Organisms (HSO's) In recent y ears a different sort of probiotics have become available known as homeostatic soil organisms. These are organisms that live naturally in the soil and used to be ingested regularly by humans before intensive farming methods removed them from the food supply.
Most of the organisms found in HSO supplements are transient bacteria meaning they don't colonize the intestines but pass through, providing a number of benefits to us as they do so.
Some of these benefits include aggressively killing pathogens, producing specific antigens that act to stimulate the immune system, create superoxide dismutase (SOD) a powerful antioxidant enzyme and help the body to metabolize proteins and eliminate toxins. Some of the benefits over traditional probiotic supplements that HSO's are said to have are there superior ability to survive stomach acid, ability to survive in any intestinal pH and their powerful ability to fight off infections in the GI tract. Many doctors and patients have reportedly had very good results using HSO's but as yet there is little good scientific research regarding their use.
Choosing a Probiotic Product Unfortunately choosing a probiotic supplement is not as simple as just picking up the first bottle you find and assuming it will do the job. Some products contain bacteria that are not even known to be normal inhabitants of the human gastrointestinal tract and the bacteria in many have not undergone any testing with regards to their ability to colonize once they reach the intestines. There are a number of factors that will determine the effectiveness of a certain bacteria as a probiotic. Some of these are:
.cndot. Ability to survive the manufacturing process.
.cndot. Ability to survive heat, light, moisture etc during the time from packaging to use.
.cndot. Ability to survive stomach acid .cndot. Ability to attach to the intestinal wall .cndot. Ability to fend off other organisms, survive in the current intestinal environment and successfully colonize.
As you can see, the fragile probiotic bacteria have a lot to deal with if they are to eventually colonize your intestines. It would be naive to assume that every species and strain of Lactobacilli and Bifidobacteria would be equally effective as probiotics. As a result it is best to research a product before you buy. Look out for the species of bacteria covered on this page but if you see a species that isn't covered listed on a supplement bottle then do some research on that bacteria online yourself to make sure it will be effective.
As a rule it is best to look for products that state the specific strains of the bacteria they contain such as L.acidophilus DDS-1 and L.rhamnosus GG, where the DDS-1 and GG respectively are the strains. You can then look for research carried out with that particular strain to assess its effectiveness. The best place online to look for scientific research on probiotic bacteria, or any subject, is the PubMed database which can be found here.
Also of importance is the ability of a products packaging to protect the bacteria from environmental factors such as light, heat, moisture and oxygen. Dark coloured glass bottles protect well from light and heat. Some products use rubber caps under the screw top of the bottle, this offers added protection from oxygen and moisture by providing an airtight seal.
However the best protection is offered by products where each dose is individually packaged in a foil sachet. This avoids the situation with a bottle where all the capsules/tablets are exposed to the environment every time you take the top off. Also of importance is how the product is stored in the store. If a product says it needs to be refrigerated, make sure this is the case in the store.
Following these guidelines should increase your chances of purchasing an effective probiotic supplement.
Prebiotics Where probiotics are the beneficial bacteria found in the intestines 'prebiotics' are special indigestible carbohydrates known as oligosaccharides that feed probiotic bacteria and encourage their growth. Oligosaccharides are found naturally in certain fruit and vegetables, including bananas, asparagus, garlic, wheat, tomatoes, Jerusalem artichoke, onions and chicory. Because of the ability of prebiotics to encourage the growth of beneficial bacteria it is worth considering a supplement when there is a need to improve the gut flora. Prebiotics can be taken on their own or with a probiotic supplement. They have an advantage over probiotic supplements in that there is no concern about oligosaccharides being destroyed while in storage or en route to the intestines through the stomach acid and digestive enzymes.
The most common types of prebiotics available in supplements are fructooligosaccharides (FOS), inulin and galactooligosaccharides. As well as, or perhaps due to, encouraging the growth of beneficial bacteria in the intestines, prebiotics have been shown to have a number of other benefits.
Fructooligosaccharides (FOS) FOS has been shown in one study in mice to increase intestinal Riga, the body's first line of defense against invaders25. In another study using pigs, FOS was shown to increase butyrate concentrations in the large intestine26. Butyrate is a short chain fatty acid (SCFA) that helps to maintain the health of the colon.
Inulin German research has shown that inulin is effective in improving the composition of the gut flora and reducing the severity of colitis symptoms when tested in rats27. In a study assessing the role of common foods in improving intestinal health cheese which contains inulin was found to have a beneficial effect, reducing bacteria and chance of infection 28.
Galactooligosaccharides In animal studies galactooligosaccharides have shown very promising results increasing populations of both lactobacilli and bifidobacteria and increasing beneficial short chain fatty acids29. A mixture of galacto and fructooligosaccharides added to standard infant formulas has has also been shown to increase both lactobacilli and bifidobacteria species in human infants30.
Probiotics and Prebiotics and be applied to:
Bifidobacteria Bifidum (Galactooligosaccharides PREBIOTICS FACILITATES THIS
PROBIOTIC) Bifidobacteria Longum (Galactooligosaccharides PREBIOTICS FACILITATES THIS
PROBIOTIC) Bifidobacteria Infantis (Galactooligosaccharides PREBIOTICS FACILITATES THIS
PROBIOTIC) Diseases where anti inflammatory:
Multiple Sclerosis (MS) Rheumatoid Arthritis (RA) Inflammatory Bowel Disease (IBD) Interstitial Cystitis (IC) Fibromyalgia (FM) Autonomic nervous dysfunction (AND neural-mediated hypotension);
Pyoderma Gangrenosum (PG) Chronic Fatigue (CF) and Chronic Fatigue Syndrome (CFS).
Chronic hepatitis Systemic lupus erythematosus Arthritis Thyroidosis Scleroderma Diabetes mellitus Graves' disease Beschet's disease and Graft versus host disease (graft rejection).
Chronic inflammatory pathologies such as aneurysms Hemorrhoids Sarcoidosis Chronic inflammatory bowel disease Ulcerative colitis Crohn's disease and vascular inflammatory pathologies Disseminated intravascular coagulation Atherosclerosis Kawasaki's pathology Coronary artery disease Hypertension Stroke Asthma Chronic hepatitis Multiple sclerosis Peripheral neuropathy Chronic or recurrent sore throat Laryngitis Tracheobronchitis Chronic vascular headaches (including migraines Cluster headaches and tension headaches) and pneumonia Neurodegenerative diseases including Demyelinating diseasessuch as multiple sclerosis and acute transverse myelitis;
Extrapyramidal and cerebellar disorders such as lesions of the corticospinal system;
Disorders of the basal ganglia or cerebellar disorders;
Hyperkinetic movement disorders such as Huntington's Chorea and senile chorea;
Drug-induced movement disorders such as those induced by drugs which block CNS
dopamine receptors;
Hypokinetic movement disorders such as Parkinson's disease;
Progressive supranucleo palsy;
Cerebellar and Spinocerebellar Disorders such as astructural lesions of the cerebellum;
Spinocerebellar degenerations (spinal ataxia) Friedreich's ataxia Cerebellar cortical degenerations Multiple systems degenerations (MencelDejerine-Thomas Shi-Drager and Machado Joseph)); and systemic disorders (Refsum's disease Abetalipoprotemia, ataxia telangiectasia and mitochondrial multi-system disorder);
Demyelinating core disorders such as:
Multiple sclerosis Acute transverse myelitis;
Disorders of the motor unit such as neurogenic muscular atrophies (anterior horn cell degeneration) such as Amyotrophic lateral sclerosis Infantile spinal muscular atrophy and juvenile spinal muscular atrophy);
Alzheimer's disease;
Down's Syndrome in middle age;
Diffuse Lewy body disease; Senile Dementia of Lewy body type;
Wernicke-Korsakoff syndrome;
Chronic alcoholism;
Creutzfeldt-Jakob disease;
Subacute sclerosing panencephalitis Hallerrorden-Spatz disease; and Dementia pugilistica Malignant pathologies involving tumors or other malignancies such as:
Leukemias (acute chronic myelocytic chronic lymphocytic and/or myelodyspastic syndrome);
Lymphomas (Hodgkin's and non-Hodgkin's lymphomas such as malignant lymphomas (Burkitt's lymphoma or Mycosis fungoides));
Carcinomas (such as colon carcinoma) and metastases thereof;
Cancer-related angiogenesis;
Infantile hemangiomas;
Alcohol-induced hepatitis.
Ocular neovascularization Psoriasis Duodenal ulcers Stem Cells Body Rejection:
Kupffer Cells, are the macrophages found in the sinusoidal lumen, attached to the liver sinusoidal endothelial cells, transplants of the liver have shown donor Kupffer cells migrate to the the recipient lymph nodes recipient derived monocytes also have been known to replace the opposite way. Kupffer cells play a role in regulating T lymphocte (not only proliferation).
Furthermore in the case of liver transplants, I postulate that the stem cells that are and can be the precursor to Kupffer Cells, the Donor's DNA replaces the source stem cells for the Kupffer cells and thus regulation of the body's immune system, which produces the majority lymph in the body.
By destroying Kupffer cells in the Liver with intravenous application of liposomeentrapped dichloromethylene diphosphonate specifically hepatocytes and sinusoidal sites on the liver we observe the production of M-CSF and GM-CSF which regulate the proliferation, differentiation, and maturation of replacement Kupffer cells (and increase neutrophils and monocytes in response to the liposomeentrapped dichloromethylene diphosphonate application) the theory is that hematoietic stem cells proliferate during the process in which the Kupffer cells are depleting. These stem cells being macrophage (lymph cell version in the liver known as - Kupffer Cells) precursors were derived from bone-marrow-derived and intrahepatic proliferating population.
Regarding the increase in neutrophils and momocytes, as part of the outcome of the liposomeentrapped dichloromethylene diphosphonate application also, their proliferation in synchronicity it is believed that the residue of the destroyed macrophages with the application of liposomeentrapped dichloromethylene diphosphonate one theory is that leukocytosis is not performed due to the lack of Kupffer cells during the depletion of Kupffer cells stage of this experiment.
It is believed that the substances resulting from the deaths of the Kupffer cells might have stimulated the bone marrow to release leukocytes and myeloid.
Focal Hematopoiesis is caused by glucan (application) to produce M-CSF and GM-CSF
(together with IL-3), all of which help the number of Kupffer cells reproliferate to the body's replenishedment.
In Conclusion of this immune system phenomenon, the macrophage precursors (Kupffer cells) found after the application of liposomeentrapped dichloromethylene diphosphonate Were comprised not of intrahepatic repopulating cells, but more importantly also bone-marrow derived repopulating cells.
For the sake of immune system rejection inorgan transplant, could we seed either the liver or the bone marrow and/or both, with the organ donor's stem cells and differentiated into precursors of the immune cells (eg. lymphatic system cells...).
One way is to apply liposomeentrapped dichloromethylene diphosphonate to both (or separately to study the results) liver and the bone marrow (perhaps where the bones have the most precursor marrow type and apply at multiple sites possibly using intravenous) and then reseeding at multiple sites with stem cells (carrying the DNA cultured from the donor of the transplant organ) possibly mixed in layered for migration adherence to the liver and bone inner walls.
As substitutes for liposomeentrapped dichloromethylene diphosphonate, we plan to use chemotherapy (GP 45%) or total body irradiation (GP 1%), cyclophosphamide with busulfan.
The novelty in our methods is that in addition to the organ (other than liver, although liver and bone marrow are probably always used together no matter what the transplant) transplant, we can grow a synthetic liver from outside the body, or grow graftable liver tissue that are the precursors, that proliferate into lymphatic cells when the immune system is stimulated.
Theses precursor tissue could be derived from the organ (always including the liver for liver diseases but applicable for other organ transplant) donors' stem sells. At the same time we repopulate the bone marrow's precursor cells to that that it would normally send to the liver to replace/repopulate with stem cells as well as cells that are precursors to immune system cells derived from the donor organ's stem cells. Bone marrow stem cells include hematopoietic stem cells, which can be extracted from the donor's bones and tissue cultured and other proliferation techniques. The secret is that by destroying the lymphatic cell populations in both the liver and the bone marrow, and then replacing (seeding) the pools of areas where the patient's original stem cells once belonged with the donor's of the transplant organ stem cells and/or precursor to the immune system's cells the patient will take on the judgement call of the Donor's DNA, and not reject the new transplanted organ.
FARMING
USING the Tea Manure Processing for sewage in poor countries we could 1) develop the cattle/swine/chicken/bio fuel crops (any and all) farms underground, then suck in the air from the rising breaths and flattulence and Tea Manure processsing plants where the manures are collected and concentrate the methane (the methane is separated from carbon dioxide via DDR zeolite membrane strengthened by porous substrate such as titanium (possibly ceramic - especially if the methan is burnt nearby) and/or carbon nano particles/tubes/fibers possibly mixed with layers of clay, and/or combination of all mixed or in layers and/or additionally we could build TALL GRAVITY TO ELECTRICITY INVENTION surrounding the (Anyand all) farms mixed with solar panels and wind farms above ground and/or underground.
We can also use my mirrors to boiler (to boil urine and therefore concentratithe nitrites in the urine) to energy and fresh water (from salt water and/or urine). We can use probiotics (mcirorganisms - eg. bokashi) and other advantageous microorganisms (probiotics; prebiotics).
See below for proper treatments for Heavy Metal Detox (taken from the Internet).
The most common source of heavy metal toxicity is from dental amalgam fillings and other metal dental appliances. In 1989, the Environmental Protection Agency (EPA) declared that amalgams are a hazardous substance under the Superfund law. Scrap dental amalgam was declared a hazardous waste in 1988 by the EPA. Outside of your mouth it has to be: 1.
Stored in unbreakable, tightly sealed containers away from heat. 2. It is not to be touched. 3. Stored under liquid glycerine or photographic fixer solution. So, once it is taken out of the mouth it is toxic, but when it is placed in the teeth it is labeled "nontoxic." You can't throw it in the trash, bury it in the ground or put it in a landfill, but they say it's okay to put it in people's mouths. It sounds like truth decay! Lead, mercury and cadmium exert most of their toxicity by destroying important proteins, many of which are enzymes, hormones, or cell receptors. Mercury will attach to sulfur amino acid building blocks in proteins. The sulfur amino acids are methionine, cysteine, and taurine. Sulfur is present in all proteins.
Numerous enzymes require intact sulfur groups and many are inactivated by mercury.
Lead binds with the sulfur groups on proteins and inactivates them. Lead suppresses neuron clusters in the brain, hindering brain development in children by stunting the mapping of sensory nerves. One of the primary ways the body gets rid of metal compounds is through a pathway that goes from the liver into the bile where it is then transported to the small intestine and excreted in the feces. Inorganic mercury is complexed with glutathione in the bile, suggesting that glutathione status is a major consideration in the biliary secretion of mercury. This same pathway is affected by a mercury induced reduction of available taurine needed to produce bile acid (taurocholic acid). When the microflora of the intestine has been reduced through stress, poor diet, use of antibiotics and other drugs, fecal content of mercury is greatly reduced. Instead of being excreted in the feces, the mercury gets recirculated back to the liver. The person that is under stress, eating a poor diet, and/or taking antibiotics will tend to maintain a higher body burden of mercury derived from dietary sources--especially if they are eating diets high in fish.
Disposal of the body's burden of mercury is via the urine and feces, although minute amounts are detectable in expired air. Excretion via the liver occurs in bile and reabsorption of some of this mercury does take place. However, the kidney is equipped with an efficient, energy-dependant mechanism for disposing of metals such as mercury. Kidney tissue contains a thiol-rich protein called metallothionein; exposure to toxic metals triggers the production of this protein which binds tightly to the metal, retaining it in the kidney tissue in a relatively harmless form. As long as the kidney's capacity for production of metallothionein is not overwhelmed, mercury excretion can eventually balance intake, thereby limiting worsening of symptoms. However, acute high doses of mercury, or an increase in the chronic dose level can readily precipitate renal failure, one of the classic symptoms of mercury poisoning.
Detoxification systems such as metallothionein, cytochrome P-450, and bile are adversely affected by mercury. Metallothionein binds toxic metals in the body to prepare them for excretion. Mercury ties up this material so it cannot clear out other metals such as lead, cadmium, and aluminum.
Mercury from amalgam binds to -SH (sulfhydryl) groups, which are used in almost every enzymatic process in the body. Mercury therefore has the potential to disturb all metabolic processes.
A small proportion of total body mercury is excreted in various forms directly in the urine without being bound to protein. In low dose, steady state conditions, such as the dentist who has worked at a similar exposure level for years, the urinary output very accurately reflects the total body burden and this is why urine monitoring is so important.
The following is a list of nutrients that facilitate the removal of heavy metals.
Mega H-: The negative hydride ions in Mega H- alter the water consumed with the food and supplements in our diet, to have a lower surface tension and an increased conductivity. A low surface tension in the extra cellular fluids is also important in the removal of toxins from the cells and into lymph and venous blood for removal from the body. Tap water has a surface tension of approximately 73 dynes/cm. The water around our cells has a surface tension of approximately 45 dynes/cm. It is necessary, that the body reduces the surface tension of water we consume in order for nutrients to pass through cell walls, and for toxins to pass out of the cells.
Mega H- in water expedites this process. Glutathione: Contains cysteine, glycine and glutamic acid. The liver manufactures glutathione whenever extra cysteine is available. Blood glutathione levels change in direct proportion to the amount of cysteine is in the diet. One 50 milligram capsule or tablet, three times a day taken on an empty stomach. Individuals with insulin deficiency should not take glutathione.
Methionine: Methionine levels are a major determinant in the liver's concentration of sulphur-containing compounds, such as glutathione and cysteine. As methionine is the precursor for the manufacture of cysteine in the body, extra supplementation of this critical amino acid should increase available cysteine. Animal studies have shown that methionine protects rats from the toxic effects of lead and mercury. Chelating agents such as DMSA
(dimercapto succinic acid) and DMPS (dimercapto-propane sulfonic acid) bind to cysteine for excretion. L-cysteine bound to mercury (L-penicillamine, N-acetyl-L-cysteine, DMSA and glutathione complexed with methylmercury) resembles the L-methionine molecule and can cross the blood brain barrier.
L-methionine inhibits the transport of these complexes into the brain.
Methionine increases the bioavailability of glutathione. Most of the cysteine required for the resynthesis of glutathione must originate from methionine and not from cysteine generated by the catabolism of glutathione. Patients taking only D-L-methionine increased mercury excretion in the urine by 60%
over the excretion rate before taking the methionine. Lead excretion was also increased. The L-form is rapidly metabolized by the liver and does not offer a sustained antioxidant level. Over half of the D-form is slowly metabolized by the same pathways as excess L, and acts identical to L as an antioxidant. The benefit of the D-L form of methionine is the D form provides sustained blood levels allowing he L-form to be converted to other sulfur antioxidants. Babies need 22 mg/Kg body weight of methionine on a daily basis while adults need 10 mg/Kg of body weight daily.
N-Acetyl-L-Cysteine (NAC): NAC forms L-cysteine, cystine, L-methionine, glutathione (GSH), and mixed di-sulfides. Stimulates the body to produce large amounts of cysteine and glutathione, thus greatly augmenting plasma and red blood cell content of both cysteine and glutathione;
Methylsulfonylmethane (MSM): MSM, like fresh garlic, provides a bioavailable dietary source of sulfur. MSM exerts a direct beneficial effect in ameliorating a variety of allergic responsees and pain associated with systemic inflammatory disorders.
Milk Thistle (silymarin): Silymarin provides support and protection against liver toxins which can cause free-radical-mediated oxidative damage.
Silymarin is many times more potent in antioxidant activity than vitamin E.
In addition, it increases liver production of glutathione and protects red blood cell membranes against lipid peroxidation and hemolysis.
Chlorella: Is a food-like all purpose mild chelator of heavy metals; it is a specially processed green-algae type of food that is taken with meals and is quite tolerable and pleasant for many. But since chlorella is so easily contaminated, the manufacturer's quality control is important. Nature's Balance is a source of high quality chlorella that can be taken as a part of a person'd detox program. The detoxification capability of Chlorella is due to its unique cell wall and the material associated with it. The cell walls of Chlorella have been shown to have three layers of which the thicker middle layer contains cellulose microfibrils. Atkinson et al found a 14nm thick trilaminar layer outside the cell wall proper which was extremely resistant to breakage and thought to be composed of a polymerised carotene like material.....Laboratory studies showed that there were two active absorbing substances - sporopollenin (a naturally occurring carotene like polymer which is resistant to degradation) and the algae cell walls." Chlorella's ability to detoxify the body is very significant because of the large amount of chemicals we are exposed to in today's modern world. This ability to detoxify chemicals is also one of the important differences between Chlorella and other "green" products."
Cilantro: stimulates the body's release of mercury and other heavy metals from the brain and CNS into other tissue. This facilitates the ability to remove heavy metal from the body using other dietary protocols, such as Chorella and other chlorophyll containing herbs such as Nettles and Alfalfa.
These herbs aid in detoxifying by denaturing the toxins, protecting and restoring normal cellular functions while promoting elimination. The major constituents of the volatile oils are: myrcene (1.71%), d-linalool (52.26%), citronellol (4.64%), geraniol (9.29%), safrole (2.67%), aterpinyl acetate (1.07%) and geraniol acetate. A typical dose is orally 6-15 drops 1/2 hr.
before or 1 hr. after meals 2x/day. For 5 days. 2 day rest and continue. Or Apply 1/4 to 1/2 dropper on wrists, joints, or affected areas twice a day.
Vitamin B6: needed in the metabolic process that converts methionine to cysteine and then into glutathione. B6 is capable of reducing and controlling the swelling and pain associated with the routine tissue and bone trauma resulting from normal dental operative procedures. You can also use Pyridoxal-5-phosphate (P5P), the active form that B6 is converted to in the body. Vitamin B1: is capable of reducing pain that may be associated with routine dental operative procedures. B, is one of two vitamins containing sulfur, the other is Biotin.
Magnesium: Magnesium availablility is essential for the proper functinoing of our immune system as well as hundreds of enzyme systems critical to human health. Organically amino acid-bound ones are more easily absorbed and are less irritating to the gastrointestinal tract as well.
Activated charcoal: taken immediately with chlorella, 15 minutes before drilling/chunking out amalgam, will bind any swallowed mercury and also prevent recirculation in the liver.
Refrain from taking any supplements that contain iron and copper. Mercury amalgam removal alone does not put an end to the mercury poisoning. The mercury which leached from the fillings in the mouth is stored in cells throughout the body and continues to exert its damaging influence. It is not unusual to see patients who have had their amalgam fillings removed and replaced ten to fifteen years prior to testing still having elevated levels of mercury in the body. Once mercury toxicity has been demonstrated, by tests such as high electrogalvanism, high mercury vapor emissions, and/or high mercury body burden, mercury amalgam removal and replacement with alternate, non-toxic materials is the recommended step. Botanical substances to assist in removing the mercury include cilantro and chlorella which are particularly effective.
Sweating The skin is the body's largest detoxiification organs and sweating can help draw mercury from the body. Saunas are a useful adjunct to safe mercury removal because they induce copious sweating. Initiate sweating and increased circulation by exercising 20 minutes three times a day on a rebounder (mini trampoline). Immediately following the exercise, sit in a sauna or under infrared lights (infrared sauna) for up to 30 minutes, then take a cool shower. The temperature from a "low heat" sauna should be between 140 to 180 degrees F. in contrast to the 200 to 210 degree F. for a non-therapeutic standard sauna. The sauna may be followed by a plunge into a bath or under a shower whose temperature is 65 degrees F. Over a period of three to four days, increase your time in the sauna to a total of up to two hours, divided into 30-minute periods with a short cooling-off period in between. It's important to shower and towel dry because the removal of sweat prevents reabsorption of toxins. While doing the sauna program, consume adequate amounts of water to avoid dehydration. this is a minimum of two quarts before and after entering the sauna. Replace your electrolytes lost to perspiration with grape or prune juice and drink vegetable juices to replace calcium and magnesium lost through the skin.
Oral Metal Chelation NDF (Nanocolloidal Detox Factors) Based on the results of comparative 24 hour urine samples analyzed by an independent clinic and lab, a person can safely excrete up to 920% (9.2 times) more heavy metals per month taking NDF daily as compared to doing one DMPS intravenous injection per month. This greatly shortens the time required to achieve detoxification, an average toxic adult person requiring a maximum dose of 2 mis. twice a day for a period of about two months. NDF also removes other toxins from the system.
The predominant route of excretion is via the urine, thus accelerating the excretion rate of the mobilized metals as compared to the fecal route, decreasing the possibility of enzyme and leaky gut mediated resorption through the bowel, and decreasing the burden on the liver. The majority of the metals to be mobilized and eliminated per dose are quickly detectable in the first urination following the dose. Fecal Element studies show an average of 38.4% reduction in fecal metals following 5 days at maximum dosage while urine levels remain elevated. Individual pathways of elimination have been noted. Independent real time digital EEG studies show a beneficial effect on the electrical activity of the brain, specifically raises the heavy metal suppressed beta waves to normal levels (from within to 113 minutes post ingestion and lasting at least 4 hours) with a concurrent dramatic increase in the urinary excretion of heavy metals and patient reports of subjective improvement. This proves that no "healing crisis" is required during heavy metal detox while using NDF.
Ingredients:
2 milliliters (2 droppers full or 52 drops) contain:
50 mgs. - Nanocolloidal cell wall decimated Chlorella Pyrenoidosa .12 mis. - Nanocolloidal Cilantro mgs. - Nanocolloidal *PolyFlor 75 mgs/liter nanocolloidal Silica Grain neutral spirits 18% as a preservative *PolyFlor microorganisms include: 12 strains of lactobacillus (including casei, acidophilus, salivarius, bulgaricus, sporogones and plantarum), 3 strains bifidobacterium including longum and bifidum, streptococcus thermophilus, and b. laterosporus.
Why "Nanonize" the Ingredients?
Chlorella is known in mining to bind heavy metals to its cell wall. Yet many people have taken Chlorella with no benefit. The reasons are that all of the available chlorella is not really "cell wall broken" and that most of it is already contaminated with heavy metals. Most of the cell walls are in tact, but the individual diatoms are tightly clustered in groups of about 500 units each. This is very difficult to digest and may explain why some people get gastro intestinal distress when taking normal chlorella but not with NDF.
Nanocolloidal cell wall decimated chlorella has never been available so far!
In addition to binding to heavy metals, Chlorella has other beneficial effects, augmented by putting it through this process, including: increased elimination of toxins, growth hormone regulation, a powerful nutritive impact and protection from radiation.
Why does it work?
The following is essential to the understanding of this supplement: The ingredients are in a nanocolloidal form. There is at least a 500-fold increase in available surface area and a dramatically reduced particle size, thus rendering each ingredient more bioavailable and effective. That means the effective bioavailable dose is roughly one five hundredth of the dose required compared to using a dose of the original ingredient. This is why 50 milligrams of nanonized chlorella achieves what 25 grams of normal chlorella cannot. Most toxin-burdened people have compromised assimilation and utilization and can't benefit from macromolecules.
In the past, Chlorella was only known to mobilize a small amount of heavy metals via the bowel. In NDF, because it is nanonized, "molecular components digested off the nano particles can be absorbed across the GI
wall into the bloodstream and have a possibility to enter the brain depending on the molecule" - a possible explanation of why it can facilitate elimination via the urine.
PolyFlor contains fulvic acid. This could be the underlying reason why healthy bowel flora is so vital to good health. However, just taking a flora supplement will not provide heavy metal detox of the same magnitude as NDF (www.fulvic.com).
The major health benefits of both live and cell wall broken beneficial bacteria are described by recent clinical research in The Handbook of Probiotics. Lee, Nomoto, Salminen, and Gorbach. Pub. Wiley & Sons, Inc.
'99. Unfortunately, once the amalgams are put into the teeth, or the toxic body burden becomes too great, or if a person only consumes processed and pesticide grown foods, these powerful allies no longer stand a chance of sharing their healing benefits with us.
Duration of Therapy So far, only how much metal is being excreted can be measured, not the total body burden, so it is impossible to exactly predict the duration or cost of therapy. We do know that there is a linear relationship between the volume of the dose and the amount of excreted metals. Therefore, the more they can take, the quicker the detox will be. However, it is preferable to maintain the dose at the level that the patient continuously reports subjective improvement as a "healing crisis" is not required to effectively remove the heavy metals with NDF.
Cost Effectiveness / Compared to DMPS
It was recently determined by an independent, comparative 24-hour urine tests conducted by Dr. J. Wright via Doctors Data that a single, 2-dropper dose of NDF pulled out 20% as much metals as an IV dose of DMPS on the same patient. Since NDF can be taken daily, and DMPS only once a month (per the protocol presented by Drs. Klinghart and Mercola), this means that up to 920% (9.2 times) more metal can be excreted per month using 2 droppers of NDF twice a day (maximum dose) without the side effects and mineral deficiencies associated with DMPS. Since there is a linear relationship between amount of the dose and percentage increase in excreted metals, 6 drops twice a day would take out about 107%, or roughly the same amount of metals per month as DMPS, making NDF very cost effective, especially when you consider that very little additional supplementation is required while using NDF. Suggested retail is now $150 for a one-month supply, equal to the cost and efficiency of one DMPS IV
push.
Rectal Chelation New Delivery Method for Chelation Therapy The newest, easiest, most convenient and efficacious technique for detoxifying heavy metals out of the body is by means of rectal chelation therapy. The method is to self-apply Detoxamin, a patented, trademarked and registered over-the-counter suppository. People exhibiting toxic metal burdens now are able to chelate themselves while sleeping by use of this non-prescription chelator. Merely insert the firm gelatin pill into the rectum, go to sleep, and awake in the morning partially detoxified. Repeat the procedure until testing show that there is no more metal poison remaining in the body. With this suppository method, the main obstacle to intravenous EDTA chelation therapy has been eliminated. Rather than spending three or more hours per infusion session in a clinic, hooked to an IV, you may take less than a minute to insert the Detoxamin suppository at home before bedtime. Since many people cringe at the thought of getting stuck with a needle for twenty or more such IV treatments, use of a suppository eliminates this psychologically stressful and time-consuming obstacle.
Rectal administration is less invasive, in no way uncomfortable, and generally greatly preferred over IV treatments.
Taking 3-5 suppositories over a 30-day period. This is medically equal to approximately 2-EDTA IV treatments. When on Detoxamin maintenance one box of Detoxamin lasts 6 to 10 months. Taken every night for 90 days or every other night for 180 days provides the medical equivalence of approximately 30 IV Chelation treatments.
Rectal chelation therapy does the job of detoxifying in a low-cost way to effuse EDTA through the bowel's walls and into your blood stream to clean toxic metals from all body cells. Detoxamin has a time-release mechanism that allows the EDTA to absorb through the colon wall over an eighty-minute period while you sleep. Almost all the blood from the rectum makes its way to the superior hemorrhoidal veins, a tributary of the portal system, so that absorption through the rectal wall carries the EDTA in Detoxamin to the portal vein.
The lower and middle hemorrhoidal veins bypass the liver-and do not undergo first pass metabolism. This means that the EDTA in Detoxamin goes directly to the organs of your body without being filtered through the liver first. Because of this, the EDTA contained in Detoxamin is very productive. Detoxamin also introduces EDTA directly into the systemic circulation, efficiently bypassing the portal circulation and the liver metabolism on the first pass. Rectal absorption may also occur through the lymphatic system and, in some cases, largely through the blood via the vena cava.
Detoxamin offers many advantages both over the expensive intravenous method of EDTA chelation. With the use of needles via the intravenous method, and risk of AIDS and other communicable blood-borne diseases, Detoxamin is becoming the logical choice over I.V. EDTA chelation and the poorly absorbed oral EDTA. The rectum has a more neutral pH and is not as acidic as the stomach, which makes this area much better for EDTA
absorption because it is not buffered and has a neutral pH, unlike the stomach. It also has very little enzymatic activity, thus enzymatic degradation does not occur. The rectal mucosa (rectum) is much more capable than the gastric mucosa (stomach) of tolerating various drug-related irritations. This is why patients who can't tolerate oral pain medication are given the same medication in suppository form. In fact, absorption with any oral EDTA tablet is so low that 135 (500mg) oral EDTA
tablets are equal to just 5 Detoxamin suppositories.
Detoxamin removes most harmful toxins from the body, safely and effectively. Detoxamin is taken at night prior to bedtime, each Detoxamin suppository contains 750mg of Calcium-disodium EDTA, and is made in a cocoa-butter base (melts on body contact), which is very therapeutic for the rectal mucosa and the colon wall. The Ca-sodium form is able to bond (chelate) effectively because it does not lower the blood pH to a level that would prohibit the bonding action. The Ca added to the salt is important in this mode of administration as it buffers the acidic quality of the active ingredient keeping the suppository from being abrasive to the mucous membrane of the rectum area. Ca-disodium EDTA has both a scientific justification for therapeutic effectiveness as well as a clinical history of effectiveness.
The Calcium EDTA in Detoxamin has an extra chemical bond compared to the older Disodium EDTA. This gives Detoxamin EDTA an affinity for Mercury. Mercury is also excreted from the body through the feces and, because Detoxamin utilizes the colon wall for EDTA assimilation; it is a powerful Mercury chelator.
Metal Removing Nutrients Calcium & Vitamin C: Just as lead will displace calcium, calcium is an excellent nutrient to utilize for displacing mercury and lead. Utilizing a combination of minerals, such as magnesium and calcium, is even more effective in clearing metals from the body. Increasing vitamin C intake is a reasonable cost-effective way to control toxic metal levels in the population.
Several studies implicate lead in causing cavities, and at least one study suggests that almost 3 million cavities in children result from lead. Vitamin C and Calcium supplementation are recommended for protection.
Chlorophyll: chlorophyll binds to heavy metals very well. In fact, it is imperative to choose a reputable source for your chlorophyll, which screens for toxins and heavy metals; or you may be getting more than you want. A
good source is juiced raw, organic greens.
Fiber: Fiber, such as oat bran and apple pectin, will bind to metals and help draw them out of the body. Montmorillinite clay also binds extremely well to toxins and metals for clearance. Fiber such as red beet root fiber is high in proanthocyanidins and antioxidants and facilitates clearance of metals through the liver.
Lipoic Acid: Lipoic acid is a potent antioxidant and has a high affinity for binding to metals. This makes it an excellent choice as a supplement to bind and clear mercury and lead from the system. It is best utilized in combination with conjugating nutrients.
Minerals: A mineral-rich diet acts as a chelating agent. Many minerals will chelate metals, including calcium, magnesium, zinc and selenium. Mercury interferes with some functions of selenium, including its powerful antioxidant function and its ability to bind to metals. A good source of bioavailable minerals is from raw sea vegetables and grass juices from wheat, barley, alfalfa, kamut, etc.
Milk Thistle (silybum marianum): Milk thistle is a renowned liver herb, and supports this major detoxification organ. Milk thistle contains silymarin, a bioflavonoid that is a very potent remedy for the liver. Silymarin inhibits free radical damage; free radicals have an adverse effect on the detoxification enzymes of the liver cytochrome P450 system, while silymarin protects those enzymes. Glutathione is destroyed by lead. Silymarin not only prevents the depletion of GSH (glutathione), it even increased this liver-detoxifying enzyme. A sulfur pathway in the liver detoxes lead, and milk thistle helps to boost liver function.
Molybdenum: Large amounts of exogenous sulfur (from outside the body) will usurp the body's stores of molybdenum to metabolize it. An easier solution is to use the nutrients which will facilitate the homocysteine pathway. Homocysteine is a toxic substance, however the pathway itself, when properly supported, is essential for a host of metabolic functions.
When the pathway is facilitated, sulfur is generated as a natural by-product at the end (molybdenum changes the toxic sulfite molecule to the much-needed sulfate). Vitamins B12, B6 and folic acid, along with trimethylglycine and dimethylglycine recycle homocysteine to methionine, and allow for Sam-e to methylate phosphatidylserine, an important brain nutrient. Usually the people who are the most deficient in sulfur will be the most sensitive to metal toxicity and vice versa.
Parotid Glandular: Parotid glandular is believed to accelerate the clearance of chemicals/heavy metals from tissues. It is best utilized in combination with detoxification nutrients that will pull the metals out of the body by detox pathways such as the bowel, kidney, lymph, lungs, blood, skin, and liver.
Sulfur: Lead, mercury and cadmium steal sulfur from important proteins, which could be enzymes, hormones, or cell receptors. Conversely, sulfur is needed in the liver detox pathway to hook onto these metals and clear them from the body. So, lead, mercury and cadmium depletes sulfur, the very nutrient needed to detox the metal overload. A depletion of sulfur will also adversely affect joint connective tissue growth, since sulfur is an essential precursor to the building blocks of cartilage, namely glucosamine sulfate, chondroitin sulfate, and hyaluronic acid. Good sources are egg yolks, garlic, kelp, kale, turnip, raspberries, onions, cabbage, and mustard.
Zinc: Zinc and copper get displaced from metallothionine, the protein that binds and carries them. This destroys many of the zinc-dependent enzymes. Zinc is important for proper functioning in a host of major metabolic pathways; it is a component of over 90 metalloenzymes in the body. Lead has always been known as a neurotoxin, with the brain being particularly susceptible to attack. Lethargy is a common symptom of lead toxicity; lead inactivates the zinc-dependent enzymes of the Kreb's cycle, which produces our energy. Zinc is also a part of the antioxidant enzyme, Zn-SOD, which fights superoxide radicals. Symptoms of lead toxicity are similar to zinc deficiency symptoms because lead can bring on a zinc deficiency. Zinc deficiency has been implicated in a wide variety of neuropsychiatric disorders, including dyslexia, epilepsy, mental depression, and attention deficit disorder. The symptoms of lead toxicity are similar to zinc deficiency because the lead destroys the zinc-dependent enzymes.
Natural Healing Home Site Map Search this site Free Catalog Contact Us Dictionary About Us Products We are also working on 1) Isolating the most effective enzymes from ant's stomachs (also bis-peptides and other amino acids - eg. to fight disease...in gene therapy, and all genetic engineering, such as making stem cells proliferate longer, by altering their genes) and any and all simpler creations, 2) then duplicating their molecular structure using (atom) teleportation technology, 3) then eventually altering the pattern of the molecule feed stock to produce new molecules (designer), from enzymes to drugs for the pharmacuetical industries and new materials such as not just diamonds, but nano particles that are safe for human biology, more strong, more flexible, more dazzling, more sensitive sensors (eg. to sound vibrations), more heat resistant, any and all materials new qualities.
If we use a quantum computer/Artificial Intelligence Node Network job sharing/Huge Main Frame we may be able to mass assemble these duplicate produced via teleportation technology economically.
We are also considering mixing stem cells with specialized cells in tissue culture as well as separate and/or together in delivery/administering as well as grafting from for example tissue culture.
Converting stem cells to organ connective tissue using a scaffold whose dimensions are standard/default/similar in proportions for a person (possibly a donor dissected and detergent removed only connective tissue left) and then measuring the patient's actual dimensions (eg.
by PET, CAT scan, x-ray) (measuring the usual and important areas) of differences in size shape (eg. veins and artery and ventricle tissue).
We could also use to replace fat, lipo suction, then replaced with high metabolic cells and/or stem cells.
We could also use the stem cells and/or specialized cells for breast augmentation and penis (and/or using scaffolding to grow a new larger penis from stem cells) augmentation. Perhaps one way is for the penis augmentation to work is to study the specialized cells relative to thickness/diameter/shape of the penis. Where is the sensation nerve connections located in the cells, how much volume increasing cells are spread out where, dose the patient have the blood supply to support a fully erect penis. To test sensations, we could test on animals (eg.
rats), what type of specialized cells provide sensations (how much is muscle memory) can stem cells be used instead (directly) in the theory that the stem cells will move change into the specialized cells that surround it. Additionally can too much sensation cells cause pain, we can tell if the rats avoids errections (even under viagra) and/or ignores a female in heat (pheromones). Furthermore, with the new enlarged penis, can the can (and how can we make the) the blood flow increase if needed? Furthermore we could study pigs which are known to have 1/2 hour orgasms (are they male or female), their cellular make up -scaffolding, connective tissue, ability to remain erect, perhaps it's in the continuous supply of blood or their mind to nerve muscle memory or their internal plumbing such as larger supply of orgasmic fluid relative to pump rate, or perhaps it's their slow fat (slown down by fat tissue) metabolism and/or types of difference in nerve cells and/or brain activity during orgasm.
Perhaps we could use neural electrodes and/or mind sounds and/or direct muscle patch to simulate mimic brain activity during orgasm creating artificial orgasms with no end in time).
We might also mimic (using neural electrodes and/or mind sounds and/or direct muscle patch) for the brain activity that causes and maintains errection and for females faster sexual escalation to orgasm. The above might be the cures for any and all sexual dysfunctional diseases (eg. impotence, early/delayed ejaculation, as well as size and hardness, and frigidity). Another option for for example opposite sexed mates is 1. a touch sensitive artificial penis - changeable sizes - diameter and lengths (for men and for robots with emotional artificial intelligence) that is controlled via two way signals (to read the sensations in both the man and also the female are being felt as the penis and vagina interact...). We do this by using neural electrodes and/or mind sounds and/or direct muscle patch for men and robots to satisfy women as well as the man (via signals back to the man's brain/mind that mimic and/or duplicates the feeling of orgasm in the mind - we could even continue this feeling for both men and women all day long) himself at the same time. 2. for women, we could use the neural electrodes and/or mind sounds and/or muscle patches that induce and/or work in synchronicity to push (flood rhythm, sensations) the woman to orgasm and/or mimic the feeling of orgasm to the brain/mind all day long. We could create a muscle patch electrode(s) (as well as vibrating) that are attached the artificial penis that will stimulate the woman's g-spot and/or any and all sensations cause the woman to orgasm - in addition to regular foreplay. It is my hope that eventually people could induce orgasms artificially without dwelling on dirty thoughts or pornography. Or at least this invention will enhance the sex lives of people who are sexually dysfunctional. We could stem cells that are either differentiated into the specialized corpus cavernosal smooth muscle, the endothelium of the sinusoids, blood vessels and the smooth muscle cells in the penis that produce transmitters and modulators...all tissue cultured in the laboratory, then either 1) we (multiple micro) inject the differentiated cells in to the places that we want to bulk up, 2) we (multiple micro) inject stem cells directly into these specialized areas of the penis in the hope that the stem cells will migrate and differentiate into the localized cells via cell to cell signalling, 3) we can create a whole new larger and longer penis that can be grafted on the patient to replace the old one.
We think exercises and more arteries/and larger arteries capacity (eg. larger inside scaffold that the arterial cells grow around the hollow hole) and inversely the less and smaller inside hollow capacity of venous outflow, the better for a more erect rather than flaccid penis. To enhance conversion of stem cells to specialize into endothelial growth, we can use 1) mechanical forces, (fluid shear stress and cyclic stretch - pulse and perodicity) eg. gels that emulate the pressure conditions of the penis at erect and rest, 2) endothelial growth factor VEGF-C, EG-VEGF, Phospho-VGFR2 (Tyr1214), VEGF121,VEGF-A, VEGF-C, VEGFD, VEGF-R1, VEGF-R1/Flt-1 (17a.aC term), VEGFR2(Ab-1214) Antibody, VEGF-R2/Flk-(188a.a C term), VEGFR2/KDR, VEGF-R3/Flt-4 (20a.a C term); TGF-B2, KIAA0101, CARP
and syntenin, CXCR-4, TGM-2, LIM-domain protein and claudin-5; we could also use these growth factors to increase proliferation of stem cells (VEGF-C) for proliferation, migration, through selective binding and phosphorylation of tyrosine kinase, growth factor receptors (eg.
kdr, flt-4 and flt-1). 3) Another way to morph the stem cells is to create a medium or serum derived from the specific cell type of large animal (fibroblasts), such as a cow, horse and/or pig for the final morphing stage of the corresponding to the same cell type/portion of penis on humans - the assumption is that the human stem cells will mature into the same cells as those surrounding it.
The idea of grafting may also be possible, but we would need to know the sensation implications in terms of pattern of nerve cells and their necessary connections to the original nerve network below. Grafting may make the sexual sensations numb if not embedded with the right pattern of nerves and furthermore rough sex may tear the graft.
We could also mix injections with grafting.
We could use micro multiple syringes to deliver (connective tissue (and/or stem cells) -which can be injected into spread out (together in conjunction with training) areas of the gut -to strengthen for example medicine bali training in boxing and/or iron shirt qi gong).
Fast twitch muscles and/or their progenitor stem cells using micro multiple injections could be used to deliver to strategic locations (areas) that correlate to shape/relative sizes or wanted body muscle proportions. The patient can exercise to make the muscles grow and perform.
This muscle augmentation can also be used for paralysed people in conjunction with stem cells and neural cells to the spine and the finger/palm therapy Gerard developed especially in cases where the muscles have deteriorated in size and strength.
Fast twitch muscles and/or their progenitor stem cells using micro multiple injections could be used to deliver to strategic locations (areas) that correlate to shape/relative sizes or wanted body muscle proportions. The patient can exercise to make the muscles grow and perform.
This muscle augmentation can also be used for paralysed people in conjunction with stem cells and neural cells to the spine and the finger/palm therapy Gerard developed especially in cases where the muscles have deteriorated in size and strength.
Additionally to create a cloned human being; we take a fertilized that has formed a blastocyst, remove the fertilized stem cells, inject an adult patient/desired stem cells (to take the place of the stem cells of the fertilized egg/sperm) that has come from tissue culture - eg.
earlier cloned stem cells (or try somatic adult stem cells - there is the caveat that somatic cells may not divide), then we attach the blastocyst to a female's uterus and grow the fetus to a cloned baby.
Additionally to create a cloned human being; we take a fertilized that has formed a blastocyst, remove the fertilized stem cells (via through the outside of the same site that the this inner cell mass (ICM) is attached to on the blastocyst - Trophectoderm outer blastocyst wall(TE)), we use the same site (by using the site where the ICM is stuck to the blastocyst TE we avoid tearing or implanting the stem cells into the wrong side (of the Mesoderm) that separates the inner cell mass from the blastocoel - fluid cavity) to inject an adult patient/desired stem cells (to take the place of the stem cells of the fertilized egg/sperm) that has come from tissue culture - eg. earlier cloned stem cells - possibly electro fusing, laser fusing and/or heat shock (or try somatic adult stem cells - there is the caveat that somatic cells may not divide), then we attach the blastocyst to a female's uterus and grow the fetus to a cloned baby. To make this work we may need create (stuff the new stem cells) enough to create the same pressure conditions as the previous fertilized egg stem cells separated by the mesoderm.
To collect single adult female stem cells for use in replacing stem cells in the blastocyst the following process can be used:
Stem Cells from female eggs can be obtained as follows:
1. Treat the eggs with oncogene c-Myc.
2. Hyper ovulate (use of fertility drugs)
3. Harvest eggs.
4. Mature them in CMRL-1066 media (Sigma), FCS (HyClone), pregnant mare serum (Sigma), human chrionic gonadotropin (Sigma), penicillin, streptomycin.
5. The eggs are incubated in CO2, inonomycin, then in 6-dimethyliaminopurine.
6. The stem cells are then removed and further media are similar to the media above (stem cell tissue culture - especially proliferation; since before we can treat patients we need sizable inventory of compatible stem cells first).
7. We could use electroshock, heat shock to get the stem cells to start dividing.
8. We could also use the above maturation cycle and incubation to proliferate stem cells produced by the traditional method (eg. Oocyte removed nucleus, micro;
laser; electro shock and replaced with somatic DNA).
laser; electro shock and replaced with somatic DNA).
9. Alternatively we could use primordial germ cells from an adult male and use the above maturation cycle and incubation to proliferate stem cells.
10. Another alternative is to use a batch of stem cells (from any of the above methods) that have stopped proliferating and either treat with the maturation cycle, then incubate to jump start the proliferation cycle again.
11. Or we could use a batch of stem cells (from any of the above methods) and microinject, laser electroshock the DNA from the stem cells (that have stopped proliferating) into a fresh Oocyte (with the nucleus removed).
12. We could also alternate between 10) and 11) or test which one is the most prolific and which one is best for maintaining the integrity of the DNA - from mutating or degenerating.
We might also use (perhaps electron/nano/quantum) video, microscopic thermal heat sensors to view the innards (internal bodies and fluids) within the cell.
We are also considering growth factors and gene therapy combinations of the following:
FGF-1 and FGF-2; and at least one of the following: VEGF, VEGFA, VEGFB, PLGF, VEGF121, VEGF145, VEGF165; VEGF189, VEGF206, FGF-1, FGF-2, including the following gene therapy is AD5(FGF4) or VEGF 165 plasmid DNA to extend stem cell proliferation.
We also suggest that if you cut the nerves to a salamander's arm the salamander may regrow an extra limb. Based on this theory we find that the salamander's nervous system senses that the limb is missing and regrow's the third limb.
Perhaps humans could regrow limbs and organs by growing using a blastema (stem cells) with the Human HOX genes and pressure that is found in that area of the body as well as cell signalling, with new doses of stem cells to be added as the stem cells migrate and form the different stages of embryonic development of the limb and/or organ.
The other option is to inject the stem cells together with activated HOX genes regularly (perhaps by Intra Venous drip GP; GV) and in time before scarring even use topical and/or abrasive dermal removal of scar tissue, even shave of the overgrown tissue in preparation for the mixture of stem cells with activated HOX gene to create a human blastema as well as cell signalling. The stem cells with activated HOX genes can be added directly to the (eg.
removed area - limb) as the progress of migration and distal tip, stage by stage embryogenesis converts and/or causes the stem cells to produce the limb/organs that is just in time method, so there is no excess or not enough stem cells with the activated HOX genes to cause unwanted growth or in the case of not enough administration scar tissue may form or the regeneration may be instructed to stop due to lack of stem cells with activated HOX
genes by whatever the body's recognition is, ... and also where the best place to administer the concoction, and amounts...
Furthermore through any and/or all gene therapies we could activate the HOX
genes in stem cells to further proliferate them.
We are considering injecting homeodomain proteins in serum mixed with/or separately, stem cells, (differentiated cells appropriate for that part of the body) eg.
dendrites, neural cells and neutrophins, into brain ill people (eg. parkinson's disease, paralysis - brain damage, alzheimer's, Mad Cow Disease...). Furthermore we could saw off part of the skull and add homeodomain proteins in serum mixed with/or separately, stem cells, (differentiated cells appropriate for that part of the body) eg. dendrites, neural cells and neutrophins (using previously artificially grown blood brain barrier tissue (and/or donor) -and/or blood brain barrier from a primate. We could fuse it to a pourous bone matrix that has blood and or artificial blood to exchange waste for nutrients needed and can be temporarily removed for cleaning - the purpose is to see what happens to the mental abilities of the subject.
This technologly of Homeodomain in the hope it will be absorbed by localized cells in conjunction with precusor stem cells and cells differentiated for that part of the body.
The first step is to study what and under what conditions (eg. pressure, salt concentrations) substances are facilitated from which side of the blood brain barriers to which side.
Humans generally contain homeobox genes in four clusters:
There is also a"distal-less homeobox" family: DLX1, DLX2, DLX3, DLX4, DLX, and DLX6.
"HESX homeobox 1" is also known as HESX1.
Short stature homeobox gene is also known as SHOX
3%
1%
3%
We are trying to revive dinosaurs' and extinct/or and nearly extinct species.
We plan to use the Hox genes in different ways.
We can add the hox genes (into the nuclear membrane and then either from micro inject and/or retro virus then electroshock, laser fuse, heat shock and fill their cytoplasm (GP 25%) and the hox and transcription factors with the building blocks at the ovum and/or zygote stage of development. And we could remove a fetus from an egg and mix the egg white of another egg with evenly spread hox building blocks (plus hox genes) and hox transcription factors then we could place the fetus in anther egg, with egg white mixed hox material and egg white even in an artificial shell matrix to incubate. We need to study whether hox should be introduced at ovum, zygote, or at fetal stage - before sometime during growth, as growth is slowing down and or when and/or after growth has stopped. We could of course study how the genes (activated versus inactivated, what is the sources of and which genes are at the top of the pecking order causing which other obviously essential genes (for continued growth into dinosaurs) to silence at the stage of fetal development where the fetus of a chicken diverge from the fetus of an alligator. What if any environmental (versus pre-past historical gene mutation programming coming evolution and natural selection) triggers signal these genes to activate, when is a an embryo of a chicken's teeth too large and what tells which genes in the chicken genome to recede the teeth ... Evolutionarily speaking it is possible that the stage of growth (eg. incubation stage) of the fetus determines at some stage in evolution oc the chicken species, mutated chickens fetuses that lose their teeth past a certain stage in the fetal development dominated (survived in their habitat) versus those that grew teeth beyond that point. So by using hox gene we expect to carry the chicken to continue teeth growth all the way to hatching (continuing the growth of its body parts through the stages that such body parts would in current evolutionary status of chickens to day to dinosaurs derived from the continued growth).
Alternatively and additionally we could protoplast fuse chickens, emus, ostriches, alligators and crocodiles.
Finally we could study chickens, emus and ostriches to see which genes are turned/turned off, activated/deactivated, silenced other than hox genes whereby chickens with teeth have certain gene drivers, that are changed from no teeth, which genes control/regulate and are if any also responsible for the suppression of dinosaur hatchlings.
To genetic engineer dinosaurs we use chickens, emus, ostriches, alligators and crocodiles.
The vertebrate homeotic complex comprises four distinct Hox gene clusters (Hox A, B, C, D) that are organized into thirteen homology (or paralogue) groups.
Unscannable item(s) received with this application To inquire if you can order a copy of the unscannable items, please visit the CIPO WebSite at HTTP://CIPO.GC.CA
We might also use (perhaps electron/nano/quantum) video, microscopic thermal heat sensors to view the innards (internal bodies and fluids) within the cell.
We are also considering growth factors and gene therapy combinations of the following:
FGF-1 and FGF-2; and at least one of the following: VEGF, VEGFA, VEGFB, PLGF, VEGF121, VEGF145, VEGF165; VEGF189, VEGF206, FGF-1, FGF-2, including the following gene therapy is AD5(FGF4) or VEGF 165 plasmid DNA to extend stem cell proliferation.
We also suggest that if you cut the nerves to a salamander's arm the salamander may regrow an extra limb. Based on this theory we find that the salamander's nervous system senses that the limb is missing and regrow's the third limb.
Perhaps humans could regrow limbs and organs by growing using a blastema (stem cells) with the Human HOX genes and pressure that is found in that area of the body as well as cell signalling, with new doses of stem cells to be added as the stem cells migrate and form the different stages of embryonic development of the limb and/or organ.
The other option is to inject the stem cells together with activated HOX genes regularly (perhaps by Intra Venous drip GP; GV) and in time before scarring even use topical and/or abrasive dermal removal of scar tissue, even shave of the overgrown tissue in preparation for the mixture of stem cells with activated HOX gene to create a human blastema as well as cell signalling. The stem cells with activated HOX genes can be added directly to the (eg.
removed area - limb) as the progress of migration and distal tip, stage by stage embryogenesis converts and/or causes the stem cells to produce the limb/organs that is just in time method, so there is no excess or not enough stem cells with the activated HOX genes to cause unwanted growth or in the case of not enough administration scar tissue may form or the regeneration may be instructed to stop due to lack of stem cells with activated HOX
genes by whatever the body's recognition is, ... and also where the best place to administer the concoction, and amounts...
Furthermore through any and/or all gene therapies we could activate the HOX
genes in stem cells to further proliferate them.
We are considering injecting homeodomain proteins in serum mixed with/or separately, stem cells, (differentiated cells appropriate for that part of the body) eg.
dendrites, neural cells and neutrophins, into brain ill people (eg. parkinson's disease, paralysis - brain damage, alzheimer's, Mad Cow Disease...). Furthermore we could saw off part of the skull and add homeodomain proteins in serum mixed with/or separately, stem cells, (differentiated cells appropriate for that part of the body) eg. dendrites, neural cells and neutrophins (using previously artificially grown blood brain barrier tissue (and/or donor) -and/or blood brain barrier from a primate. We could fuse it to a pourous bone matrix that has blood and or artificial blood to exchange waste for nutrients needed and can be temporarily removed for cleaning - the purpose is to see what happens to the mental abilities of the subject.
This technologly of Homeodomain in the hope it will be absorbed by localized cells in conjunction with precusor stem cells and cells differentiated for that part of the body.
The first step is to study what and under what conditions (eg. pressure, salt concentrations) substances are facilitated from which side of the blood brain barriers to which side.
Humans generally contain homeobox genes in four clusters:
There is also a"distal-less homeobox" family: DLX1, DLX2, DLX3, DLX4, DLX, and DLX6.
"HESX homeobox 1" is also known as HESX1.
Short stature homeobox gene is also known as SHOX
3%
1%
3%
We are trying to revive dinosaurs' and extinct/or and nearly extinct species.
We plan to use the Hox genes in different ways.
We can add the hox genes (into the nuclear membrane and then either from micro inject and/or retro virus then electroshock, laser fuse, heat shock and fill their cytoplasm (GP 25%) and the hox and transcription factors with the building blocks at the ovum and/or zygote stage of development. And we could remove a fetus from an egg and mix the egg white of another egg with evenly spread hox building blocks (plus hox genes) and hox transcription factors then we could place the fetus in anther egg, with egg white mixed hox material and egg white even in an artificial shell matrix to incubate. We need to study whether hox should be introduced at ovum, zygote, or at fetal stage - before sometime during growth, as growth is slowing down and or when and/or after growth has stopped. We could of course study how the genes (activated versus inactivated, what is the sources of and which genes are at the top of the pecking order causing which other obviously essential genes (for continued growth into dinosaurs) to silence at the stage of fetal development where the fetus of a chicken diverge from the fetus of an alligator. What if any environmental (versus pre-past historical gene mutation programming coming evolution and natural selection) triggers signal these genes to activate, when is a an embryo of a chicken's teeth too large and what tells which genes in the chicken genome to recede the teeth ... Evolutionarily speaking it is possible that the stage of growth (eg. incubation stage) of the fetus determines at some stage in evolution oc the chicken species, mutated chickens fetuses that lose their teeth past a certain stage in the fetal development dominated (survived in their habitat) versus those that grew teeth beyond that point. So by using hox gene we expect to carry the chicken to continue teeth growth all the way to hatching (continuing the growth of its body parts through the stages that such body parts would in current evolutionary status of chickens to day to dinosaurs derived from the continued growth).
Alternatively and additionally we could protoplast fuse chickens, emus, ostriches, alligators and crocodiles.
Finally we could study chickens, emus and ostriches to see which genes are turned/turned off, activated/deactivated, silenced other than hox genes whereby chickens with teeth have certain gene drivers, that are changed from no teeth, which genes control/regulate and are if any also responsible for the suppression of dinosaur hatchlings.
To genetic engineer dinosaurs we use chickens, emus, ostriches, alligators and crocodiles.
The vertebrate homeotic complex comprises four distinct Hox gene clusters (Hox A, B, C, D) that are organized into thirteen homology (or paralogue) groups.
Unscannable item(s) received with this application To inquire if you can order a copy of the unscannable items, please visit the CIPO WebSite at HTTP://CIPO.GC.CA
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002629555A CA2629555A1 (en) | 2008-05-14 | 2008-05-14 | Related/overlapping innovations in health/energy/transport/farming and infrastructure |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002629555A CA2629555A1 (en) | 2008-05-14 | 2008-05-14 | Related/overlapping innovations in health/energy/transport/farming and infrastructure |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2629555A1 true CA2629555A1 (en) | 2009-11-14 |
Family
ID=41297176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002629555A Abandoned CA2629555A1 (en) | 2008-05-14 | 2008-05-14 | Related/overlapping innovations in health/energy/transport/farming and infrastructure |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2629555A1 (en) |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104012693A (en) * | 2014-06-21 | 2014-09-03 | 浙江省新昌县澄潭茶厂 | Multifunctional temperature-varying tea fixation machine |
EP2968128A4 (en) * | 2013-03-12 | 2016-11-16 | Applied Biores Inc | Chelation suppository for improved drug delivery |
CN107935639A (en) * | 2017-12-04 | 2018-04-20 | 山东庞大生物集团有限公司 | The preparation method of efficient calcic organic fertilizer |
US10921492B2 (en) | 2018-01-09 | 2021-02-16 | Corning Incorporated | Coated articles with light-altering features and methods for the production thereof |
US11079725B2 (en) | 2019-04-10 | 2021-08-03 | Deere & Company | Machine control using real-time model |
CN113637481A (en) * | 2021-07-23 | 2021-11-12 | 浙江大学 | Application of chitosan and derivatives thereof in reducing antibiotic resistance gene pollution in soil |
US11178818B2 (en) | 2018-10-26 | 2021-11-23 | Deere & Company | Harvesting machine control system with fill level processing based on yield data |
US11234366B2 (en) | 2019-04-10 | 2022-02-01 | Deere & Company | Image selection for machine control |
US11240961B2 (en) | 2018-10-26 | 2022-02-08 | Deere & Company | Controlling a harvesting machine based on a geo-spatial representation indicating where the harvesting machine is likely to reach capacity |
US20220110251A1 (en) | 2020-10-09 | 2022-04-14 | Deere & Company | Crop moisture map generation and control system |
US11467605B2 (en) | 2019-04-10 | 2022-10-11 | Deere & Company | Zonal machine control |
US11474523B2 (en) | 2020-10-09 | 2022-10-18 | Deere & Company | Machine control using a predictive speed map |
US11477940B2 (en) | 2020-03-26 | 2022-10-25 | Deere & Company | Mobile work machine control based on zone parameter modification |
US11592822B2 (en) | 2020-10-09 | 2023-02-28 | Deere & Company | Machine control using a predictive map |
US11589509B2 (en) | 2018-10-26 | 2023-02-28 | Deere & Company | Predictive machine characteristic map generation and control system |
US11635765B2 (en) | 2020-10-09 | 2023-04-25 | Deere & Company | Crop state map generation and control system |
US11641800B2 (en) | 2020-02-06 | 2023-05-09 | Deere & Company | Agricultural harvesting machine with pre-emergence weed detection and mitigation system |
US11650587B2 (en) | 2020-10-09 | 2023-05-16 | Deere & Company | Predictive power map generation and control system |
US11675354B2 (en) | 2020-10-09 | 2023-06-13 | Deere & Company | Machine control using a predictive map |
US11672203B2 (en) | 2018-10-26 | 2023-06-13 | Deere & Company | Predictive map generation and control |
US11711995B2 (en) | 2020-10-09 | 2023-08-01 | Deere & Company | Machine control using a predictive map |
US11727680B2 (en) | 2020-10-09 | 2023-08-15 | Deere & Company | Predictive map generation based on seeding characteristics and control |
US11778945B2 (en) | 2019-04-10 | 2023-10-10 | Deere & Company | Machine control using real-time model |
US11825768B2 (en) | 2020-10-09 | 2023-11-28 | Deere & Company | Machine control using a predictive map |
US11845449B2 (en) | 2020-10-09 | 2023-12-19 | Deere & Company | Map generation and control system |
US11844311B2 (en) | 2020-10-09 | 2023-12-19 | Deere & Company | Machine control using a predictive map |
US11849672B2 (en) | 2020-10-09 | 2023-12-26 | Deere & Company | Machine control using a predictive map |
US11864483B2 (en) | 2020-10-09 | 2024-01-09 | Deere & Company | Predictive map generation and control system |
US11874669B2 (en) | 2020-10-09 | 2024-01-16 | Deere & Company | Map generation and control system |
US11889787B2 (en) | 2020-10-09 | 2024-02-06 | Deere & Company | Predictive speed map generation and control system |
US11889788B2 (en) | 2020-10-09 | 2024-02-06 | Deere & Company | Predictive biomass map generation and control |
US11895948B2 (en) | 2020-10-09 | 2024-02-13 | Deere & Company | Predictive map generation and control based on soil properties |
US11927459B2 (en) | 2020-10-09 | 2024-03-12 | Deere & Company | Machine control using a predictive map |
US11940593B2 (en) | 2020-07-09 | 2024-03-26 | Corning Incorporated | Display articles with diffractive, antiglare surfaces and methods of making the same |
US11946747B2 (en) | 2020-10-09 | 2024-04-02 | Deere & Company | Crop constituent map generation and control system |
US11957072B2 (en) | 2020-02-06 | 2024-04-16 | Deere & Company | Pre-emergence weed detection and mitigation system |
US11983009B2 (en) | 2020-10-09 | 2024-05-14 | Deere & Company | Map generation and control system |
-
2008
- 2008-05-14 CA CA002629555A patent/CA2629555A1/en not_active Abandoned
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2968128A4 (en) * | 2013-03-12 | 2016-11-16 | Applied Biores Inc | Chelation suppository for improved drug delivery |
CN104012693B (en) * | 2014-06-21 | 2016-01-13 | 浙江省新昌县澄潭茶厂 | A kind of multi-functional alternating temperature tea water-removing machine |
CN104012693A (en) * | 2014-06-21 | 2014-09-03 | 浙江省新昌县澄潭茶厂 | Multifunctional temperature-varying tea fixation machine |
CN107935639A (en) * | 2017-12-04 | 2018-04-20 | 山东庞大生物集团有限公司 | The preparation method of efficient calcic organic fertilizer |
US10921492B2 (en) | 2018-01-09 | 2021-02-16 | Corning Incorporated | Coated articles with light-altering features and methods for the production thereof |
US11240961B2 (en) | 2018-10-26 | 2022-02-08 | Deere & Company | Controlling a harvesting machine based on a geo-spatial representation indicating where the harvesting machine is likely to reach capacity |
US11672203B2 (en) | 2018-10-26 | 2023-06-13 | Deere & Company | Predictive map generation and control |
US11178818B2 (en) | 2018-10-26 | 2021-11-23 | Deere & Company | Harvesting machine control system with fill level processing based on yield data |
US11589509B2 (en) | 2018-10-26 | 2023-02-28 | Deere & Company | Predictive machine characteristic map generation and control system |
US11079725B2 (en) | 2019-04-10 | 2021-08-03 | Deere & Company | Machine control using real-time model |
US11467605B2 (en) | 2019-04-10 | 2022-10-11 | Deere & Company | Zonal machine control |
US11234366B2 (en) | 2019-04-10 | 2022-02-01 | Deere & Company | Image selection for machine control |
US11829112B2 (en) | 2019-04-10 | 2023-11-28 | Deere & Company | Machine control using real-time model |
US11650553B2 (en) | 2019-04-10 | 2023-05-16 | Deere & Company | Machine control using real-time model |
US11778945B2 (en) | 2019-04-10 | 2023-10-10 | Deere & Company | Machine control using real-time model |
US11957072B2 (en) | 2020-02-06 | 2024-04-16 | Deere & Company | Pre-emergence weed detection and mitigation system |
US11641800B2 (en) | 2020-02-06 | 2023-05-09 | Deere & Company | Agricultural harvesting machine with pre-emergence weed detection and mitigation system |
US11477940B2 (en) | 2020-03-26 | 2022-10-25 | Deere & Company | Mobile work machine control based on zone parameter modification |
US11971519B2 (en) | 2020-07-09 | 2024-04-30 | Corning Incorporated | Display articles with antiglare surfaces and thin, durable antireflection coatings |
US11940593B2 (en) | 2020-07-09 | 2024-03-26 | Corning Incorporated | Display articles with diffractive, antiglare surfaces and methods of making the same |
US11977206B2 (en) | 2020-07-09 | 2024-05-07 | Corning Incorporated | Display articles with diffractive, antiglare surfaces and thin, durable antireflection coatings |
US11675354B2 (en) | 2020-10-09 | 2023-06-13 | Deere & Company | Machine control using a predictive map |
US11874669B2 (en) | 2020-10-09 | 2024-01-16 | Deere & Company | Map generation and control system |
US11727680B2 (en) | 2020-10-09 | 2023-08-15 | Deere & Company | Predictive map generation based on seeding characteristics and control |
US11650587B2 (en) | 2020-10-09 | 2023-05-16 | Deere & Company | Predictive power map generation and control system |
US11825768B2 (en) | 2020-10-09 | 2023-11-28 | Deere & Company | Machine control using a predictive map |
US11635765B2 (en) | 2020-10-09 | 2023-04-25 | Deere & Company | Crop state map generation and control system |
US11845449B2 (en) | 2020-10-09 | 2023-12-19 | Deere & Company | Map generation and control system |
US11844311B2 (en) | 2020-10-09 | 2023-12-19 | Deere & Company | Machine control using a predictive map |
US11849672B2 (en) | 2020-10-09 | 2023-12-26 | Deere & Company | Machine control using a predictive map |
US11864483B2 (en) | 2020-10-09 | 2024-01-09 | Deere & Company | Predictive map generation and control system |
US11871697B2 (en) | 2020-10-09 | 2024-01-16 | Deere & Company | Crop moisture map generation and control system |
US11711995B2 (en) | 2020-10-09 | 2023-08-01 | Deere & Company | Machine control using a predictive map |
US11889787B2 (en) | 2020-10-09 | 2024-02-06 | Deere & Company | Predictive speed map generation and control system |
US11889788B2 (en) | 2020-10-09 | 2024-02-06 | Deere & Company | Predictive biomass map generation and control |
US11895948B2 (en) | 2020-10-09 | 2024-02-13 | Deere & Company | Predictive map generation and control based on soil properties |
US11927459B2 (en) | 2020-10-09 | 2024-03-12 | Deere & Company | Machine control using a predictive map |
US11592822B2 (en) | 2020-10-09 | 2023-02-28 | Deere & Company | Machine control using a predictive map |
US11946747B2 (en) | 2020-10-09 | 2024-04-02 | Deere & Company | Crop constituent map generation and control system |
US11474523B2 (en) | 2020-10-09 | 2022-10-18 | Deere & Company | Machine control using a predictive speed map |
US20220110251A1 (en) | 2020-10-09 | 2022-04-14 | Deere & Company | Crop moisture map generation and control system |
US11983009B2 (en) | 2020-10-09 | 2024-05-14 | Deere & Company | Map generation and control system |
CN113637481A (en) * | 2021-07-23 | 2021-11-12 | 浙江大学 | Application of chitosan and derivatives thereof in reducing antibiotic resistance gene pollution in soil |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2629555A1 (en) | Related/overlapping innovations in health/energy/transport/farming and infrastructure | |
Chippaux | Snake venoms and envenomations | |
CN101072866A (en) | Method of altering cell properties by administering RNA | |
HU230800B1 (en) | Novel probiotics for pet food applications | |
CN107028981A (en) | Adherent cell from fat or placenta tissue and its purposes in the treatment | |
KR20090074044A (en) | Expansion method for adult stem cells from blood, particularly peripheral blood, and relative application in medical field | |
CN107809999A (en) | For treating the composition of lesion tissue | |
CN109106728A (en) | The preparation method and application of human placenta stem cell extract freeze-drying powder | |
CN1704120A (en) | Compound biological product conposition and preparation method thereof | |
Berkson | The Alpha Lipoic Acid Breakthrough: The Superb Antioxidant That May Slow Aging, Repair Liver Damage, and Reduce the Risk of Cancer, Heart Disease, and Diabetes | |
CA2639023A1 (en) | Bioscience iii | |
CN103446628B (en) | Preparation method for tissue engineering nerves of compound seed cells | |
Haas | A study of the viability of bone after removal from the body | |
CN1938419B (en) | Tissue-like organization of cells and macroscopic tissue-like constructs, generated by macromass culture of cells, and the method of macromass culture | |
TW200418363A (en) | Cultivating method for pleurotus nebrodensis and a prophylaxis and ameliorate for disease containing pleurotus nebrodensis | |
Campbell-McBride | Gut and Physiology Syndrome: Natural Treatment for Allergies, Autoimmune Illness, Arthritis, Gut Problems, Fatigue, Hormonal Problems, Neurological Disease and More | |
CN1393222B (en) | Use of composition of sterol compounds dissolved in oil | |
Morse | The Detox Miracle Sourcebook: Raw Foods and Herbs for Complete Cellular Regeneration | |
Wilson | Biobased Materials for Medical Applications | |
JP6711682B2 (en) | 20-Hydroxyecdizone-containing plant extract and method for producing the same, and use of 20-hydroxyecdysone-containing plant extract | |
CN205235020U (en) | Icariin - small intestine submucosa patch | |
Siegfried | Anatomy & physiology for dummies | |
JP2019136035A (en) | Bone density improving food composition, bone density improving agent, precursor osteoblast proliferating food composition, bone differentiation promoting food composition, bone enhancing food composition, anti-osteoporosis food composition, precursor osteoblast proliferation agent, bone differentiation promoting agent, bone enhancing agent, anti-osteoporosis agent, method for producing bone density improving agent, method for producing precursor osteoblast proliferation agent, method for producing bone differentiation promoting agent, method for producing enhancing agent and method for producing anti-osteoporosis agent | |
Vujasinović-Stupar et al. | Supplementation with bio-calcium from shells Pinctada maxima in postmenopausal women with decreased mineral bone density: Pilot study | |
KR101464267B1 (en) | Gleditsia sinensis Lam. extracts for inhibiting differentiation of osteoclast and use of thereof as bone resorption inhibitory products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |